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Chapter I. General introduction and aims of the work 
 
Drug discovery and development is recognized as a long, costly, and financially hazardous 
process. Pharmaceutical companies are facing serious challenges because of rising R&D costs 
and declining success in new drug approvals. It now takes about 10 – 15 years to introduce a 
new therapeutic agent on the market, with costs ranging from hundreds of millions to several 
billion euro. Much of this expense is the result of costly late-stage failures [1]. Several stages 
can be distinguished in the development process, which are illustrated in Figure I-1. 
 
 
Figure I-1: From discovery to market launch of a new drug. Based on [1,2]. 
 
As can be seen in Figure I-1, a broad range of tests is needed during each stage of the 
development process, causing the elimination of most compounds after each consecutive step 
and a very high (> 99 %) overall attrition rate. In modern drug design, a lot of effort is put in 
the prediction of drug delivery. The reason for doing this is obvious: the sooner a lead 
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compound is found (or an uninteresting compound can be eliminated), the sooner the final 
drug can get marketed and the lower the total cost of the drug development. 
In vivo, in vitro and in silico methods have been developed for the prediction of drug 
delivery. Prediction in these methods is mainly focused on absorption, distribution, 
metabolism and excretion (ADME) and drug delivery (see preclinical development, Figure I-
1). Intestinal permeability and blood-brain barrier transport are predicted most often, although 
the prediction of drug delivery in specific organs (e.g. lungs, skin; [3]) has also been studied. 
Most methods are only capable to predict passive absorption, although some methods also try 
to account for carrier-mediated transport in the prediction [4]. Since total drug absorption is a 
combination of several mechanisms (see II.1.1), the latter type of methods is somewhat more 
realistic. 
The fastest (and cheapest) way to predict drug delivery is based on in silico (= via computer 
simulation) predictions. This can even be performed before actual drug synthesis; therefore, it 
is a very good method to find lead compounds in initial studies.  
As mentioned, predictions can also be made based on in vivo (in a living organism, e.g. rat) or 
in vitro (outside the body of an organism) measurements. Although in vivo measurements 
provide the best predictions, they are increasingly avoided (especially during the early drug 
discovery phases) because of high cost, low throughput and ethical considerations. In vitro 
methods are very useful after initial synthesis of the product, since they are much faster and 
cheaper than in vivo methods. Both for lead identification and optimization, there is a need for 
in vitro systems with high reproducibility and reliability. Several in vitro systems have been 
developed, each with certain advantages and disadvantages. These systems are experimentally 
simple and can model passive transport, which is mostly either completely or partially 
responsible for drug uptake. However, there is as yet no industrial standard for in vitro 
measurements to predict drug delivery. The search for such a method is still ongoing, since 
the creation of this method could lead to a significant reduction in the total cost of drug 
development. 
This thesis will focus on in vitro systems based on high-performance liquid chromatography 
(HPLC), which has been proposed as an alternative to other in vitro methods. The basic 
processes of chromatographic separations are considered to be similar to the dynamic 
processes of drug action. Under adequate experimental conditions, the same basic properties 
(hydrophobic, electronic and steric) determine the behavior of chemical compounds in both 
the biological and chromatographic environments. Therefore, chromatography can be used as 
a powerful technique for estimating biological activity [5]. The two major HPLC-based 
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techniques in the prediction of drug delivery – micellar liquid chromatography (MLC) and 
immobilized artificial membrane liquid chromatography (IAMLC) – will be experimentally 
compared in this thesis. The general objective of this thesis is to develop improved in vitro 
methods which are able to provide useful data for the prediction of in vivo behavior of 
pharmaceutical compounds. More specifically, the aims are:  
 The development of new in vitro methods, which could allow faster analyses, better 
predictions and/or a wider application range. 
 A fundamental comparison of existing and new in vitro methods and evaluation of the 
performance of these methods. In order to get a realistic comparison, a range of in 
vitro methods should be tested. This should allow to conclude which method is suited 
best. 
 
In chapter II, the prediction of blood-brain barrier (BBB) transport is explained. First, some 
general information about the BBB is provided. Then, the most common delivery systems are 
presented. Finally, most of the methods for the prediction of BBB transport are provided and 
the processing through mathematical modeling is discussed. 
In chapter III, several common MLC and IAMLC methods are compared and evaluated 
towards the prediction of transport across the BBB. 
In chapter IV, the synthesis of a sphingomyelin stationary phase for IAMLC is presented 
based on a solid-phase inspired methodology. The potential of this new stationary phase as an 
in vitro prediction tool was evaluated by a proof-of-concept model. 
Chapter V compares the most common IAM phase and two other IAM phases (including the 
new sphingomyelin phase) towards in vitro prediction of transport across the BBB. 
In chapter VI, the lipid composition of brain membranes is studied, with a focus on the main 
lipid classes. Both extraction and quantification procedures are presented. Afterwards, the 
main lipid classes in white and grey matter of newborn piglets are determined. 
The results of chapter VI indicated that phosphatidylcholine is indeed the most prominent 
phospholipid in membranes and that C16 and C18 carbon chains are the most common in 
membrane phospholipids. Therefore, we decided to use the lipid analog miltefosine as MLC 
surfactant in chapter VII, since this phosphocholine-based lipid has a C16 carbon tail and thus 
has a similar (but less complicated) structure compared to phosphatidylcholine. In this 
chapter, not only transport across the BBB is predicted, but also the prediction of human 
intestinal absorption (HIA) was evaluated. 
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In chapter VIII, several topics are treated. The first section in this chapter involves a test, 
where MLC conditions are used on an IAM column; creating a different setup for the 
prediction of log BB and HIA values. In the second section, MLC and IAMLC methods from 
chapters III, V, VII and VIII are compared, in which both HIA and BBB transport are 
investigated. The third section shows how well the different descriptors are correlated. 
Finally, multiple linear regression was performed and compared to the partial least squares 
regression that was used throughout this thesis. 
In chapter IX, the general conclusions resulting from this thesis are summarized and 
discussed. Proposals on how future research could contribute to better predictions are also 
made.  
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Chapter II. Description of the structure, function and 
delivery across the Blood-Brain Barrier 
 
In the first part of this chapter, the structure and function of the blood-brain barrier (BBB) is 
explained. Then, the focus is put on drug delivery across the BBB and prediction thereof. 
Finally, some prediction models are presented.  
II.1 Structure and function of the blood-brain barrier 
The blood-brain barrier (BBB) is a selective barrier formed by the endothelial cells that line 
cerebral microvessels (Figure II-1). The principal components of the BBB are the endothelial 
cells, astrocytes, and pericytes. Some other cellular elements like neurons or microglia may 
also play a significant role in the function of BBB. From the point of view of the permeability, 
the most important cell types of the BBB are the cerebral endothelial cells, which form a 
continuous sheet covering the inner surface of the capillaries. Endothelial cells are 
interconnected by tight junctions which form a belt-like structure at the apical region of the 
cells. Endothelial cells are sitting on the basal lamina. The basal lamina is the extracellular 
matrix layer produced by the basal cell membrane, used as an anchoring and signaling site for 
cell-cell interactions. Engulfed in the basal lamina are the pericytes, which cover 
approximately 22-32 % of the endothelium. Pericytes play an important role in the regulation 
of endothelial proliferation, angiogenesis and inflammatory processes. Astrocytes are capable 
to induce BBB properties in endothelial cells. Endfeet of astrocytes cover a significant part of 
the endothelial surface and provide the cellular link to the neurons. Neurons can regulate 
important aspects of BBB function and can induce the expression of BBB-related enzymes in 
cultured cerebral endothelial cells. Microglial cells are also found in the perivascular space. 
Their contribution to the BBB properties is not well characterized, although it is known that 
they play a very important immunological role [1-5]. 
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Figure II-1: Cellular constituents of the blood-brain barrier (BBB). Cerebral endothelial cells form tight junctions 
which restrict the paracellular pathway. Pericytes are distributed discontinuously along the length of the cerebral 
capillaries and partially surround the endothelium. Both the cerebral endothelial cells and the pericytes are 
surrounded by a basal lamina. Astroglial endfeet form a complex network surrounding the capillaries and 
provide the cellular link to the neurons. Microglia are CNS-resident immune cells. Modified from [6]. 
 
Barriers at three interfaces separate the blood from the brain interstitial fluid: the blood-brain 
barrier (BBB), formed by the endothelial cells that form the walls of the capillaries; the blood-
cerebrospinal fluid barrier (BCSFB), formed by the choroid plexus epithelium, which also 
secretes cerebrospinal fluid (CSF); and the avascular arachnoid epithelium, which forms part 
of the meningeal covering. At each of these layers, cell:cell tight junctions form the ‘physical’ 
barrier, specific transport proteins mediate uptake and efflux (‘transport’ barrier), and 
enzymes add a ‘metabolic’ barrier. Together, these mechanisms regulate molecular traffic of 
drugs, nutrients, hormones, metabolites and other constituents between blood and brain, both 
inward and outward. The BBB, with the largest surface area (12-18 m² for the average human 
adult) and shortest diffusion distances (typically < 10-15 µm) to neurons, is the most 
important in regulating drug permeability to the brain. The BBB also supplies key nutrients 
and protects the brain from neuroactive and potentially toxic compounds circulating in the 
plasma. However, for some drugs and pathological conditions, the other two barriers may also 
be relevant [7,8]. The CSF is secreted across the choroid plexus epithelial cells into the brain 
ventricular system, while the remainder of the brain extracellular fluid, the interstitial fluid 
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(ISF), is derived by secretion across the capillary endothelium of the BBB. The avascular 
arachnoid epithelium, underlying the dura, completely encloses the CNS.  This completes the 
seal between the extracellular fluids of the central nervous system and that of the rest of the 
body. The avascular nature and relatively small surface area of the arachnoid epithelium 
indicate that it does not represent a significant surface for exchange between the blood and the 
CNS. A schematic overview of the barriers at the three interfaces is given in Figure II-2.  
 
 
Figure II-2: Blood-brain and blood-CSF barriers. Three principal barrier sites exist between blood and brain: (A) 
The arachnoid barrier in the meningeal compartment. The brain is enveloped by the arachnoid membrane lying 
under the dura. Endothelial cells from the subarachnoid space are joined by tight junctions and form an effective 
seal. Transport across the arachnoid is not an important route for the entry of solutes into brain. (B) The BBB 
itself, created at the level of the cerebral capillary endothelial cells by tight junction formation. Once the BBB is 
crossed, diffusion distances to neurons and glial cells for solutes and drugs are short. Therefore, targeting a drug 
across the BBB is the favoured route for global delivery of drugs to all brain cells. (C) The blood-CSF barrier 
(BCSFB) lies at the choroid plexuses in the ventricles of the brain where tight junctions are formed between the 
choroid plexus epithelial cells. These epithelial cells produce the CSF. Barriers (A) and (B) continue into the 
spinal cord. Modified from references [3,6,9]. 
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At all three interfaces mentioned in this figure, the barrier function results from a combination 
of physical barrier (tight junctions between cells reducing flux via the intercellular cleft or 
paracellular pathway), transport barrier (specific transport mechanisms mediating solute flux), 
and metabolic barrier (enzymes metabolizing molecules in transit). The barrier function is not 
fixed, but can be modulated and regulated, both in physiology and in pathology [10]. 
The blood-brain barrier has peculiar characteristics among the various physiological barriers. 
Diffusion of drugs across this endothelium separating the blood from the central nervous 
system (CNS) is more restrictive than elsewhere. Each of the cellular elements of the brain 
microvasculature that compose the BBB (endothelial cells, astrocyte end-feet, and pericytes) 
have specific functions [11].  
Endothelial cells provide a crucial interface between blood and tissue environments. The free 
diffusion of chemicals across endothelia is prevented by endothelial tight junctions, of which 
the permeability varies considerably depending on tissue and conditions. In peripheral tissues 
(e.g. intestine, kidney, salivary gland) these cell barriers have fenestrations enabling almost 
free exchange of water and solutes. The endothelial barrier separating the blood from the CNS 
is however characterized by tight junctions of severely limited permeability (excluding 
molecules with a diameter larger than 10-15 Å), no fenestrae, and an attenuated pinocytosis. 
The tight junctions significantly reduce permeation of polar (hydrophilic) solutes through 
paracellular diffusional pathways between the endothelial cells from the blood plasma to the 
brain extracellular fluid [12]. This forces molecular traffic to take a largely transcellular route 
across the brain endothelium [13-15]. Adjacent endothelial cells are connected by tight 
junctions. The difference in tightness in different regions is explained by the number of fusion 
point between tight junctions [16]. 
Two main types of astrocyte cells can be distinguished in the brain. Protoplasmic cells exist in 
the grey matter, and fibrillary cells are present in the white matter. Protoplasmic astrocytes 
have large nuclei and thick cytoplasmic appendices. The endings of these appendices form 
cap-like structures known as end-feet that tightly attach to neurons on one side and blood 
vessels on the other [16]. 
Pericytes are small vessel wall-associated cells that are developed in the mesoderm. They are 
separated from endothelial cells by the basal lamina (basement membrane), but gap junctions 
provide contact spots. In the brain, pericytes are responsible for the regulation of endothelial 
cell activity, mediation of inflammation, and control capillary-like structure formation and 
capillary diameter. They therefore play an important and composite role in the maintenance of 
the BBB and brain homeostasis [16]. 
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Although the blood-brain barrier has some typical characteristics, at a molecular level, the 
main building blocks of its biological membranes are similar compared to other physiological 
barriers. Biological membranes have as structural framework a bilayer resulting from the 
orientation of amphiprotic lipids (phospholipids, glycolipids) and cholesterol in the aqueous 
medium. In many biological animal membranes, these lipids are distributed asymmetrically. 
The outer half of the bilayer comprises mainly zwitterionic lipids, for example 
phosphatidylcholine (PC) and phosphatidylethanolamine (PE), whereas the inner part contains 
negatively charged lipids, particularly phosphatidylserine (PS) [17]. Figure II-3 gives a 
schematic representation of a typical biological membrane according to the fluid mosaic 
model. Proteins and other substances (e.g. steroids and glycolipids) are either associated with 
its surface or embedded in it to different degrees. The polar heads of phospholipid molecules 
are orientated to form an almost continuous polar layer on both the inner and outer side of 
membranes. In contrast, the long hydrophobic chains of phospholipids molecules extend into 
the central core of the membrane. The peripheral and integral proteins located in the 
membranes are responsible for carrying out many of the active functions of membranes, such 
as acting as receptors and transportation routes for various substances in and out of cells. The 
formation of pores, including ion channels, is also associated with integral proteins [18]. 
 
 
Figure II-3: The fluid mosaic model of biological membranes. Modified from references [18,19]. 
 
Most cell membranes are composed of both around 50 weight% lipid and protein. This means 
that about 50 % of the cell surface area (the semipermeable surface created by membrane 
lipids) is available for drug penetration. However, BBB cells are composed of only around 15 
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weight% of lipids (see Figure II-4), which means that only 15 % of the cell’s plasma 
membrane area represents the surface area available for diffusion [20]. 
 
 
Figure II-4: Composition of typical and BBB cell membranes. Based on [20]. 
 
II.1.1 Transport across the blood-brain barrier 
Cells forming the BBB depict a high negative charge density on the surface from PS. 
Negatively charged membranes are difficult for compounds to cross. This is one of the 
reasons why many CNS active compounds are hydrophobic amines since they have affinity 
for negatively charged surfaces and they can partition into the membrane as a result for their 
hydrophobicity [20]. CNS drugs can be classified according to their action mechanism as 
general or non-specific CNS drugs and selective modifiers of CNS functions [21]. Drugs 
whose mechanisms currently appear to be general or non-specific act by diverse molecular 
mechanisms affecting different target cells. They can have the ability to depress excitable 
tissue at all levels of the CNS or may stimulate the CNS (e.g. anesthetics, hypnotics and 
sedatives). Drugs classified as selective modifiers of CNS functions produce the effects 
through an identifiable molecular mechanism specific for the target cells that bear receptors 
for them. These drugs can be classified more definitively according to their site of action or 
specific therapeutic usefulness (e.g. anticonvulsants, psychopharmacological agents such as 
antipsychotics, antidepressants, etc.). Certain drugs that are unable to cross the blood-brain 
and blood-CSF barriers may sometimes produce a profound effect on the CNS as part of their 
pharmacological actions. Some of these drugs also produce side effects or toxic reactions that 
can affect the CNS (e.g. antihistamines) [22]. 
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Since the BBB is the most important in regulating drug permeability to the brain, we will limit 
ourselves to this pathway. Permeation across the cell membranes takes place by three main 
mechanisms: transcellular diffusion, paracellular diffusion and active transport (either 
transport into the cells or efflux out of the cells). Paracellular permeation is mainly governed 
by the size and the number of the pores between the cells, as well as the size and charge of the 
drug. Active transport processes require specific binding of the drug to the transporter protein. 
Diffusion across the cell membranes and transcellular permeation through the cells constitute 
the most important mechanisms, by which drugs cross biological membranes [23]. The main 
physical barrier of the transcellular pathway is the lipid matrix of the membranes, whereas 
that of the paracellular pathway are the intercellular tight junctions [17]. Most common drugs 
traverse cellular barriers by transcellular pathways. These pathways require movement of 
solutes across and through cells and include passive diffusion, carrier-mediated and vesicular 
transport mechanisms. 
It has long been assumed that synthetic drugs pass cellular barriers by passive diffusion only, 
which would favour lipophilic
1
 drugs. However, carrier-mediated membrane transport is not 
only a pathway for endogenous molecules (i.e. amino acids, oligopeptides, monosaccharides, 
water-soluble vitamins, etc.), but also a transport route that can be used by xenobiotics 
(molecules found within an organism that are normally not present there) [24]. Large 
molecules can be transported through a vesicle-based migration mechanism across the cell, 
i.e. transcytosis [17]. 
Paracellular transport, the tendency of a solute to follow the aqueous extracellular route, 
might be the primary pathway by which hydrophilic compounds of relatively low molecular 
weight cross epithelial and some endothelial barriers. Transport of larger hydrophilic 
molecules might be enhanced by modulation of junctional pores or addition of so-called drug 
absorption promoters. Translocation of solutes via the paracellular route takes place primarily 
by passive diffusion. Because of ionisable side-chains in tight junction proteins, the junctional 
space has an electrostatic field with a negative net charge that might affect the paracellular 
flux of solutes via ionic interactions [25]. Even if paracellular penetration occurs, the 
compound must still cross the cell membrane at the target cell to have its effect. A schematic 
representation of the various pathways involved in the BBB permeability is shown in Figure 
II-5.  
 
                                                 
1
 Lipophilicity is a measure for the lipid solubility of an agent, typically estimated as log P, the octanol:water 
partition coefficient. 
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Figure II-5: Potential routes for transport across the brain endothelium forming the blood-brain barrier. a Tight 
junction modulation may occur, which gives way for the paracellular aqueous diffusional pathway. b Solutes 
may passively diffuse through the cell membrane and cross the endothelium. This process is favoured for solutes 
with greater lipid solubility. c Active efflux pumps intercept some of these passively penetrating solutes and 
pump them out of the endothelial cell. d Many essential polar molecules, such as glucose, amino acids and 
nucleosides are transported into the CNS by carrier-mediated influx. e Leukocytes may cross the BBB adjacent 
to the tight junctions or by modification of the tight junctions. f Some macromolecules, proteins and peptides are 
transported by receptor-mediated transcytosis. g Adsorptive transcytosis appears to be induced by positively 
charged macromolecules and may result in transport across the BBB. Modified from references [6,26]. 
 
Passage of compounds that are important in metabolism is facilitated by the presence of 
specific transporters in the plasma membranes of the endothelium. Separate transporters for 
glucose, large neutral amino acids and monocarboxylic acids, plus several others have been 
found. Common inorganic ions and essential trace metals also have specific transport systems 
at the barrier. Iron is present in extracellular fluids in combination with the protein transferrin. 
It is generally transported into cells by receptor-mediated endocytosis of this iron-transferrin 
[27]. 
Some of the uptake transporters of the brain endothelium may work bidirectional, also 
regulating efflux. However, several families of transporters have been identified that are 
capable of transporting solutes out of the brain endothelial cells. They are able to restrict the 
CNS entry of a number of potentially harmful, toxic or lipophilic agents circulating in the 
blood [8]. 
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For many CNS drug-like molecules, plasma concentrations can quickly equilibrate with brain 
concentrations, even though their BBB permeability can vary substantially. Therefore, a lead 
compound should not be eliminated as a candidate compound only because it shows low BBB 
permeability [28]. 
 
II.1.2 Functions of the blood-brain barrier 
The BBB has several roles. It controls molecular traffic, keeps out toxins, supplies the brain 
with essential nutrients and mediates efflux of many waste products. It restricts ionic and fluid 
movements between the blood and the brain, allowing specific ion transporters and channels 
to regulate ionic traffic, to produce a brain ISF that provides an optimal medium for neuronal 
function. ISF is similar in composition to blood plasma, but thanks to the BBB, it has a much 
lower protein content, and lower K
+
 and Ca
2+
 concentrations but higher levels of Mg
2+
. More 
importantly, the BBB protects the brain from fluctuations in ionic composition that can occur 
after a meal or exercise, which would disturb synaptic and axonal signaling. The barrier helps 
to keep separate the pools of neurotransmitters and neuroactive agents that act centrally (in 
the CNS) and peripherally (in the peripheral tissues and blood), so that similar agents can be 
used in the two systems without ‘crosstalk’ [3,6]. The restricted and highly controlled access 
to the brain is due to several factors: (i) tight junctions which are sealing the intercellular gap, 
(ii) reduced rate of pinocytosis from the luminal side which prevents uncontrolled cell 
entrance, (iii) no fenestration which blocks the intercellular passage of the endothelium, (iv) 
an enzymatic barrier which presents the second line protection against unintentionally entered 
molecules, proteins and viruses, and (v) efflux transporter systems such as P-glycoproteins 
and others which remove small molecules from the endothelial cells before they reach the 
abluminal or basal side [29]. 
 
II.1.3 Controlling the permeability of the blood-brain barrier 
The apparent permeability of the BBB to a solute may be modified in at least three primary 
ways. Firstly, the effectiveness of transport depends on the magnitude and distribution of 
blood flow in the brain. Secondly, tight junctions may be partially or fully opened, 
introducing or enlarging a water-filled route for entry of solutes into cerebral interstitial fluid. 
Lastly, specific transport mechanisms may be regulated, e.g. the transport of glucose [27]. 
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The BBB can be broken down by different physiological and pathological conditions, 
including hypertension, hyperosmolality of the blood, exposure to microwave or radiation, 
infection, trauma, ischemia and inflammation [30]. There is a growing list of pathologies 
involving alterations of BBB function and abnormal astrocyte-endothelial cooperation; some 
pathologies even cause multiple BBB deficits. A short overview of pathologies causing BBB 
breakdown or disorder is given in Table II-1.  
 
Table II-1: Overview of several CNS pathologies together with (some of) their effects on the BBB. Based on 
[3,10,26]. 
CNS pathology Main expressions of BBB dysfunction 
Alzheimer ‘s disease * Decreased levels of P-glycoprotein transporter expression 
 * Decreased glucose transport 
 * Altered cellular relations at the BBB 
Brain tumors * Breakdown of the BBB 
 * Loss of the tight junctions in the tumor vascular system 
Epilepsy * Transient BBB opening in epileptogenic foci 
 * Upregulated expression of P-glycoprotein and other drug efflux 
    transporters in astrocytes and endothelium 
Glaucoma * Opening of the BBB 
HIV * Disruption of tight junctions in the BBB 
 * Apoptosis of endothelial cells 
Infectious or inflammatory * Examples include bacterial infections, meningitis, 
processes    encephalitis and sepsis 
 * Permeability of BBB tight junctions is affected 
 * Interferon-β prevents BBB disruption 
 * Alterations in P-glycoprotein expression and activity in the BBB 
Multiple sclerosis * Breakdown of the BBB 
 * Downregulation of laminin in the basement membrane 
 * Tight junction disruption 
(Inflammatory) pain * Alters BBB tight junction protein expression and BBB permeability 
    due to activated astrocytes 
Parkinson's disease * Dysfunction of the BBB by reduced efficacy of P-glycoprotein 
Stroke * Proteolysis of the vascular basement membrane/matrix 
 * BBB disruption 
 * Downregulation of the brain capillary endothelial 
Trauma * Opening of the BBB 
 
Considering the BBB dysfunctions caused by CNS pathologies, a concern within the CNS 
drug discovery environment is that the vast majority of studies are conducted using healthy 
preclinical tissue, while this might not give a representative image [26,31,32]. Given the 
evidence for involvement of BBB damage in many neurological conditions, there is growing 
interest in the BBB as a therapeutic target. For many pathologies, directing therapies to 
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protect or repair the BBB endothelium may prove an effective way to reduce the severity of 
neurological symptoms or delay onset of neurodegeneration [8,3]. 
 
II.2 Principles of drug delivery across the blood-brain barrier 
The BBB significantly hinders drug delivery to the brain. Because of this barrier, many 
therapeutics which could potentially treat neurological conditions cannot be delivered in an 
intravenous way. Overcoming this hindrance could mean potential therapies for a wide range 
of disorders, including Alzheimer’s and Huntington’s diseases, amyotrophic lateral sclerosis 
(ALS), neuro-AIDS, stroke, brain or spinal cord trauma, autism, lysosomal storage disorders, 
fragile X syndrome, inherited ataxias, and blindness [33]. 
For drugs that do not readily cross the BBB, there are several options. The existing molecule 
can be modified to cross the BBB directly, the barrier can be bypassed physically or 
specialized delivery vehicles can be used to evade the BBB mechanism [34]. An overview of 
possible methods for drug delivery across the BBB is given in this section. All developed 
brain-targeted delivery systems must be assessed for their safety, risk and benefit for patients. 
So far, the safety issue has been largely overlooked during the research stage, yet this issue 
will become critical when the drug to be delivered is intended for a long term therapy. It is 
extremely important that any developed delivery system should have no significant impact, 
short or long term, on the functions of the brain [26].  
It has been suggested by Lennernäs [35] that purely passive diffusion is universal for 
membranes with different physiological functions and physicochemical properties. Therefore, 
the factors that determine a compound’s intestinal absorption should also, to some extent, 
determine the BBB permeability. Some techniques mentioned in II.2 and II.3 are mainly 
focused on intestinal absorption, but are also illustrated based on their potential regarding 
BBB delivery or prediction.  
 
II.2.1 Non-mediated delivery 
Some compounds are able to cross the BBB directly making use of the paracellular aqueous 
pathway or the transcellular lipophilic pathway (passive diffusion). The extent and speed of 
penetration can however be totally different. Therefore, methods to improve penetration of 
these compounds are desirable. The improvement of passive penetration of the brain can be 
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achieved by developing lipophilic pro-drugs that are taken up into the brain and metabolized 
to release active parent compounds [36]. This lipidization strategy is limited since drug 
lipidization also increases its penetration in other tissues. In practice, lipidization 
modifications are difficult, and the only example of a (street) drug where the effectiveness of 
this approach can be demonstrated is heroine. This molecule, synthesized by di-acetylation of 
morphine, increases brain uptake more than 30-fold. This approach has limited applicability 
to drugs greater than 400-450 Da [37,38]. 
A lot of molecules showing lipophilic properties potentially enabling them of passive 
permeation of the BBB nevertheless exhibit unexpected low penetration rates. This 
observation may be explained by the presence of ATP-binding cassette (ABC) transporters, 
which effectively efflux a broad spectrum of molecules. Therefore, there are limits to the 
strategy to design CNS drugs exhibiting high lipid solubility as it increases the probability 
that the drug will not sufficiently reach the intended targets [39].  
The major efflux transporters in the BBB are P-glycoprotein (P-gp), breast cancer resistance 
protein (BCRP) and multidrug resistance proteins. P-gp can be used for increase or decrease 
of brain delivery of drugs. P-gp is an ATP-dependent pump, the protein acts as an efflux 
pump with broad substrate specificity, resulting in the restricted accumulation of some 
cytotoxic and lipophilic drugs. Several drugs are potential ligands for P-gp and have restricted 
transfer through the brain endothelial cell and in brain tumors, since they are pumped out by 
the transporter. A pharmacological strategy consists of co-administration of P-gp reversing 
agents (inhibitors) such as verapamil as a means of increasing drug delivery to the brain by 
competition on the P-gp specific sites. Conversely, the use of inducers of P-gp such as 
phenobarbital could decrease adverse central side-effects of drugs acting in the periphery 
[40,41]. The BCRP efflux transporter plays an important role in the efflux of CNS acting 
drugs and anticancer therapeutics. Various attempts have been made for the development of 
predictive models for this protein [42]. A recent study [42] developed a model to calculate a 
BCRP value, after which is was incorporated in the model development for log BB (the 
logarithm of the brain:blood (or plasma) ratio, see section II.3.1). Compounds which fulfilled 
the criteria for BBB permeability, but showed low log BB values, were proven to be 
substrates for the BCRP transporter, thus indicating the important role of BCRP in BBB 
permeability. 
Another possibility for the improvement of delivery across the BBB lies within the 
development of drugs which are transported into the brain via endogenous BBB transporters 
[37]. 
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While these methods are promising and offer the ability to easily administer drugs to the CNS 
as in other organs, they do require the expense and time of developing new agents, and they 
result in drugs being delivered to the entire brain, which may not always be desirable [33]. 
 
II.2.2 Drug delivery across the blood-brain barrier by liposome systems 
A possible alternative route would be the use of liposome systems. Liposomes have become 
more and more important as strategy for brain-targeted drug delivery. The most interesting 
features of liposomes are their ability to incorporate and deliver large amounts of drug and the 
possibility to place different ligands on their surface [43]. Liposomes can provide an 
increased cellular uptake and a reduced efflux through ABC transporters. New therapeutic 
strategies for using liposome-carried drugs in different conditions have been developed, 
affecting CNS tumors and neurodegenerative diseases to viral infections and epilepsy [44]. 
Liposomes (Figure II-6) can be prepared by weighing the desired lipids (e.g. 
dimyristoylphosphatidylcholine (DMPC, represented in Figure II-7)) and dissolving these 
lipids in an organic solvent. A lipid film is formed on the wall of a round-bottom flask 
following rotary evaporation. The resulting dried film can be hydrated in a swelling (e.g. a 
phosphate buffer) solution by vortex or mixing, which results in the formation of 
multilamellar vesicles (MLVs, multilamellar liposomes) [45,46]. Compared to classical 
micelles, these liposomes are much bigger. However, they offer more possibilities towards the 
incorporation of drugs, since both hydrophilic and hydrophobic spaces are available. Also, the 
bilayer of the liposomes is a much more realistic mimic of the membrane bilayers compared 
to micelles. 
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Figure II-6: Schematic representation of a unilamellar and a multilamellar liposome. Water-soluble compounds 
can be encapsulated in the aqueous core, while lipid-soluble compounds can be incorporated into the lipid 
bilayer of the liposome. Modified from references [20,47]. 
 
Liposome suspensions prepared from phospholipids exhibit structural similarities to the 
phospholipid bilayer found in cell membranes. Several quantitative structure-activity 
relationship (QSAR) studies have successfully correlated drug activities with drug liposome 
partition coefficients [48,49]. Liposomes can model both polar and nonpolar drug-membrane 
interactions, but they are difficult to model experimentally. Limitations of this delivery 
mechanism include the large size of liposomes and controlled release of the encapsulated 
drugs from the vesicles [41].  
 
II.2.3 Bicelles as an alternative delivery system 
Bilayered micelles, or bicelles, are a popular model membrane system. Depending on 
composition, concentration, and temperature, bicelle mixtures may adopt an isotropic phase or 
form an aligned phase in magnetic fields. Therefore, bicelles have interesting characteristics 
in Nuclear Magnetic Resonance studies. 
Chapter II 
21 
 
To a certain extent, the morphology of bicelles is similar to liposomes. Bicelles consist of a 
mixture of long-chain phospholipids, such as DMPC, and short-chain phospholipids, such as 
dihexanoylphosphatidylcholine (DHPC). Bicelles were proposed to consist of disk-shaped 
bilayer domains, whose edges were coated by a curved DHPC rim. The radius of the disk-
shaped bilayer depends on the chosen molar ratio (of long- to short-chain phospholipid). 
Figure II-7 depicts a bicelle, consisting of short- and long-chain phospholipids (i.e. DHPC and 
DMPC). As can be seen, DMPC lipids dominate the disk-shaped bilayer domain of radius R, 
which is coated with a DHPC rim with radius h/2 [50]. To the best of our knowledge, bicelles 
have not been used for brain-targeted drug delivery. 
 
 
Figure II-7: The disk-shaped bicelle model, in which the planar bilayer domain consists of long-chain 
phospholipids (DMPC), and the rim consist of short-chain phospholipids (DHPC). R is the bicelle disk radius, h 
is the total bilayer thickness. Based on [50]. 
 
Like micelles, bicelles are noncompartmentalized, optically transparent, and effectively 
monodisperse. On the other hand, bicelles have a much lower detergent content than classical 
mixed micelles and maintain some key bilayer properties that are absent in micellar systems. 
Bilayers can – to a limited extent – mimic membrane bilayers. A more realistic model could 
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be achieved with other classes of lipids, such as those with longer acyl chains and higher 
degrees of chain unsaturation than DMPC [51] (see chapter VI). 
 
II.2.4 Cell-penetrating peptides and molecular Trojan horses 
Cell-penetrating peptides and molecular Trojan horses can be used for targeting the entire 
brain. They perform well as delivery molecules. Cell-penetrating peptides are not brain 
specific but can provide efficient traversal of the BBB, and tandem systems with targeting 
molecules may produce extremely effective brain drug delivery tools. The molecular Trojan 
horse technique involves using a targeting ligand such as a serum protein, monoclonal 
antibody, or another high affinity targeting molecule that binds to its receptor and activates 
endocytosis of the complex into a vesicle that is transported to, and released from the opposite 
pole (i.e. transcytosis; Figure II-5) [33]. Molecular Trojan horses are thus limited by the 
quantity of relevant receptors. They can however be very selective for the BBB endothelium 
and have shown promise in gene therapy [34]. 
 
II.2.5 Drug delivery through nanocarriers 
Nanocarriers are an emerging class of drug delivery systems that can be easily tailored to 
deliver drugs to various parts of the body, including the brain. It has been attracting increasing 
attention for its use in transport of drugs across the BBB due to the rapid increase in our 
understanding of receptors and the fast development in polymer chemistry and 
nanotechnology. Nanocarriers are unique because of their size and easily tailored structures 
due to the material (biodegradable polymers) used. They can behave like macromolecules, but 
they can carry much more drug payload and are capable of controlling drug release. They can 
carry a range of drugs and their surface properties can be modified. These properties make 
nanocarriers an attractive alternative for transporting drugs across the BBB [26,52]. One of 
the limiting factors upon the systemic use of nanoparticles is their rapid clearance from the 
blood circulation. Nanoparticles with a longer circulation time are in contact with the BBB for 
an increased time, and thus have a longer time to deliver their cargo to the brain. Drug 
delivery through the BBB can be enhanced by cationic nanoparticles, since these can interact 
with the negative charges present on the cell membrane of endothelial cells [53]. 
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Nanoscale drug carriers consist of particles in the size range from 10 to 1000 nm. Some ideal 
properties for drug delivery are: (i) nontoxic, biodegradable and biocompatible, (ii) particle 
size less than 100 nm (except for transport via monocytes or macrophages), (iii) stable in 
blood and prolonged blood circulation time, (iv) BBB-targeted moiety, (v) tunable drug 
release profiles, and (vi) applicable to carry small molecules, proteins, peptides or nucleic 
acids [54,55]. 
Despite a large variety of nanocarriers developed so far, only amphiphilic molecule-formed 
liposomes and polymeric nanoparticles have been extensively exploited for brain drug 
delivery (e.g. poly(butylcyanoacrylate) nanoparticles further coated with polysorbate-80 allow 
brain delivery of dalargin and loperamide) [56]. 
Solid lipid nanoparticles show several advantages as drug delivery systems, which explains 
why they can be used as vehicles to cross the BBB. Advantages include good 
biocompatibility, an interesting production process that can be performed easily on a large 
scale, a relevant drug loading capacity and a controlled drug release that can be made to last 
several weeks. However, the real potential of solid lipid nanoparticles for delivering drugs to 
the CNS is not clear, especially since data regarding the extent of permeation is often 
contradictory. It is however clear that the drug concentration in the brain is effectively 
increased using these nanoparticles, making them interesting to use for delivery across the 
BBB [53]. 
 
II.2.6 Tight junction opening using focused ultrasound 
In the past two decades, some modulators have been discovered which can be used for 
opening the BBB (in several cases: opening of tight junctions). These modulators range from 
chemical (e.g. cyclodextrin and poloxamers) and biological (e.g. virus and macrophage) 
substances to physical stimuli such as high frequency focused ultrasound (FUS) and 
electromagnetic fields. FUS is a very promising technique since it provides a non-invasive 
alternative that may prove more desirable for acute treatment of brain tumors and other 
conditions requiring local tissue necrosis. An excellent overview of these modulators, their 
course of action and their impact on the BBB is provided by Chen et al. [26]. FUS has several 
advantages over other approaches because it is readily repeatable, noninvasive, and able to 
disrupt the BBB in a targeted way [41]. The rationale for modulating tight junction opening to 
enhance the paracellular approach is fourfold: (i) the tight junction opening (BBB leakage) is 
a phenomenon associated with many brain diseases (Table II-1) and stimuli, and many 
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modulators have already been characterized; (ii) enhanced paracellular transport will increase 
the delivery of small water soluble molecules into the brain; (iii) modulated tight junction 
opening may also improve the BBB passage of macromolecules and drug delivery systems 
including liposomes, nanocarriers, micelles, polymer conjugates, and their distribution in the 
brain; (iv) using physical stimuli such as ultrasound and electromagnetic fields will 
temporarily provide local BBB disruption, therefore, concentrated drug doses can be delivered 
locally [26].  
FUS can be used in combination with circulating microbubbles. The microbubbles 
concentrate the ultrasound effects to the microvasculature, greatly reducing the FUS exposure 
levels needed to produce bioeffects. This offers a potential way to disrupt the BBB in a 
targeted, noninvasive, and repeatable manner to deliver a wide range of drugs to the brain and 
to brain tumors. The technique also offers the potential to control the magnitude of BBB 
disruption at each focal target through modification of the ultrasound parameters, enabling a 
level of control over drug delivery that is not available with other technologies. The gas-filled 
microbubbles interact with the vessel wall through oscillation. At higher acoustic pressures, 
they implode. After collapsing, their gaseous content or drugs packed within their shells are 
released. The sonifications do not appear to have any deleterious effects on the brain and 
studies on animals have demonstrated that treatments can be performed safely without 
causing tissue damage even after repeated weekly sessions. This flexibility, along with the 
noninvasiveness, and lack of need for general anesthesia make FUS a potentially 
transformative technology. Given the availability of clinical FUS devices capable of focusing 
ultrasound through the intact human skull, along with recent safety studies demonstrating the 
method can be performed safely in nonhuman primates, it appears that the method is ready for 
initial clinical tests [33,57,58]. 
 
II.2.7 Intranasal delivery as a drug delivery system 
Two routes have been proposed for the direct passage of drugs from the nose to the brain: an 
intraneuronal and an extraneuronal pathway [59]. Even large molecules like peptides could be 
transported from the nasal cavity to the CNS. Most pharmaceuticals are water soluble or have 
MW > 400 Dalton, and do not freely traverse biological barriers [37]. The main advantage of 
intranasal administration is the minimal invasiveness, although the usefulness of this 
technique will be limited to compounds with large therapeutic indices. The major 
disadvantages of intranasal drug delivery are the challenge of reproducibility, the limited 
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absorption across the nasal epithelium, which restricts the application to particularly potent 
substances, and the fact that drugs are delivered to the whole brain through this route [60]. 
Nevertheless, the technique is a promising route to bypass the BBB and is currently being 
investigated by numerous researchers [33,61]. A wide range of therapeutics, such as peptides, 
proteins, gene vectors and stem cells, have been successfully delivered through intranasal 
administration to small animal brains and have shown efficacy in treating CNS diseases, such 
as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, depression, anxiety, 
autism spectrum disorders, seizures, drug addiction, eating disorders and stroke [62]. 
Since neurological diseases do not generally affect the brain in a global manner, and drugs are 
delivered to the whole brain through intranasal delivery, a new strategy was proposed for 
enhancing drug delivery efficiency at the sites requiring treatment while minimizing the 
exposure to other brain sites. This method uses transcranial FUS in combination with 
microbubbles [62]. The authors concluded that FUS can enhance intranasal drug delivery 
efficiency at the targeted brain location and that this technique achieves similar drug delivery 
efficiency within the targeted region compared with the conventional FUS approach. 
The field of drug delivery to the brain via the nasal route is rather immature. The mechanistic 
understanding of the pathways of drug transport from the nose to the brain is limited, and their 
efficiency is not clear [61]. 
 
II.2.8 Other delivery systems 
Controlled-release intracranial polymer implants and particle injections are the clinical state 
of the art with regard to localized delivery, although these approaches can impose significant 
surgical risks [34]. This type of delivery yields the highest degree of targeting, although it is 
limited by invasiveness and diffusion restrictions [63]. 
High local drug concentrations can be achieved by inserting a needle or catheter into the brain 
and directly injecting or infusing drugs or by implanting drug-releasing devices. However, 
because of their invasiveness, there are some risks of infection or brain trauma, and they may 
not be amenable for repeated treatments or for drug delivery to large areas of the brain [33]. 
Intracerebroventricular and intrathecal administrations deliver the drug directly into the CSF 
compartment, either in the lateral ventricle or in the subarachnoid space. These routes are less 
invasive than direct intracerebral injection and allow access to a much wider area of the CNS 
through CSF circulation pathways. Limiting factors are diffusional and cellular barriers for 
penetration into surrounding tissue [64]. 
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Opening of the BBB using intracarotid infusion of hyperosmolar solutions (such as mannitol) 
has had some success in increasing drug delivery to tumors. This procedure causes shrinkage 
of endothelial cells and consequent stretching of tight junctions through which drugs may pass 
[41,65,66]. While this procedure can be effective to deliver drugs to large brain regions, it is 
invasive, requires general anesthesia and can have side effects (e.g. oedema). Therefore, 
therapeutic BBB opening needs to be kept as brief as is practical or it would be desirable to 
have a less-invasive way to achieve this disruption [33]. 
Chemical-mediated BBB disruption involves exposing the BBB to an agent that increases 
BBB permeability. These agents induce a transient inflammatory reaction within the 
endothelium, resulting in enhanced paracellular permeability [67]. 
 
II.3 Measurement and prediction of drug transport across the blood-brain barrier 
In the CNS related drugs, the probability of success in obtaining a marketing authorization is 
less than 7 % and the time needed, considering clinical and regulatory phases, is around 10.5 
years, the longest compared to other therapeutic areas. Therefore, reliable methods for 
selecting the best candidates in the early preclinical phases are urgently needed in order to 
reduce the risk of costly later failures in clinical phases [68]. In vivo rodent models for 
studying BBB permeation are not time and cost effective enough to be applied as screening 
models during the early drug discovery phases. Owing to low costs and high throughput, in 
silico models are useful for the preliminary assessment of BBB permeability and 
classification of test compounds in the hit to lead phase. During the lead identification and 
optimization stages, there is a need for in vitro models with higher reproducibility and 
reliability [69]. During the lead optimization stage, the data resulting from in vitro and in vivo 
assessments of CNS penetration may be used for the development of more locally (regarding 
chemistry space) relevant and quantitatively predictive models [70]. In the last stages of drug 
discovery, in vivo tests become increasingly important. An overview of the commonly used 
methods during the drug discovery stages is given in Figure II-8. 
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Figure II-8: Application of in silico, in vitro, and in vivo CNS penetration assessment methods during the various 
stages of drug discovery. Modified from [70]. 
 
II.3.1 In vivo methods for assessing blood-brain barrier permeability 
The most important in vivo methods are discussed in this section. Two of the methods for 
assessing BBB permeability in vivo are widely used: determination of the logarithm of the 
ratio of the concentration in the brain versus blood (or plasma), leading to the log BB value 
(section II.3.1.1); and measurement of the permeability-surface area product (PSP) [7] 
(section II.3.1.2). In general, extrapolation of animal permeability or absorption data to 
humans should be performed with caution because of potential species differences [71]. 
Species similarity and differences in absorption, distribution, metabolism, excretion and 
toxicity (ADMET), with the limitations in extrapolating data from animals to humans, have 
been described previously [72,73]. 
When animals are required for experiments, a difference can be made between tissue assays 
and whole animal assays. The former indicates a long(er)-lasting method without constant 
need for the sacrifice of animals, while the latter indicates a single test per animal for oral 
bioavailability information. The main disadvantages of performing in vivo experiments are 
the cost and the time required for the surgical procedures, especially for brain microdialysis 
and in situ brain perfusion. This has continued to drive the development of in vitro and in 
silico based approaches [74]. 
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II.3.1.1 Determination of the logarithm of the brain versus blood ratio (log BB) 
A common measure of the extent of BBB permeation is the ratio of the steady-state 
concentration of a drug molecule in the brain to its concentration in the blood, usually 
expressed as log (Cbrain/Cblood) or log BB [75]. Measurement of BBB permeation is typically 
based on intravenous administration of a radiolabeled compound to anesthetized rodents 
(mostly rats, sometimes mice or rabbits) followed by exsanguination when radioactivity in the 
blood reaches a plateau. The brain is removed and the concentration of the corresponding 
drug is measured by use of a scintillation counter. Measurement is time-consuming, 
expensive, and difficult, but it is still very important because in vivo animal experiments 
enable the best prediction of log BB values [76]. Single time-point log BB determinations are 
of limited value as they depend on the chosen time and the relation between the concentration 
in blood and brain at this time point. The ratio of the areas under the curve is more useful. 
However, these measurements are generally made over several hours, with several animals 
required per data point, increasing the cost and workload. Quite often, data at only one or two 
data points are obtained, and the assumption is made that equilibrium has been reached [77]. 
Some factors, like metabolism, also affect the brain distribution, so that log BB is not a pure 
measure of BBB permeability but rather a partitioning value [7,74]. 
Over the last few decades, the log BB values of some compounds were determined in vivo. 
An overview of these compounds is given in Appendix A. When several log BB values were 
found, the average value was calculated. The use of this data is however not without risk, 
since these values were obtained in several research groups and conditions of the experiments 
were not always identical (e.g. the use of mice, rats or rabbits). 
 
II.3.1.2 Measurement of the permeability-surface area product (PSP) 
Drug action in the brain is a function of drug receptor occupancy. This is a function of the free 
drug in brain cells and not the total drug concentration (as determined by log BB). 
Unfortunately, it is not easy to measure free drug in brain experimentally. A good index of 
BBB permeability is the BBB PSP, which has units of 
µ𝐿
min 𝑔
 and is a measure of unidirectional 
clearance from blood to brain across the BBB. The measurement of the BBB PSP can be 
performed either in vitro using a tissue culture model of the BBB, or in vivo using 
quantitative animal models [78]. The PSP is commonly regarded as the most relevant measure 
of a compound’s ability to cross the BBB, because it is not compromised by metabolism, 
Chapter II 
29 
 
plasma protein binding and nonspecific brain binding owing to the short exposure time [79]. 
The PSP values can be obtained after determination of the unidirectional uptake coefficient 
(Kin) using the in situ saline-based perfusion method. The saline composition of the perfusate 
can be controlled, and plasma protein included if needed to test the effect of protein binding. 
If perfusate flow is also measured, Kin can be converted to the PSP. These values can be 
compared across preparations and tissues, and used to follow changes under altered conditions 
(e.g. pathological) [7]. This method is resource-intensive, requires microsurgical expertise and 
has therefore a low throughput. However, considering the greater mechanistic clarity of log 
PSP compared with log BB, the former is likely to be more informative as a measure of CNS 
penetration for use in lead optimization. Unfortunately, only limited log PSP values are 
available in literature and few studies have thus far been published using this data [70]. 
 
II.3.1.3 Microdialysis for the measurement of brain penetration 
Another technique for measuring brain penetration in vivo is intracerebral microdialysis. 
Using this method, a quantitation of the BBB permeability can be done in an intact animal. It 
allows determination of the brain extracellular concentrations of a drug over time. The basic 
principle is the stereotaxic
2
 implantation of a microdialysis probe. The probe consists of a 
semipermeable membrane; molecules lighter than the molecular weight cut off can be 
transported into or out of the perfusate from a higher to a lower concentration. The 
concentration of the molecules of interest is then monitored using a sensitive separation 
method [30]. This method is relatively cheap and simple, measures free drug concentrations 
and is suited to characterize slowly changing brain drug concentrations [80]. The 
disadvantage is that brain microdialysis requires the most surgical skill of all the available in 
vivo methods [74].  
Based on microdialysis, the unbound brain-to-unbound plasma concentration ratio can be 
determined. This ratio thus measures the unbound concentration gradient across the BBB, 
which equals 1 for drugs undergoing passive transfer. A value less than 1 suggests passage 
across the BBB is restricted by either inherently low permeability (e.g. atenolol) or by active 
efflux through a transporter, such as P-gp. A value greater than 1 would indicate that uptake 
into the brain is facilitated in some way, perhaps via active influx [74]. 
 
                                                 
2
 A method to locate the site to be operated on within the brain using an external, three-dimensional frame of 
reference usually based on the Cartesian coordinate system. 
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II.3.1.4 The measurement of cerebrospinal fluid (CSF) concentrations 
A lot of models concerning the prediction of BBB penetration have been published. In several 
of these models, the total (i.e. bound + free) drug concentration in the brain is predicted, 
expressed as the log BB. This total drug concentration is however not entirely relevant to 
pharmacological action, since effects in the CNS are mainly caused by the free drug 
concentration. The CSF has been suggested as a better indication for pharmacological 
activity, since the amounts of a drug in the CSF and in the free plasma are similar for most 
drugs [81]. 
This does however not necessarily mean that the drug concentration in the CSF is a good 
surrogate for the drug concentration in extracellular fluid (ECF). For compounds where BBB 
diffusion is both rapid and passive, CSF concentrations agree well with brain ECF 
concentrations. There are however instances where CSF and ECF brain concentrations do not 
correlate well, such as when the drug is subject to a slow rate of uptake across the BBB, 
active transport or local metabolism [74]. Despite these issues, the measurement of CSF 
provides a relatively simple means to estimate unbound drug concentration within the CNS 
system [82]. So far, the available CSF data is limited, which inhibits its use in prediction 
models [83]. 
Systematically administered drugs can reach CSF either directly via passage across the 
choroid plexus, or indirectly by passage across the BBB followed by diffusion/convection 
transport from the ISF to CSF. The major site of blood-CSF exchange is the choroid plexus, 
although microvessels in the pia- and dura-arachnoid membranes are also sites of exchange. It 
is generally assumed that diffusional exchange of solutes across the BCSFB is minimal 
because of the very limited (< 0.1 %) surface area compared to that of the BBB. However, in 
early drug discovery and development, CSF sampling is more practical than ISF sampling by 
microdialysis in terms of effort, cost and throughput. For antibiotics and antivirals, CSF 
sampling provides crucial information as to whether adequate drug concentration is achieved 
to eradicate the infectious organism or virus in the CSF. In these cases, CSF concentration 
serves as a direct therapeutic check. Overall, CSF concentration is a reasonably good 
discriminating indicator of drug availability to the CNS for hydrophilic or large molecular 
weight compounds with poor to moderate permeability. The presence of a drug in the CSF 
only reflects extracellular drug availability and does not reveal access of drugs to the 
intracellular sites within the brain parenchyma. The brain ISF concentration can differ 
remarkably from the CSF concentration, even if the receptor resides on the cell membrane 
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surface where it is readily accessible from the extracellular aspect. This has dispelled the 
simplistic notion that there is a free exchange of drug between the ISF and CSF, and that at 
steady-state CSF drug concentration represents the effective free drug concentration that 
pervades the CNS. A downward CSF-to-ISF concentration gradient is a concern when efflux 
transport at the BBB is likely [84]. 
 
II.3.1.5 In situ perfusion to study drug absorption 
The development of the in situ brain perfusion technique by Takasato et al. [85] provided a 
simple method for performing short-term studies of brain uptake following feasible surgery. 
The in situ brain perfusion method involves cannulation of the carotid artery and infusing 
whole blood, physiological buffer, or saline containing the compound of interest. Because of 
the possibility of extending perfusion time, this model allows transport studies of slowly 
penetrating an metabolically unstable drugs [86]. Transport in the brain can be measured for 
an undisturbed BBB when a radiolabeled tracer is added to a suitable perfusate solution. The 
perfusate can be adjusted to study mechanistic aspects of permeation and identify the 
responsible transport systems [6].  
After decapitation, the radiolabeled test and reference compounds are measured and the BBB 
permeability-surface area product (PSP) is quantitated. The radiolabeled tracer is quantitated 
in the brain tissue by scintillation counting or autoradiography [30]. The biggest advantage of 
the in situ system compared to the in vitro techniques (section II.3.2) is the presence of an 
intact blood and nerve supply in the experimental animals [71]. Compared to the 
determination of log BB, the in situ perfusion method offers the advantages of the ability to 
tailor the perfusion fluid, the constant infusion concentration, and the absence of compound 
metabolism in other organs [87]. This methodology is found to be highly accurate for 
predicting the permeability of passively transported compounds, although the use of a scaling 
factor has been recommended for predicting permeability of carrier-mediated compounds 
[88]. Disadvantages are that a large number of animals is required to get statistically 
significant absorption data and relatively high amounts (> 10 mg) of test compounds are 
required to perform studies [71]. 
In situ brain perfusion is a widely accepted method for measuring BBB permeability; the 
technique has been simplified over the years by using shorter perfusion time and less complex 
surgery. However, this method is not commonly performed, because it is labor intensive and it 
does not directly provide unbound brain concentration [79]. 
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In situ experiments for studying intestinal drug absorption involve the perfusion of a drug 
solution prepared in a physiological buffer through isolated cannulated intestinal segments. 
Absorption is assessed based on the disappearance of the drug from the intestinal lumen. In 
this technique, the difference in the concentration of the inlet and outlet flow is used to 
calculate the permeability. The presence of an intact blood supply, nerve, and clearance 
capabilities at the site of absorption lead to an excellent experimental system that mimics in 
vivo conditions. Also, the input of compounds can be closely controlled with respect to 
concentration, pH, flow rate, and intestinal region [71]. 
 
II.3.1.6 Other in vivo methods 
Other in vivo methods include intravenous injection [89], positron emission tomography 
imaging [80], bolus carotid intravenous method [90], indicator dilution technique [40], brain 
uptake index [91], capillary depletion technique [40], and brain efflux index [92]. Most of 
these methods need radiolabeled compounds, expensive infrastructure and are labor intensive, 
which prevents their use for high throughput screening [76]. 
 
II.3.2 In vitro systems for the prediction of drug transport 
Transcellular routes of drug penetration include not only passive but also active and facilitated 
mechanisms. Although physicochemical methods are only able to model passive transport, 
they remain one of the most common screens used in drug discovery for two reasons:  
 They are experimentally the simplest methods 
 Passive transport is mostly either completely or partially responsible for drug uptake  
Nevertheless, multiple drug transport pathways through cells should not be ruled out when 
evaluating data. This is why there is still no consensus on which model best predicts 
biologically relevant drug membrane interactions [20]. 
 
II.3.2.1 High-performance liquid chromatography 
In High-performance liquid chromatography (HPLC), several techniques have been used to 
model drug action, although most attention has been paid to micellar liquid chromatography 
(MLC) and immobilized artificial membrane (IAM) LC. Possibilities offered by these 
techniques will be outlined below. General disadvantages of these techniques are that they do 
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not consider the potential role of paracellular transport, carrier-mediated transport, drug 
metabolism, and efflux transporters on permeability. Overlooking the possible influence of all 
these factors can be dangerous and may provide a very limited view of the true absorption 
potential of a compound [93]. 
Biopartitioning chromatography (BPC) has been proposed as a non-cell-based and high-
throughput screening platform for drug membrane permeability and biological activity. BPC 
introduces biomembrane-mimetic structures (such as liposome, phospholipid monolayer, 
micelle, microemulsion, vesicle, bicelle, etc.) into chromatographic systems, i.e. liquid 
chromatography or capillary electrophoresis (CE), and thereby emulates drug-membrane 
interactions. BPC is therefore a generic name for micellar and microemulsion liquid 
chromatography (MLC and MELC), immobilized artificial membrane (IAM) 
chromatography, micellar and microemulsion electrokinetic chromatography (MEKC and 
MEEKC), liposome electrokinetic chromatography (LEKC), etc. [94-96]. An overview of 
HPLC-based BPC methods can be found in this section, some CE-based BPC methods are 
illustrated in section II.3.2.2. 
 
II.3.2.1.1 Micellar liquid chromatography for the prediction of drug transport 
In quantitative structure-activity relationship (QSAR) methods, the biological activities of 
solutes or their ability to penetrate the different hydrophobic barriers (membranes) are related 
to their physico-chemical properties. The hydrophobicity of a compound, expressed as log P, 
is of great importance in QSAR studies [97]. One of the main drawbacks is that many 
biologically active compounds of interest in QSAR studies are ionic at physiological pH and 
ionic organic compounds are not or only weakly retained in reversed-phase liquid 
chromatography (RPLC).  
To circumvent this problem, micellar liquid chromatography (MLC), a mode of RPLC which 
uses a surfactant solution above the critical micellar concentration (CMC) as mobile phase 
[98], proved to be a very useful method. The use of micellar solutions produces the adsorption 
of surfactant monomers to the stationary phase and increases the thickness of the stationary 
phase. Above the CMC, a change in surfactant concentration is translated in an increase in the 
concentration of micelles in the solution, whereas the number of monomers of surfactant in 
the mobile phase remains constant. Adsorption of an approximately fixed amount of 
surfactant monomers on the stationary phase is also produced, giving rise to a stable modified 
column and regular retention behavior [99,100]. Micellar mobile phases have been used for 
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all kinds of purposes in RPLC. In this thesis, only the possibilities of this technique towards 
the prediction of drug absorption will be presented, an application based on previous 
publications, such as [22,101-103]. 
Surfactants in MLC can be charged positively, negatively or can be neutral. The retention of a 
compound in MLC depends on the type of interaction (electrostatic and/or hydrophobic) with 
the micelles and with the surfactant-modified stationary phase. Non-ionic solutes are 
supposed to be only affected by hydrophobic interactions, charged solutes can be subject to 
hydrophobic and/or electrostatic interactions [97]. When the net charge is the same for 
structurally related compounds, differences in retention arise from differences in 
hydrophobicity. 
The main advantages of MLC are: (i) simultaneous separation of charged and uncharged 
compounds, (ii) direct on-column injection of physiological fluids, (iii) unique separation 
selectivity, (iv) low cost and toxicity, (v) enhanced luminescence detection, and (vi) the 
biodegradability of the solvents used [104,105]. However, MLC is not a very popular 
technique due to poor separation efficiency and the relatively weak solvent strength of 
micellar eluents. The two main approaches that have been used to enhance efficiency in MLC 
are to add low amounts of organic modifier to the mobile phase and to increase the 
temperature. 
The use of an organic modifier is certainly not recommended for compounds with low 
hydrophobicity. For highly hydrophobic compounds, the addition of an organic modifier is 
advised to reduce compound retention times and to improve peak efficiency and resolution. 
The amount of organic solvent is however crucial, since a high percentage can disrupt the 
micelle structure; the maximal allowable concentration depends on the organic solvent and 
the nature of the surfactant [97,100]. 
The retention of a solute in a MLC system can be modified by changing the eluent 
composition in terms of the nature of the surfactant and its concentration, pH (in the case of 
ionizable compounds), ionic strength and/or by the addition of organic modifiers at different 
concentrations [106]. 
McCormick et al. [107,108], provided another possible solution to circumvent the weak 
eluting power of micellar mobile phases compared to conventional hydro-organic mobile 
phases in RPLC. According to them, a possible explanation for the weak eluting power is that 
micelles are excluded from the pores, within which most of the stationary phase is located and 
where analytes spend most of their time. In order to determine whether wide-pore stationary 
phases would overcome this limitation, a study was performed in which several C8 and C18 
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stationary phases with pores ranging from 100 to 4000 Å were investigated using a diverse set 
of test solutes and micellar solutions of anionic, neutral, and cationic surfactants as mobile 
phases. As the pore size of a porous material is increased, the specific surface area is reduced. 
As a consequence, the volume of bonded stationary phase is also decreased. Therefore, under 
equal mobile phase conditions, the retention of a solute in a large-pore column is smaller than 
on an otherwise identical small-pore column. Stationary phases with larger pore sizes 
augmented the eluting power of the MLC mobile phases, also taking into account the drop in 
retention factor with increasing pore size. This could be explained by a better penetration of 
the micelles into the larger pores, such that they are able to reach the solutes at the internal 
surface of the stationary phase better, and elute them in less time [100]. Although all 
surfactant types showed improvement, the greatest effect was achieved with a neutral 
surfactant. Large-pore stationary phases were also found to be effective for the analysis of 
mixtures with varying properties, including highly hydrophobic solutes, which are strongly 
retained on the conventional small-pore stationary phases. 
In order to speed up MLC-analyses, Detroyer et al. [109] tested the performance of a 
monolithic column. In theory, due to the larger porosity, higher flow rates can be applied 
while maintaining the retention characteristics, providing better efficiency and performance. 
The authors concluded that the MLC methods on both monolithic and particle-based columns 
provided highly correlated information. MLC methods could thus be speeded up using 
monolithic columns without major changes in retention characteristics. 
When organic solvents are used in MLC, they partition to the micellar aggregates, and the 
degree of association increases with their hydrophobicity. Like other compounds, organic 
solvent molecules can be located outside the micelles, entry into the palisade, or into the 
micelle core. The first two effects might favour the formation of micelles, whereas the latter 
can substantially increase the amount of organic solvent inside the micelle and produce a 
microemulsion [110]. 
Short-chain alcohols added to an ionic micellar mobile phase show an interesting range of 
behaviors [111]. Methanol, with the shortest carbon chain, is more polar and soluble than the 
other alcohols. It can solvate surfactant monomers more easily, which hinders micelle 
formation, and consequently, a greater amount of surfactant is required to form the micellar 
assemblies (i.e. the CMC increases with added methanol). The effect of ethanol and propanol 
is opposed to methanol. These alcohols remain mainly outside the micelles, dissolved in the 
bulk liquid, but they interact with the micelle surface, reducing repulsion among the ionic 
heads of the surfactant monomers. This favours the formation of micelles and reduces the 
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CMC. Finally, butanol and pentanol are inserted into the micellar assembly, owing to their 
particular structure that combines a polar group with a non-polar chain, similarly to surfactant 
molecules. These alcohols align with the surfactant molecules in the micelle palisade, the 
polar hydroxyl group of the alcohol oriented towards the outer layer and the alkyl chain 
located in the non-polar micelle core. This gives rise to swollen mixed micelles. The use of 
acetonitrile is another possibility, but it should be noted that the effect of acetonitrile on the 
CMC is similar to methanol, in spite of the differences in polarities and structure [100,111]. 
 
II.3.2.1.2 The use of microemulsion liquid chromatography to assess membrane 
permeation 
Microemulsions are dispersions of nanometer-sized droplets of an immiscible liquid within 
another liquid. They can be classified as either oil-in-water or water-in-oil (see Figure II-9), of 
which the latter has only limited applications so far. Oil-in-water microemulsions contain 
droplets of oil (e.g. heptane, octane) dispersed throughout an aqueous buffer. Droplet 
formation is facilitated through the addition of a surfactant and usually also a cosurfactant. 
The surfactant lowers the oil-water surface tension and the cosurfactant usually has the effect 
of reducing the intermolecular repulsion experienced by the surfactant molecule head groups 
by positioning itself in-between them around the oil droplet. Droplets in the microemulsion 
are less than 10 nm in diameter, and therefore do not scatter white light, resulting in the 
solution being optically transparent [112]. As in MLC, the stationary phase is also modified 
by the adsorption of surfactant in microemulsion liquid chromatography (MELC) and a 
secondary partitioning mechanism also exists in MELC where solutes partition from both the 
mobile and stationary phase into the microemulsion droplets. Solutes can easily penetrate the 
microemulsion surface, since this is not rigid as in MLC. In MELC, more complex solute-
solvent interactions exist since the cosurfactant (e.g. butanol) and oil molecules can also be 
adsorbed to the stationary phase. An increase in surfactant, cosurfactant or microemulsion oil 
content gives rise to a decrease in solute retention [113,112].   
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Figure II-9: Schematic representation of oil-in-water and water-in-oil microemulsions. Cosurfactant molecules 
position themselves between the surfactant molecules and reduce the intermolecular repulsion. Modified from 
[114]. 
 
According to Liu et al. [113], a MELC-SDS system containing 1.6 % heptane was superior to 
a MLC-SDS system (with butanol as organic modifier) concerning the capability of predicting 
drug penetration across the BBB for a set of 37 compounds. However, subsequent studies 
illustrated that retention times in some MELC systems were not stable for most drugs, with an 
increasing tendency over time. Therefore, Liu et al. [94] made some adaptions to the MELC-
system, including optimized mobile phase compositions and a rinsing step with water (to 
remove the buffer salt) and with methanol (to remove the adsorbed components) at the end of 
a work session. Also, the retention times of compounds for long-term operations were 
corrected by an internal standard method. Methyl paraben and propranolol could be used as 
internal standards for correcting the retention times. 
 
II.3.2.1.3 Immobilized Artificial Membrane Liquid Chromatography for the 
prediction of drug transport 
Cell membranes provide an environment for several types of molecular processes. In IAMLC, 
an attempt is made to mimic the environment of cell membranes on a chromatographic solid 
support. This type of chromatography, pioneered by Pidgeon et al. [115], started with lecithin 
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as the bonded phase to a silica solid support. Since phosphatidylcholine (PC) is the most 
abundant fraction in lecithin, this is considered as the first phospholipid-based stationary 
phase. 
Based upon this research, a series of innovative IAM chromatography packing materials was 
created. Rhee et al. immobilized lysophosphatidylcholine ligands on aminopropyl silica [116]. 
Hereby, the effect of differences caused by different endcapping groups was also studied, 
indicating that the chromatographic surface endcapped with dodecanoic cyclic anhydride 
provided the most stable column. Ong et al. created a whole new set of IAM chromatography 
packing material [117]. This time, single chain ether phospholipids were immobilized on 
aminopropyl silica. The ether phospholipid ligands were analogs of phosphatidylglycerol 
(PG), phosphatidylserine (PS), phosphatidylethanolamine (PE) and phosphatidic acid (PA). 
These ether phospholipid ligands were also prepared by Qiu et al. [118] using a general 
synthetic route. The biggest difference for these ligands compared to PC ligands, is the 
presence of amines, carboxyls, hydroxyls or phosphate groups that require protection prior to 
immobilization. 
In 1994, the first mixed ligand immobilized artificial membranes were created [49]. These 
IAMs contained two immobilized membrane phospholipids: one PC analog and PE, PS, PG 
or PA as other analog. The second analog was however bonded at only 6-10 mol% relative to 
the molar amount of immobilized PC. The higher amount of PC is – to a certain extent – 
logical, since PC is usually the major phospholipid with a typical cell concentration of around 
40 % of the total lipid. In BBB cells, PS can have a concentration of up to 15 %, creating a 
negatively charged cell membrane. This is why Yang et al. [20] were convinced that an IAM-
surface prepared from PC and a negatively-charged phospholipid could provide a better IAM 
model. As assumed, they obtained better predictions using the IAM surface with both PC and 
PS than with the a purely IAM.PC column. The authors also suggested that the development 
of IAM columns with a phospholipid composition resembling various barriers, such as the 
intestinal barrier and the BBB, might provide intriguing results. However, technical 
limitations with concerns about column consistency and quality control impeded the 
development of this type of columns. 
In 1995, Ong et al. compared a set of three different phosphatidylcholine ligands to study the 
effect of lipid structure on drug binding to IAMs [119]. The three ligands were: (i) a 
diacylated PC ligand, (ii) a single chain ether PC ligand, and (iii) a single chain PC ligand that 
lacks a glycerol backbone (Figure II-10). In this study, solute retention data were almost 
identical for those IAMs, indicating that the structure of the immobilized PC ligand was not 
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critical for the binding of solutes. The most interesting conclusion was that the removal of the 
glycerol backbone was not critical for drug binding of the solutes. Additional study showed 
that a normal IAM.PC column required end-capping with C10 and then C3 alkyl groups. Only 
after end-capping the IAM surfaces, the exact structure of the immobilized phospholipid was 
not critical for predicting the binding of solutes to membranes. End-capping of the residual 
amines is also crucial for an increased column stability. On end-capped IAM surfaces, lipid 
leaching is reduced but not totally suppressed, and retention factors may decrease during a 
column’s lifetime (aging) [116,120].  
 
 
Figure II-10: Structures of three different IAM.PC surfaces used to study the effect of the lipid structure on drug 
binding to IAMs. From left to right: a diacylated PC ligand; a single chain ether PC ligand; a single chain PC 
ligand that lacks a glycerol backbone. The superscript C10/C3 indicates the end-capping with C10 and then C3 
alkyl groups. Modified from [119]. 
 
After additional tests, Pidgeon et al. [121] concluded that the glycerol backbone, the type of 
linkage (ester or ether) between the glycerol backbone and the acyl chain, and the number of 
acyl chains are not important in evaluating the rank order of drug partitioning into membranes 
containing phosphocholine analogues. Based on these findings, the 
δG
IAM.PC
C10/C3
 column (= 
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silica solid support with a single chain PC ligand that lacks a glycerol backbone, end-capped 
with C10 and then C3 alkyl groups) was chosen as column for predicting drug transport since it 
was the easiest to synthesize. Equally important, this column also had significantly shorter 
retention times compared with the other columns. The 
δG
IAM.PC
C10/C3
 column has been 
commercialized by Regis Technologies under the name IAM.PC.DD (see Figure II-11), 
where DD denotes Drug Discovery. As illustrated by Caldwell et al. [120], IAM.PC.DD 
columns are somewhat subject to premature column failure. Data in this study suggested that 
either silica support dissolution occurred or that some of the stationary phase was removed by 
a buffered mobile phase after 7000 column volumes, leading to significant peak broadening 
and decreased k values. 
Another IAM.PC surface has been developed and is known as IAM.PC.DD2 (see Figure II-
11). This column type is less amenable to premature aging. This HPLC column is a 
combination of two other commercialized products: diacylated phosphatidylcholine is 
immobilized on aminopropyl silica and the residual amino groups are end-capped using C10 
and C3 alkyl chains. End-capping can also be established with glycidol and methyl glycolate 
(MG). This converts the residual amino groups into chemically neutral amides, but introduces 
hydroxyl groups, which causes a change in selectivity compared to the IAM.PC.DD and 
IAM.PC.DD2 surfaces. This type of surface is available as IAM.PC.MG (Figure II-11) [122].  
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Figure II-11: Structures of commercially available immobilized artificial membranes. Modified from [122]. 
 
In 1996, Ong et al. [123] tested the ability of surface hydroxyl and methoxy groups to predict 
drug membrane interactions. To do this, 12-methoxy dodecanoic acid and 12-hydroxy 
dodecanoic acid were immobilized on aminopropyl silica. The authors concluded that surface 
PC headgroups, surface OH groups and surface OCH3 groups all provide the properties 
necessary to predict drug membrane interactions better than reversed-phase C18 surfaces. 
However, the IAM.PC column was a much better in vitro screen for predicting drug-
membrane interactions compared to the OH and OCH3 bonded phases. Here, they also 
compared the double-chain IAM.PC.DD2 and the single-chain IAM.PC.DD stationary phases 
using 16 compounds from three structurally related series. A good correlation was found 
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between the two surfaces, and the results indicated that the double-chain IAM.PC.DD2 is 
more hydrophobic. 
Pidgeon et al. [124] also suggested that IAM chromatography, unlike n-octanol:water 
partitioning, can predict membrane transport of structurally unrelated drugs. Therefore, 
Salminen et al. compared the IAM retention factor (on a IAM.PC.DD column) with the n-
octanol:water partition coefficient as a descriptor in multiple regression models for predicting 
the brain/blood concentration ratios [125]. They found that carboxylic acids, which were 
almost completely in the anionic form at pH 7.4, formed a subgroup that behaved differently 
in IAM chromatography than the n-octanol:water partition coefficients (log Koct). The authors 
concluded that IAM chromatography seemed a useful method for the prediction of solute 
distribution in membranes. They did however not consider the log kIAM values to be better 
performing than the log Koct as a parameter in models predicting brain/blood concentration 
ratios of drugs. 
Reichel et al. [126] also investigated the potential of the IAM technology for the prediction of 
drug delivery to the brain. Although this study was based on a limited set of compounds, it 
suggested that IAM columns were suitable for ranking compounds towards entering the brain. 
They suggested that the predictive potential of log kIAM was comparable to the physico-
chemical descriptors log D7.4, log P and log kw for lipid soluble compounds, but was superior 
for more polar compounds. Therefore, they concluded that IAMLC was a suitable approach to 
predict drug penetration across the BBB.  
Another way to construct IAM stationary phases has been introduced by Krause et al. [127]. 
They reported on the use of noncovalent IAM surfaces, which are constructed by dynamic 
coating of a reversed-phase C18 column with phospholipids, thereby resulting in a bilayer 
structure. The column stability was found to be sufficient for multiple column runs in the 
presence of reasonable eluent concentrations [23]. 
Until now, research in IAMLC was almost exclusively performed on the commercially 
available PC-based stationary phases. This is however not completely realistic, since PC is 
only one of the phospholipids present in membranes. Very recently, Zhao et al. [128] 
developed a novel mixed phospholipid functionalized monolithic column through an easy 
one-step co-polymerization approach. They illustrated that is was possible to quantitatively 
and accurately adjust the phospholipid composition on the monolithic column. A possible 
advantage of mixed phospholipid functionalized column is that they can better mimic the 
binding of drugs to a specific biomembrane and better predict corresponding 
pathophysiological effects. The test results on the columns were reproducible. The 
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introduction of the negatively charged PS into the stationary phase significantly enhanced the 
contribution of electrostatic interaction. Acidic analytes were subject to a stronger 
electrostatic repulsion (resulting in a shorter retention time); while a stronger electrostatic 
interaction for the basic analytes resulted in a higher retention. 
 
As in all other HPLC-related in vitro techniques, the drug retention factor (k) can be 
calculated from the retention time (tr) of drug molecules on IAM chromatography columns 
according to the equation, 
 
𝑘 =  
𝑡𝑟 −  𝑡0
𝑡0
 (1) 
where t0 corresponds to the column dead time or void volume. The retention factor is linearly 
related to the equilibrium partition coefficient K: 
 
𝑘 =  
𝑉𝑠
𝑉𝑚
 𝐾 (2) 
Where Vm is the total volume of solvent within the IAMLC column and Vs is the volume of 
the IAM interphase created by the immobilized phospholipids. The phase ratio Vs/Vm is 
constant for a given IAM column. Therefore, it is not necessary to make the difficult 
experimental measurement of Vs. By measuring k, the drug partition coefficient into the IAM 
interphase can be determined [121,123]. 
For hydrophilic compounds, retention factors can be determined by using a purely aqueous 
mobile phase. For lipophilic drugs, it is necessary to add an organic modifier (methanol or 
acetonitrile) to the mobile phase to accelerate the elution, after which an extrapolation to 0 % 
modifier should be performed. Concerning the obtained log k values, the choice between 
methanol and acetonitrile causes no significant difference. However, methanol is more 
appropriate for charged compounds [122]. The obtained log k values can be used for the 
prediction of drug transport across biological barriers. For most authors, the retention factor 
derived from IAMLC alone is not sufficient to predict drug intestinal absorption or log BB 
values, and the addition of other descriptors (e.g. molecular weight, hydrogen-bonding, …) is 
generally needed to enhance the correlations [129]. 
 
II.3.2.1.4 Other HPLC-based techniques 
The retention of compounds on RPLC using octadecyl silica (ODS) stationary phases was 
first used to correlate with biological activity. However, with this stationary phase, electronic 
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interactions between solutes and the polar lipid head groups of the membranes are not 
modeled [119]. 
Immobilized liposomes have been proposed as stationary phases for chromatographic analysis 
of membrane-solute interactions. Traditionally, drug-liposome studies have been carried out 
with free liposomes suspended in aqueous solutions. Immobilized liposome chromatography 
(ILC) uses stationary phases where liposomes are steric, hydrophobic, electrostatic or 
covalently immobilized into gel beads. The column preparation is simple and they are stable 
for a long time. These systems seem to be more similar to natural membranes than other, 
more simplified models. ILC turned out to be a good approach to study drug-membrane 
interactions since the phospholipid ratios used to prepare the liposomes can be modulated to 
get liposomes with phospholipid, protein and cholesterol ratios very similar to the 
composition of the membrane of interest, except for the biological membrane asymmetry 
[130-132].  
Special columns for quantifying the interaction of drugs with serum proteins (bovine serum 
albumin, human serum albumin (HSA) and α-acid glycoprotein (AGP)-columns), keratin, and 
collagen [133] have also been developed [22]. The HSA column contains a chemically 
bonded protein stationary phase. Although HSA binding is mainly related to lipophilicity, 
some compounds (acidic and neutral) show stronger binding, which can be related to known 
binding sites [134]. AGP is a serum protein that binds mainly basic drugs. AGP has only one 
common drug binding site, which binds drugs through hydrophobic and electrostatic 
interactions [133]. Affinity HPLC on immobilized protein stationary phases can be a 
convenient tool for studying drug-protein interactions. These interactions are important, since 
high plasma protein binding can reduce brain penetration [135] as it affects the unbound (free) 
drug concentration that is available to diffuse from the blood and reach the target tissue [136]. 
Both HSA binding and IAM partition showed similar octanol/water partition coefficients for 
neutral compounds. However, it was found that the positively and negatively charged 
compounds bind differently to HSA and IAM. Negatively charged compounds bind more 
strongly to albumin, whereas positively charged compounds bind more strongly to the 
immobilized phosphatidylcholine phase. It has been found that the difference between the 
IAM binding and HSA binding showed good correlation with the volume of distribution of 
the compounds. These findings support the general observations that positively charged 
compounds have a larger volume of distribution [137]. 
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II.3.2.2 The assessment of membrane permeation by capillary electrophoresis 
As mentioned before, the concept of biopartitioning chromatography (BPC) also led to the 
introduction of the use of biomembrane-mimetic structures in capillary electrophoresis (CE). 
The biomembrane-mimetic structures can be immobilized physically or chemically on the 
capillary wall, forming a stationary phase for the compounds to partition in. This is called 
capillary electrochromatography (CEC). They can also be added into the running buffer in CE 
to form a pseudostationary phase in electrokinetic chromatography (EKC), such as micellar 
electrokinetic chromatography (MEKC), microemulsion electrokinetic chromatography 
(MEEKC), liposome electrokinetic chromatography (LEKC), vesicle electrokinetic 
chromatography (VEKC), and bicelle electrokinetic chromatography (BEKC) [114]. A 
schematic representation of the corresponding membrane-mimetic structures of these 
techniques is provided in Figure II-12. So far, the use of CE-based techniques to predict drug 
penetration across the BBB is scarce (to our knowledge only in LEKC); therefore, this section 
should be considered rather as an indication of possible future extensions. 
CEC can be considered as a combination between HPLC and CE, since there is both 
electrophoretic migration of the solutes and interaction between the solutes in the mobile 
phase and the stationary phase. According to Wang et al. [138], the most popular strategy to 
reduce protein adsorption to the silanol groups on the surface of fused-silica capillaries is to 
shield the silanols with a coating. The authors proposed a “semipermanent” surfactant coating 
using the unsaturated phospholipid 1,2-dioleoyl-sn-glycero-3-phosphocholine. The authors 
demonstrated that the coatings were stable for up to 20 h. The reproducibility was, however, 
inferior to permanent coatings. Because of the possibilities in phospholipid choice, this 
technique could provide a good alternative type of in vitro BBB predictions. 
Micellar Electrokinetic Chromatography (MEKC), a mode of capillary electrophoresis (CE) 
that incorporates micelles acting as pseudo-stationary phases has proven to be useful for 
describing the biological behavior of different kinds of compounds. MEKC can be viewed as 
a hybrid of MLC and capillary zone electrophoresis (CZE) [22]. MEKC is an excellent tool 
for the analyses of neutral compounds. In some cases, the use of MEKC is limited because of 
a poor solubilization capacity of micelles for hydrophilic molecules and large molecules 
[139]. Recently, Lamalle et al. [140] studied the effective mobilities of neutrals, cations and 
anions at neutral, basic and acidic pH with the background electrolyte containing increasing 
SDS concentrations and acetonitrile proportions. At high SDS concentrations and low 
acetonitrile proportions, the migration order was reversed compared to CZE: electroosmotic 
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flow (EOF) first, then anions, then neutrals and cations. The analytes-micelles interactions 
became weaker with decreasing SDS concentration and increasing acetonitrile proportion. 
Using a high acetonitrile proportion, the migration order is again comparable to that in CZE. 
Using these considerations in a proper way, MEKC can be an attractive tool not only for the 
separation of neutral compounds, but also for variously charged analytes. 
The possibility of utilizing microemulsions in electrokinetic chromatography of ionic and 
non-ionic samples has been demonstrated for the first time by Watarai [141]. The 
microemulsions are similar to micelles in that they can solubilize hydrophobic compounds, 
but with a much larger capacity because of the larger droplet size. As with MELC, there are 
two principal types of MEEKC: oil-in-water and water-in-oil. Again, oil-in-water 
microemulsions are typically employed, which contain oil droplets (e.g. n-octane), suspended 
in buffered water. Droplet formation is facilitated by addition of a surfactant above its CMC 
and a short-chain alcohol (e.g. 1-butanol) is added as a cosurfactant, which further lowers 
surface tension and stabilizes the microemulsion system. As solutes can penetrate the surface 
of the microemulsion droplets more easily than the more rigid MEKC micelle, MEEKC can 
be applied to a wider range of solutes. MEEKC has therefore been found to be superior to 
MEKC regarding separation efficiency, probably due to the improvement in mass transfer 
between the microemulsion droplet and the aqueous phase, mediated by the cosurfactant [142-
144]. In MEEKC, separation of charged analytes occurs based on their charge and relative 
electrophoretic migration toward the anode or cathode. At high pH values, the EOF is strong 
and sweeps all solutes (even anions) toward the cathode and through the detector. The 
microemulsion droplet acts as a pseudo-stationary phase and allows separation of neutral as 
well as charged analytes. The more hydrophobic the solute is, the more it will partition into 
the microemulsion droplet and the longer it will take to migrate to the detector [145]. 
The first report in which LEKC was tested as a tool to profile drug penetration across the 
BBB was published in 2007 [146]. LEKC has some advantages compared to IAM, such as 
shorter analysis time and lower cost. The composition of liposomes is also easy to be 
controlled via adjusting the type and mole fractions of phospholipids [96,147] as well as 
incorporating cholesterol and even proteins. Some additional info about liposomes can be 
found in section II.2.2. 
Vesicles (in VEKC) are large aggregates of amphiphiles containing a spherical bilayer 
structure encapsulating an internal cavity of solvent, while liposomes are simple vesicles 
formed specifically by phospholipids. The bilayer structure of a vesicle makes it attractive as 
a good membrane-mimetic structure. In contrast to the poor stability and laborious preparation 
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procedures for liposome, selected amphiphiles can form stable unilamellar vesicles 
spontaneously by simply mixing different amphiphiles solution in the proper ratio 
[114,148,149]. 
In BEKC, a characteristic bicelle structure is introduced in CE. The bicelle has intermediate 
morphology and properties between lipid vesicles and classical mixed micelles. As micelles, 
they are non-compartmentalized, optically transparent, uniform and stable dispersion system 
in a wide pH range and in varying ionic strength. As vesicles, bicelles are readily prepared in 
aqueous solution by simply mixing the long-chain lipid DMPC and the short-chain lipid 
DHPC in the proper ratio [114,150]. Additional information about bicelles can be found in 
section II.2.3. 
 
 
Figure II-12: A schematic representation of immobilized biomembrane-mimetic structures (CEC) and these 
biomembrane-mimetic structures as pseudo-stationary phase (other techniques). Modified from [151,152,114]. 
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II.3.2.3 Parallel artificial membrane permeation assay to predict drug transport 
The main objective of the parallel artificial membrane permeation assay (PAMPA) is the 
classification of passively absorbed compounds, focusing on the transcellular transport route. 
PAMPA is based on a 96-well microtiter plate technology. The technique involves a donor 
compartment and an acceptor compartment separated by a filter supporting a liquid artificial 
membrane. The artificial membrane can be composed of a variety of phospholipid mixtures. 
The compound to be tested is placed in the donor compartment and is allowed to permeate 
between the donor and the acceptor compartments through the artificial membrane [153]. 
This assay enables measurement of hundreds of compounds per day. The greatest potential 
lies in the screening of chemical libraries. A PAMPA-BBB study using porcine brain lipids 
has been suggested as an improvement of the prediction of BBB penetration. Advantages of 
this assay were the high throughput, accuracy and reproducibility, low cost and low amount of 
sample required (< 0.5 mg) [154]. Unfortunately, PAMPA is a poorly characterized system 
which enables only a simple classification of compounds, e.g. low, intermediate and high 
absorption probability. Also, PAMPA underestimates the absorption of compounds that are 
actively transported or hydrophilic compounds with a low molecular weight [155]. 
PAMPA also requires UV absorbance, which many compounds do not exhibit. The long 
incubation time (up to 15 hours) may present problems with unstable compounds. PAMPA 
also ignores the role of enzymes, influx and efflux transporters, and the paracellular pathway 
[93]. A test was also performed by Galinis-Luciani et al. [156] regarding the usefulness of 
PAMPA. The authors stated that augmenting the alkyl chain length results in an increased 
PAMPA value, indicating that PAMPA was largely a measure of lipophilicity. After 
comparing PAMPA values with log D7.4 values, the authors concluded that the calculated log 
D7.4 provided almost the same outcome, which indicated the limited asset of PAMPA in drug 
discovery. 
 
II.3.2.4 Bio-mimetic artificial membrane permeation to predict drug transport 
Bio-mimetic artificial membrane permeation (BAMPA) was introduced as an improved 
version of PAMPA by Sugano et al. [157]. Like PAMPA, BAMPA can be used to predict 
transcellular pathway permeation. In BAMPA, the composition of the lipid membrane was 
modified to mimic the intestinal brush border membrane. Based on this composition, only 
predictions for intestinal drug absorption have been made; not for BBB transport. The effect 
of the chain length of the organic solvents (alkyldienes) and the effect of modification of the 
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lipids was studied. Shorter chain alkyldienes showed larger permeability of the compounds. 
Modification of the lipid composition had a significant effect on the permeability of charged 
drugs. 
Sugano et al. [158] also used the paracellular pathway prediction model in combination with 
BAMPA. This way, the permeability of both transcellular and paracellular pathway was 
estimated separately, and combined to predict total passive intestinal absorption. This model 
was shown to predict the total passive intestinal permeability more adequately than BAMPA 
alone. 
 
II.3.2.5 The use of cell lines for the prediction of intestinal absorption 
The Caco-2 cell line, derived from a human colon adenocarcinoma, has provided an in vitro 
cellular epithelium model to predict the intestinal permeability of drugs [115]. These cell lines 
are cultivated as monolayers on permeable filters for studies of the transepithelial transport of 
drugs. The studies have shown that cell monolayers can be used to identify drugs with 
potential absorption problems and possibly also to predict in vivo drug absorption [159]. The 
transport of drugs across the intestinal epithelium may occur by one or more of four different 
routes: the passive transcellular and paracellular routes, the carrier mediated route and by 
transcytosis. Caco-2 monolayers have been used to study drug transport by all four routes. 
The Caco-2 cell line results can be subjected to some variability. The properties of Caco-2 
monolayers vary based on differences in passage number [160], time in culture [161], the 
extracellular (filter) support [162] and the cell culture medium [163]. All sources of 
variability should be taken into account when results from different laboratories are compared 
[159]. The results obtained with Caco-2 monolayers suggest that the best correlation with the 
in vivo absorbed fraction is obtained for passively transported drugs. 
Using Caco-2 cells, false negatives are likely to be generated with actively transported drug 
candidates. Thus, the Caco-2 cell model can only serve as a one-way screen: compounds with 
high permeability in the model are typically well absorbed in vivo, while compounds with low 
permeability cannot be ruled out as poorly absorbed compounds in vivo [71]. 
Caco-2 cells provide a high throughput in vitro model for the evaluation of a large number of 
drug candidates for their intestinal absorption potential. Preparing a fully differentiated 
confluent Caco-2 cell monolayer is, however, very time-consuming and generally requires a 
3-week cell culture period with 8-10 laborious cell feedings. Therefore, alternatives for this 
long preparation were sought and evaluated. Chong et al. [164] reported the use of a 3-day 
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alternative preparation step. This method also provided a reasonable correlation between the 
in vitro permeability through the adapted Caco-2 cell monolayer and the in vivo absorption in 
humans. The authors thus concluded that the new type of monolayer appeared to be a more 
convenient and productive absorption screening tool compared to the conventional 3-week 
system. Also, the use of an automatic liquid handling system has been reported to increase 
capacity and significantly decrease the need for manpower during experiments [165]. 
Several authors have isolated numerous subclones from the Caco-2 parental cell line, among 
which the TC-7 clone. Although TC-7 had similar morphological characteristics compared to 
Caco-2 cell monolayers, the TC-7 clone was more homogenous and its growth rate and cell 
density were greater. Regarding some parameters, the TC-7 clone would be a more valuable 
tool for investigating transport characteristics compared to parental Caco-2 cells [166].  
 
II.3.2.6 The use of Madin-Darby canine kidney cells for the prediction of drug 
transport 
Madin-Darby canine kidney (MDCK) cells differentiate into columnar epithelial cells and 
form tight junctions when cultured on semipermeable membranes. A membrane permeability 
comparison between MDCK and Caco-2 cells gave a satisfactory correlation to human 
absorption [167]. Given the fact that Caco-2 cells are derived from human colon carcinoma 
cells whereas the MDCK cells are derived from dog kidney cells, it is very likely that the 
expression level of various transporters greatly differs in these two cell lines.  
One of the major advantages of MDCK cells over Caco-2 cells is the shorter cultivation 
period (3 days vs. 3 weeks). This shorter cell culture time becomes a significant advantage 
considering reduced labor and reduced downtime in case of cell contamination [71]. The 
MDCK assay has been extended to predict passive BBB permeability. It gave good prediction 
qualitatively for the extent of brain exposure and reasonable prediction of the rate of brain 
uptake in vivo for a small set of compounds [79]. However, a study on a large set of CNS 
drugs with diverse physicochemical properties showed that MDCK had low prediction of 
passive BBB permeability in vivo based on in situ brain perfusion assay [86]. 
 
II.3.2.7 Other methods 
Two other in vitro models for the BBB are RBE4 cells and the ECV304 cell line cocultured 
with C6 glioma cells. RBE4 is an immortalized rat brain microvessel endothelial cell line that 
expresses several BBB transporters. ECV304 cells have an endothelial phenotype, although 
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they are a clonal derivative of the bladder carcinoma cell line. The cells show upregulation of 
BBB features when cocultured with C6 glioma cells [168].  
Bovine and porcine brain microvessel endothelial cell (BMEC) cultures have also been 
developed. Although most research has focused on the development and characterization of 
bovine BMEC cultures as in vitro models for the BBB, studies have shown that porcine 
BMECs can also serve as an appropriate model [169]. BMEC monolayers is a carrier-
mediated mechanism which can be used for in vitro log BB computation [170,171]. The 
monolayers are mostly made based on bovine BMECs, which are soaked in a buffer on both 
sides. BMECs form a complete monolayer after 10-14 days in culture, these monolayers can 
be used for permeability studies. The model created by Usansky et al. [171] demonstrated a 
reasonable ability to compute in vivo log BB values, regardless of the involvement or 
mechanisms of carrier-mediated transport. 
Human umbilical endothelial cells have also been used as BBB models [172]. The advantage 
of these cells is that they are a human cell line, however, not of cerebral origin. 
The octanol:water system has been very successful and became the basis of the QSAR 
methodology. Unfortunately, this system can only explain membrane transport for a 
homologous series of drugs. The reason is that the bulky n-octanol isn’t an ideal model for a 
biomembrane. A biomembrane consists of ordered hydrophilic and lipophilic regions with 
anisotropic and interfacial properties, while n-octanol is an isotropic
3
, bulky solvent. Also, 
drug-membrane interactions are the sum of diverse intermolecular forces, including 
hydrophobic force, electrostatic force, hydrogen bond and steric effect; the octanol:water 
system only models hydrophobic force and partial hydrogen bond [114]. The conventional 
shake-flask measurements are time-consuming and tedious to make, and require relatively 
large amounts of solute. Some solutions to these problems were provided, including 
microscaling and an automated parallel plate assay [23]. 
Liquid liposomes possess the most structural similarity to the bilayer biomembranes. It has 
been shown that solute partitioning into liposomes is virtually identical to solute partitioning 
into cell plasma membrane [48]. However, the liposome procedure is time-consuming and 
tedious and includes four steps: (i) preparation of the liposome, (ii) equilibration of the solute 
in the liposome suspension, (iii) quantitation of the free solute in the presence of liposomes, 
and (iv) correction for the amount of drug that has partitioned into the aqueous space of the 
liposomes [121]. Other disadvantages of the liposome method are: difficulty in separating the 
                                                 
3
 Uniform physical properties throughout the system 
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free drug, sample amount and purity requirement and poor reproducibility. These factors limit 
the use of liposomes as an in vitro model for the large-scale screening of drug permeability in 
early drug development [114]. Additional information about liposomes can be found in 
section II.2.2. 
 
II.3.3 The prediction of drug transport across the blood-brain barrier with in silico 
systems  
Apart from experimental techniques, computational approaches have been developed to 
predict the BBB permeation of new chemicals. These computational approaches are referred 
to as in silico systems. In silico systems offer several advantages compared to in vivo and in 
vitro systems: they are fast and cheap and can be performed even before the compound is 
synthesized.  
Over the years, various authors have attempted to predict BBB transport using parameters 
such as lipophilicity (log P), solvatochromic parameters, H-bonding capacity, topological 
indices, polar surface area (PSA), and a variety of descriptors [173]. Since in silico procedures 
are very fast and fully automated, the prescreening of virtual libraries and other compound 
sets prior to synthesis or purchase is possible. Therefore, in silico calculations can and should 
certainly be performed as an initial step in drug discovery projects where BBB penetration is 
an issue [174]. 
The lack of reliable data on which to base the development of the models is, however, a point 
of concern. Large and well-balanced datasets of reliable and structurally diverse data are a 
prerequisite for the development of computational models that can be implemented as routine 
screens in the drug development process. Unless the models are derived from such databases, 
their utility will remain limited to compounds closely related to the training sets used to 
develop the models [93,23]. Since the amount of in vivo log BB data is limited (only around 
350 compounds, of which most are mentioned in Appendix A), the scope of in silico models 
is also limited. 
 
II.3.3.1 Examples of in silico predictions of log BB values 
In 1992, Vandewaterbeemd et al. [175] established a relationship between the calculated polar 
molecular surface areas of drug molecules and uptake in the BBB. The polar molecular 
surface area is here defined as the sum of the parts of the surface area associated with polar 
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atoms, e.g. oxygen, nitrogen and hydrogen attached to polar atoms. It was however 
demonstrated that the relationship was very poor for compounds outside the training set, 
suggesting that the training set was insufficient to derive a generally applicable QSAR for 
predicting log BB [176]. 
In 1999, Clark [174] published his results for the log BB calculation using only the PSA and 
calculated log P as variables. Using 55 compounds, a correlation coefficient of 0.887 was 
obtained. The obtained equation was also applied on two test sets and proved to perform 
better than other in silico methods. Unfortunately, the use of only two terms introduces an 
overdependence on consistent log P estimates. Also, for compounds with many rotatable 
bonds, the PSA term may be influenced by the conformational choice [177]. 
Liu et al. [178] defined a new hydrophobicity descriptor and developed a simple predictive 
model of BBB penetration for early screening in drug discovery. The so-called lipoaffinity 
descriptor was calculated by adding the contributions to the log P values of all but nitrogen 
and oxygen atoms. The final model used only the molecular weight (MW) and the lipoaffinity 
descriptor and still provided a correlation coefficient of 0.889 for the training set of 55 
compounds used in the study of Clark [174]. Since the calculation time for MW and the 
lipoaffinity descriptor is very short, the authors concluded that their model was at least as 
good as other models reported in literature. 
In 2003, Subramanian et al. [177] proposed several PLS-based models starting with the 
assumption that PSA and log P terms are interesting for log BB prediction. The correlation 
coefficients for the derived models ranged from 0.90 to 0.92 for a training set of 58 
compounds using only 7 descriptors. The most effective model was able to classify 90 % of 
the molecules correctly for qualitative CNS permeation prediction. 
In 2004, Fu et al. [179] obtained a simple two-descriptor (molecular volume and PSA) model 
for a training set of 79 compounds with a correlation coefficient of 0.83. The log BB values 
predicted for the test set were in good agreement with the experimental ones. 
Abraham et al. [77] used the general linear free energy relationship to predict the log BB 
values. For a set of 302 compounds, a correlation coefficient of 0.87 was obtained. When 138 
of these compounds were used as a test set, the correlation coefficient still reached 0.84, a 
very good correlation based on the large number of compounds. The authors emphasized that 
the predictive value of the training set was only valid for a restricted chemical space. 
Therefore, predictions of compounds in the test set are only valid if the compounds occupy 
the same (or a similar) chemical space as the training set. 
Description of the structure, function and delivery across the BBB 
 
54 
 
In 2006, Garg et al. [180] tried to generate accurate and reliable BBB models able to mimic 
the in vivo situation closely. Therefore, they tried to take active transport of the molecules 
into consideration in the form of their probability of becoming a substrate to P-gp. Their 
results indicated that the P-gp plays a role in BBB permeability for some of the molecules. 
Seven descriptors were used for model building and a correlation coefficient of 0.90 was 
achieved for a training set of 132 compounds. 
Fu et al. [75] created a predictive model for BBB penetration using only the molecular weight 
and the number of polar atoms (oxygen, nitrogen and attached hydrogen atoms) as structural 
descriptors. Using a training set of 86 compounds and a test set of 25 compounds, a 
correlation coefficient of 0.86 was achieved. From the derived equation, it could be concluded 
that the log BB of a compound is inversely correlated with its hydrogen-bonding capacity. 
Because of its simplicity and easy computations, the model was proposed to be suitable for 
the rapid prediction of the BBB penetration of drug candidates. 
Guerra et al. [181] used an artificial neural network for the prediction of BBB permeation. 
The molecules were defined by the CODES program, for which only the SMILES codes (i.e. 
the chemical structures) were needed. The developed model had a correlation coefficient of 
0.89, the correlation coefficient for the external test set was 0.85. 
Shen et al. [182] developed a chemometric method called genetic algorithm based variable 
selection for modeling the BBB penetration. In this method, each combination of variables 
was represented as an individual, whose fitness was determined by MLR analysis. The genetic 
operations were executed so that a “fitter” population could be obtained after several 
regulations. The best model contained six descriptors with a correlation coefficient of 0.85. 
The predicted correlation coefficient for an external test set was 0.84. 
Yan et al. [183] achieved a correlation coefficient of 0.90 using MLR analysis with 14 
descriptors on a training set of 198 compounds. The correlation coefficient of the test set of 
122 compounds was still 0.89. 
Although log BB values were nicely predicted by these in silico models, we chose to perform 
predictions based on in vitro chromatographic models. Previously, it was shown that 
chromatographic descriptors can add valuable information to in silico models based on 
theoretical descriptors [184]. The use of computational in silico models can help in initial 
screening and effectively accelerate the drug development process, but in vitro and in vivo 
studies will remain necessary tools to support clinical studies and advancements in drug 
discovery [185]. 
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II.3.3.2 Classification systems for the prediction of drug transport 
Several rule-based methods for BBB permeation have been published in the literature. Van de 
Waterbeemd et al. [186] analysed 125 marketed drugs and proposed a limit for the polar 
surface area (PSA) of 90 Å and for the molecular weight of about 450. On the basis of 776 
orally administered potential CNS drugs, Kelder et al.[187] found a lower limit for the PSA 
(60-70 Å). Norinder et al. [188] proposed a simple system based on two rules: (i) if the 
number of N + O is five or less in a molecule, it has a high chance of entering the brain, and 
(ii) if log P – (N + O) > 0, then log BB is positive. Up to 90 % of correct classifications were 
obtained by testing these classification rules on several data sets. Pardridge [37,189] stated 
that a drug is probably a poor CNS-penetration molecule if the MW of the drug is > 400 
Dalton, if the molecule is a substrate for active efflux transporters and/or the drug forms 8 or 
more H-bonds. 
For classification purposes, very often artificial neural networks (ANN, see next section) are 
used. They are robust to noise and allow fast and accurate predictions. 
 
II.4 Regression models for the prediction of blood-brain barrier transport 
The prediction of the log BB values of compounds can be performed by various 
computational methods, such as multiple linear regression (MLR), principal components 
analysis (PCA), partial least squares (PLS), multivariate adaptive regression splines (MARS), 
ridge regression (RR), Volsurf, genetic algorithms, ANN, k Nearest Neighbor and molecular 
dynamics [132,153,180,190,184,191]. Most of these computational models are briefly 
explained in section II.4.1. These models can be used for quantitative structure-retention 
relationship (QSRR), QSAR, and quantitative retention-activity relationship (QRAR) methods 
(section II.4.2). 
 
II.4.1 Computational models to establish relationships between descriptors and 
values of interest. 
Linear regression is an approach for modeling the relationship between a dependent variable y 
and one or more independent variables X. When there is more than one independent variable, 
and both dependent and independent variables are numerical, the process is called multiple 
linear regression (MLR). This approach examines relations between the independent variables 
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and the dependent variable at the same time, which can deliver a prediction model following 
equation (3). 
 𝑌 =  𝛽0 +  𝛽1𝑋1 + 𝛽2𝑋2 + ⋯ + 𝛽𝑛𝑋𝑛 (3) 
In principle, MLR can be used with very many independent variables. However, if the number 
of independent variables gets too large (e.g. greater than the number of observations), the 
model will likely fit the sampled date perfectly but will fail to predict new data well. This 
phenomenon is called overfitting. In such cases, there may be only a few underlying or latent 
factors that account for most of the variation in the response. The general idea of PLS is to try 
to extract these latent factors. The latent variables in PLS are linear combinations of the 
descriptive variables in the data set, but instead of maximizing the variance in the matrix with 
descriptive variables, the covariance with the response variable is maximized. The scores on 
the PLS factors are used as input for MLR after selection of the optimal number of PLS 
factors to be considered. If the number of extracted factors is greater than or equal to the rank 
of the sample factor space, PLS is equivalent to MLR [184,192,193]. 
With PCA, the number of original variables is reduced to a few latent ones called principal 
components, that still contain the main information from the original data set. The first new 
variable is chosen in the direction of the largest variance in the data and thus contains the 
main information. The second principal component is defined so that it is orthogonal to the 
first one and it represents a maximum of variance that was not explained by the first one, etc 
[194]. A drawback of the PCA technique is that no importance is given to how each variable 
may be related to the dependent or target variable. In a way it is an unsupervised dimension 
reduction technique. Due to the supervised nature of its algorithm, PCA is less efficient than 
PLS when a dependent variable for a regression is specified [193]. 
MARS is a local modeling technique dividing the data space in several, possible overlapping 
regions and fitting truncated spline functions in each region. In general, a MARS analysis 
consists of three steps. In the first step, the variable for which the selected pair of spline 
functions gives the best description of the response is selected as starting point for the model. 
After the selection of this first pair of splines, new spline functions are added stepwise. In 
each step, the pair of splines is added that gives the best improvement in the description of the 
training set. In the second step of the analysis, the global MARS-model is pruned using a 
sequence of general cross-validations alternated with 10-fold cross-validations. In the final 
step, the optimal model is selected using a cross-validation technique [184]. 
An artificial neural network is a biologically inspired computer algorithm designed to treat the 
data in a manner emulating the learning pattern in the brain. The computer-based network 
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accepts a set of input values, transforms these, and generates an associated set of output 
values. Through an iterative learning process, the network refines the information derived 
from the input values (descriptors) in order to reproduce an associated set of property values 
(e.g. log BB). A potential problem with the use of an ANN is that it may overtrain i.e. derive a 
relationship which is too specialized. This problem is averted by delegating a portion of the 
compounds to serve as a validation set. By tracking the validation set error, the optimal set of 
weights to be used as the final predictive model can be identified [195]. Complex methods 
like PLS and ANN suffer from the drawback of being hard to interpret, whereas simple 
methods like MLR often yield less accurate results or even only rough guidelines [196]. 
The k Nearest Neighbor method is very similar to the local lazy regression. The latter is a 
modeling approach that utilizes linear models for individual neighborhoods and obtains a 
prediction for a query molecule using its local neighborhood, rather than considering the 
whole data set. The neighborhood of a query molecule in the data set is determined on the fly. 
The k Nearest Neighbor method has been utilized as a classification method, to predict 
penetrating and nonpenetrating BBB structures, and to estimate log BB values [191]. 
There are several programs available that are able to perform one or more of the above-
mentioned computational models, such as: Microsoft Excel, Matlab, R, Minitab, Codessa Pro, 
QSAR-BENCH, SAS, SPSS, … 
 
II.4.2 The use of QSRR, QSAR and QRAR 
The principal aim of QSRR is to predict retention data from the molecular structure. 
However, this methodology can also be used for the prediction of physical properties (e.g. log 
P values) from retention data. QSRR is a technique for relating the variations in one (or rarely 
several) response variables (Y-variables) to the variations of several descriptors (X-variables), 
with predictive or at least explanatory purposes. Y-variables are normally called dependent 
and X-variables are called independent variables. One of the Y- or X-variables should be 
related to chromatographic retention, the others should comprise the molecular structure. 
Héberger [197] provided an excellent overview about QSRR, including QSRR examinations 
performed in micellar liquid chromatography. 
QSAR describes the effect of the molecular structure (in terms of lipophilic, electronic and 
steric descriptors) on the biological activity of a compound. In classical QSAR based on MLR 
analysis, the number of samples required is preferably more than ten times the number of 
molecular descriptors needed to obtain both interpretative and predictive equations, which is 
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the main purpose of QSAR studies. However, most of the time it is almost impossible to 
collect enough data for the QSAR studies of a family of drugs. This problem can be solved in 
two ways: (i) the use of latent variables as an alternative to the original descriptors and 
activities, such as those obtained by PCA or PLS methods; and (ii) the reduction of the 
number of descriptors. Unfortunately, for most situations several descriptors must be included 
in order to obtain adequate models [22]. 
The integration of chromatographic experiments leads to the field of QRAR. QRAR is often 
used if the retention data are used as independent variables to predict biological activity of the 
molecules. 
 
II.4.3 Validation of the computational models 
Model validation can be performed by cross-validation methods. Both leave-one-out cross-
validation (LOOCV) and leave-group-out cross-validation (LGOCV) are often performed. In 
the LOOCV procedure, each compound is removed once from the dataset, and the remaining 
compounds are used to develop a new model, with which the left-out compound is then 
predicted [173]. The LGOCV works according to a similar procedure, with the major 
difference that a group of compounds is removed from the dataset instead of one compound. 
LGOCV should actually be preferred over the LOOCV method for assessing the predictive 
power of MLR models, since it is known to be statistically more valid. However, the number 
of reports including LGOCV statistics is very small, mainly due to the lack of such a function 
in common statistical packages [198]. A LGOCV can also be named a leave-many-out cross-
validation, leave-k-out cross-validation or a leave-X %-out cross-validation [183]. 
In this thesis, the LOOCV method is used to obtain a good model, although a lot of other 
methods and variants thereof could have been used. These methods include the Akaike 
information criterion (AIC), the Bayesian information criterion (BIC) [199,200], the 
‘predictive divergence for incomplete observation models criterion’ [201], streamwise 
regression, risk inflation criterion [202], accumulative prediction error, stochastic complexity 
[199], and ‘least absolute shrinkage and selection operator’ [203]. Among these methods, the 
AIC and BIC have been extensively used. 
While the AIC was proposed as an approximately unbiased estimator of the ‘mean expected log 
likelihood’ of a model [204], the BIC is an approximation of the posterior probability that a 
model is the best model [205]. The AIC asymptotically selects the model that minimizes the 
mean squared error of a prediction or estimation. The AIC also minimizes maximum possible 
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risk in finite sample sizes [200]. The LOOCV error of a linear model has been shown to be 
asymptotically equivalent to the AIC [206,207]. However, when many different models are 
being considered (for example, different combinations of features), there is a danger of 
overfitting when cross-validation is used [202]. The BIC is consistent in model selection: it is 
guaranteed to select the true model as the sample size grows, as long as the true model is 
among the candidate models being considered [200]. 
 
II.4.4 Model selection 
All computational models have certain advantages (e.g. easy to interpret or to program) and 
disadvantages (e.g. longer calculation time, hard to interpret or to program). PLS was chosen 
throughout this thesis as computational model. In chapter VIII, MLR is also used and 
compared to the results of the more sophisticated PLS model. Model validation was 
performed using the LOOCV technique. PLS and LOOCV were performed with Matlab 
version 8.1, MLR was performed with RStudio (R version 3.1.0) software. 
The emphasis in this thesis was put on the comparison of the results of several 
chromatographic methods using only one computational model and one cross-validation 
method. Although the selection of other (even more sophisticated) computational models and 
cross-validation methods might have led to improved correlations, this was not considered to 
be the main goal and was therefore not performed.  
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Chapter III. Predicting drug penetration across the 
blood–brain barrier: comparison of micellar liquid 
chromatography and immobilized artificial 
membrane liquid chromatography
4
  
 
III.1 Summary 
Several in vitro methods have been tested for their ability to predict drug penetration across 
the blood–brain barrier (BBB) into the central nervous system (CNS). In this chapter, the 
performance of a variety of micellar liquid chromatographic (MLC) methods and immobilized 
artificial membrane (IAM) liquid chromatographic approaches were compared for a set of 45 
solutes. MLC measurements were performed on a C18 column with sodium dodecyl sulfate 
(SDS), polyoxyethylene (23) lauryl ether (Brij35), or sodium deoxycholate (SDC) as 
surfactant in the micellar mobile phase. IAM liquid chromatography measurements were 
performed with Dulbecco’s phosphate-buffered saline (DPBS) and methanol as organic 
modifier in the mobile phase. The corresponding retention and computed descriptor data for 
each solute were used for construction of models to predict transport across the blood–brain 
barrier (log BB). All data were correlated with experimental log BB values and the relative 
performance of the models was studied. SDS-based models proved most suitable for 
prediction of log BB values, followed closely by a simplified IAM method, in which it could be 
observed that extrapolation of retention data to 0 % modifier in the mobile phase was 
unnecessary. 
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blood-brain barrier: comparison of micellar liquid chromatography and immobilized artificial membrane liquid 
chromatography. Anal Bioanal Chem 405 (18):6029-6041 
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III.2 Introduction 
An essential prerequisite for a pharmaceutical compound designed to affect the central 
nervous system (CNS) is satisfactory transport through the blood–brain barrier (BBB) [1]. As 
discussed in chapter II, this obstacle severely restricts the diffusion of both small molecules 
and larger objects (for example bacteria) into the cerebrospinal fluid (CSF). A common 
measure of the extent of BBB permeation is the ratio of the steady-state concentration of the 
drug molecule in the brain to the concentration in the blood, usually expressed as log 
(Cbrain/Cblood) or log BB [2]. In the last decade, emphasis has been set on modeling of BBB 
permeation to avoid in vivo measurements. Both in silico and in vitro models have been 
proposed for this [3-5].  
In vitro chromatographic models mimic the lipid environment of the barrier by dynamically or 
covalently immobilizing lipids on a column. The affinity of the solutes for the immobilized 
phase is then combined with physicochemical data or molecular descriptors for optimum 
model construction.  
Micellar liquid chromatography (MLC) uses a surfactant solution above the critical micellar 
concentration (CMC) as mobile phase [6]. Neutral polyoxyethylene (23) lauryl ether (Brij35) 
is the most widely used surfactant for BBB permeation modeling, but anionic sodium dodecyl 
sulfate (SDS) and cationic cetyltrimethylammonium bromide (CTAB) have also been used 
[7]. MLC is a fascinating example of the benefits of secondary equilibrium in RPLC. The 
primary equilibrium is solute partitioning between bulk solvent and the stationary phase. A 
secondary equilibrium is established with the micelles in the mobile phase. Both equilibria are 
affected by a variety of factors, for example the nature and concentration of the surfactant and 
additives (e.g. salts), temperature, ionic strength, and pH. This allows for improved 
mimicking of the BBB environment.  
In contrast with MLC, immobilized artificial membranes (IAMs) mimic the lipid environment 
of a cell membrane by anchoring synthetic phospholipid analogues to silica particles, which 
are subsequently used as HPLC column packing material [8-11]. This type of column is 
particularly interesting for prediction of drug partitioning into biological membranes, because 
it avoids the use of micellar solutions, enabling more conventional gradient HPLC operation 
and MS detection with volatile buffers. The MLC eluents used in this chapter contained no 
organic solvent, although the solutes had a broad hydrophobicity range. However, for IAMs, 
addition of an organic modifier is required for solute elution. According to Taillardat-
Bertschinger et al. [10], extrapolation to 100 % aqueous phase is required to enable 
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comparison of retention factors, irrespective of the amount and type of organic co-solvent and 
to avoid the use of fictitious interaction scales because of the differences in the order of 
elution which occur at different percentages of co-solvent.  
To enable comparison of chromatographic IAM and MLC methods, the quality of the model 
achievable with input from different experimental setups was compared in this work, in which 
45 pharmaceutical drugs with known log BB values were used. The drugs were analyzed by 
MLC with SDS, Brij35, and sodium deoxycholate (SDC) as surfactants, and on a PC.DD2 
phosphatidylcholine IAM column. The corresponding models were constructed by use of 
partial least-squares regression (PLS). 
 
III.3 Materials and methods 
III.3.1 Chemicals 
Solutes were obtained from several sources: 2,2,2-trifluoroethyl vinyl ether, 2,6-
diisopropylphenol, acetaminophen, acetylsalicylic acid, aminopyrine, amitriptyline, 
amobarbital, antipyrine, atenolol, caffeine, carbamazepine, chlorambucil, cimetidine, 
clonidine, cotinine, desipramine, domperidone, eserine, ethylbenzene, fluphenazine, 
hexobarbital, hydroxyzine, ibuprofen, imipramine, mianserin, N-methyl-2-
pyridineethanamine, omeprazole, oxazepam, pentobarbital, phenylbutazone, phenytoin, 
propranolol, pyrilamine, quinidine, ranitidine, ropinirole, salicylic acid, theobromine, 
theophylline, toluene, valproic acid, verapamil and zidovudine (Sigma–Aldrich, St Louis, 
MO, USA or Steinheim, Germany); indomethacin (Fluka, St Louis, MO, USA), and benzene 
(Acros, Geel, Belgium). 
 
III.3.2 Apparatus 
MLC and IAM retention analysis was performed on an Alliance, Waters 2690 chromatograph 
(Milford, MA, USA) with a quaternary pump and an automatic injector. A Waters 2487 dual-
wavelength absorbance detector was used. The detection wavelength was set between 210 nm 
and 300 nm, depending on the compound analyzed (the exact wavelengths are presented in 
Table C-1; Appendix C). Data acquisition and processing were performed with a PeakSimple 
Chromatography Data System (model 202) and PeakSimple software (SRI Instruments, 
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Torrance, CA, USA). MLC and IAM experiments were performed on Grace GraceSmart C18 
(3 μm, 150 mm×2.1 mm; Deerfield, IL, USA) and Regis IAM.PC.DD2 (10 μm, 150 mm×4.6 
mm; Morton Grove, IL, USA) columns, respectively. For MLC experiments, analysis was 
performed at 37 °C with a flow rate of 0.2 mL min
−1
. For IAM experiments, analysis was 
performed at 25 °C with a flow rate of 1 mL min
−1
. 
 
III.3.3 Mobile phase and sample preparation 
Two MLC mobile phases were composed of aqueous solutions of 0.05 mol L
−1
 
polyoxyethylene (23) lauryl ether (Brij35) (Sigma–Aldrich) or 0.05 mol L−1 sodium dodecyl 
sulfate (SDS) (Acros). pH was adjusted with pH 7.4 phosphate buffer, prepared with 0.05 mol 
L
−1
 disodium hydrogen phosphate (Sigma–Aldrich) and potassium dihydrogen phosphate 
(Sigma–Aldrich). To reproduce the osmotic pressure of biological fluids, NaCl (9.20 g L−1) 
(Sigma –Aldrich) was added to the micellar mobile phase. The 0.05 mol L−1 sodium 
deoxycholate (SDC) (Sigma–Aldrich, BioXtra, ≥98.0 %) MLC phase was prepared in 0.05 
mol L
−1
 borate buffer, obtained by dissolving 12.5 mmol L
−1
 sodium tetraborate decahydrate 
(Sigma–Aldrich) and adjusting to pH 7.5 with boric acid (Sigma–Aldrich). IAM mobile 
phases consisted of different ratios of methanol (HPLC-grade; Biosolve, Valkenswaard, The 
Netherlands) and Dulbecco’s phosphate buffered saline (DPBS) (20:80, 30:70, or 40:60 v/v). 
The latter was composed of 2.7 mmol L
−1
 KCl, 1.5 mmol L
−1
 potassium 
dihydrogenphosphate, 137 mmol L
−1
 NaCl, and 8.1 mmol L
−1
 disodium hydrogenphosphate 
(Sigma–Aldrich). The pH of the mobile phase, which was altered by addition of methanol, 
was adjusted to 7.4 by use of phosphoric acid (Sigma–Aldrich). Before use, all mobile phases 
were vacuum-filtered through 0.20 μm nylon membranes (Grace, Lokeren, Belgium).  
Stock solutions of all drugs were prepared by dissolving 10 mg in 1 mL methanol except for 
quinidine and theobromine, for which stock concentrations of 1 mg mL
−1
 and 200 μg mL−1 
were used, caffeine and theophylline, which were dissolved in water (10 mg mL
−1
), and 
domperidone, which was dissolved in dimethyl sulfoxide (10 mg mL
−1
). Stock solutions were 
stored at 5 °C, except for atenolol and zidovudine, which were stored at −20 °C. Working 
solutions were prepared by dilution of the stock solutions (to 50 μg mL−1) with mobile phase. 
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III.3.4 Data sources, software, and processing 
A total of 45 values of the logarithm of brain–blood distribution coefficients (log BB) were 
collected [1,12,13]. The experimental values of log BB (Table C-1) ranged between −1.70 
and 1.51. Values of acidity constants (not shown in Table C-1) were obtained from Refs. 
[14,15] or were calculated. The acidity constants were used to calculate the total molar charge 
(α) values at pH 7.4. Structural data (molar refractivity (MR), molar volume (MV), parachor 
(Pr), and polarizability) were calculated by use of ACD/Chemsketch software. Other data (log 
P, log D7.4, intrinsic aqueous solubility (log WSo), pH solubility profile (WS7.4), plasma 
protein binding (PB), Ames test mutagenic index (MI and MIA), and human intestinal 
absorption (HIA)) were predicted by use of Chemsilico prediction software (Chemsilico free 
trial version). The values for these are presented in Table C-1. The experimental logarithms of 
the retention factors (log k) are listed in Table III-1 for the MLC and IAM experiments. All 
retention data are averages from triplicate determination. Microsoft Excel (Microsoft 
Corporation, v. 2007) and Matlab (version 7.12) were used to perform statistical analysis of 
the results. 
 
III.4 Rationale 
The accuracy of prediction of a model depends on the type of model selected, the relevance, 
diversity, and orthogonality (independence) of the input variables used therein and on the 
shortlist of those which have been retained after model optimization, the size of the training 
set, and the similarity of the test molecules to those in the training set.  
Next to in silico strategies, applying only mathematically processed descriptors [1,4,16,17], 
the approach whereby chromatographic retention data are used as additional input in these 
models is labeled by the terminology quantitative retention–activity relationships (QRAR) or 
quantitative structure–retention relationships (QSRR). The latter have been well reviewed by 
Héberger [18]. This type of multivariate problem is typically solved by the multivariate 
calibration family of algorithms, for example multiple linear regression (MLR), principle-
component regression (PCR), and partial least-squares (PLS) methodology. There are also 
reports on the application of artificial neural networks (ANN) in combination with pure in 
silico strategies [19,17]. The implementation of ANN strategy is nevertheless more 
sophisticated and the optimized mathematical model cannot be expressed with explicit 
functions or equations. 
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Table III-1: Log k values of compounds measured by MLC and IAM liquid chromatography
a,b
. 
Nr. Compound log kBrij35 log kSDC log kSDS log kIAM log kIAM log kIAM log kIAM 
  0.05 M 0.05 M 0.05 M 40% 30% 20% 0 % MeOH 
     MeOH MeOH MeOH extrapolation 
1 2,2,2-trifluoroethyl vinyl ether 0.928 0.694 1.080 -0.089 0.095 0.207 0.5142 
2 2,6-diisopropylphenol 1.254 1.598 1.750 1.156 1.544 1.866 2.5867 
3 acetaminophen 0.261 -0.231 -0.095 -0.657 -0.372 -0.160 0.3479 
4 acetylsalicylic acid -0.498 -1.004 -0.688 -0.964 -0.664 -0.413 0.1455 
5 aminopyrine 0.474 1.438 1.527 -0.547 -0.206 0.100 0.7528 
6 amitriptyline 2.386  2.123 1.519 1.975  3.3437 
7 amobarbital 0.936 0.693 1.249 0.112 0.457 0.755 1.4066 
8 antipyrine 0.268 0.964 1.053 -0.694 -0.368 -0.077 0.5458 
9 atenolol -0.093 1.253 1.189 -0.436 -0.206 0.007 0.4525 
10 benzene 1.039 1.120 1.207 0.155 0.338 0.485 0.8218 
11 caffeine 0.073 0.485 0.767 -0.948 -0.590 -0.313 0.3344 
12 carbamazepine 0.799 1.236 1.226 0.202 0.593 1.075 1.9334 
13 chlorambucil 1.530 0.261 -0.889 0.397 0.793 1.096 1.8106 
14 cimetidine 0.301 0.934 1.031 -0.491 -0.145 0.214 0.9157 
15 clonidine 0.584 1.877 1.500 0.227 0.458 0.713 1.1948 
16 cotinine 0.194 1.100 1.110 -1.139 -0.711 -0.404 0.3524 
17 desipramine 1.704  1.991 1.462 1.864  3.0696 
18 domperidone 0.984 1.891 1.924 1.461 2.042  3.7854 
19 eserine 0.987 2.074 1.547 0.014 0.355 0.691 1.3682 
20 ethylbenzene 1.233 1.476 1.636 0.718 0.994 1.211 1.7127 
21 fluphenazine 1.553  2.046 2.022 2.596  4.3172 
22 hexobarbital 0.789 0.769 1.260 -0.064 0.253 0.516 1.1044 
23 hydroxyzine 1.271  2.010 1.276 1.800 2.240 3.2172 
24 ibuprofen 0.693 0.194 0.565 0.123 0.499 0.780 1.4527 
25 imipramine   2.096 1.409 1.838  3.1229 
26 indomethacin 0.730 0.291 0.738 0.541 1.061 1.577 2.6142 
27 mianserin 1.940  2.173 1.439 1.843  3.0535 
28 N-methyl-2-pyridineethanamine 0.454 1.977 1.560 -0.419 -0.249 -0.120 0.1845 
29 omeprazole 0.974 1.562 1.764 0.223 0.713 1.206 2.1888 
30 oxazepam 0.945 1.244 1.439 0.702 1.118 1.491 2.2866 
31 pentobarbital 0.932 0.739 1.274 0.150 0.489 0.800 1.4558 
32 phenylbutazone 0.701 -0.179 0.594 0.041 0.477 0.829 1.6306 
33 phenytoin 0.933 0.898 1.349 0.392 0.761 1.220 2.0319 
34 propranolol 1.326 2.270 1.936 1.119 1.474 1.860 2.5955 
35 pyrilamine   2.001 0.747 1.132 1.516 2.2850 
36 quinidine 1.282 1.408 1.590 0.937 1.346 1.810 2.6738 
37 ranitidine 0.283 1.756 1.191 -0.331 -0.045 0.207 0.7514 
38 ropinirole 0.936 1.938 1.636 0.102 0.385 0.692 1.2789 
39 salicylic acid 0.179 -0.998 -0.672 -1.057 -0.656 -0.427 0.2313 
40 theobromine -0.191 -0.076 0.275 -1.334 -0.932 -0.670 0.0177 
41 theophylline 0.011 -0.091 0.312 -0.945 -0.621 -0.368 0.2202 
42 toluene 1.260 1.395 1.511 0.450 0.683 0.858 1.2767 
43 valproic acid    -0.098  -0.135 -0.689 -0.546 -0.430 -0.1656 
44 verapamil 1.652  2.197 1.055 1.663 2.295 3.5322 
45 zidovudine 0.085 -0.252 0.303 -0.670 -0.482 -0.185 0.2817 
a
 All log k data are averages from three analyses 
b
 Empty boxes in the table indicate that log k values were not obtained, mostly because of too long elution times 
 
Within the multivariate calibration family of algorithms, both MLR and PLS models have 
thus far been proposed for prediction of drug absorption whereby mathematically generated 
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descriptors are combined with retention data [19,14,20]. MLR achieves maximum correlation 
between the variable matrix X and the log BB vector y. However, the performance of MLR is 
significantly affected by the variables selected, especially as there is strong correlation among 
these variables. PCR is one means of dealing with ill-conditioned problems by capturing the 
maximum variance in X. A weak point of PCR is that it does not make use of the information 
in y, with the result that some principal components are not relevant for prediction but only 
relevant for describing variance in X. To overcome these problems, PLS tries to do both by 
maximizing the covariance between X and y [21]. Instead of finding hyperplanes of minimum 
variance between y and X, PLS finds a linear regression model by projecting y and X to a new 
space, where the projected original variables are transformed as latent variables in 
nomenclature. PLS regression is particularly suitable for problems when the number of 
samples is fewer than the number of independent variables and where there is probably a large 
correlation among X values. All the above-mentioned methods from the multivariate 
calibration family can provide an equation of the type y = b0 + b1 x1 + b2 x2 + … + bn xn, 
where y is the predicted (log BB) value, b0–bn are constants and x1–xn are variables 
(descriptors). Obtaining a suitable equation of this type is important for this type of work.  
As the accuracy of the response (in this case log BB) of the model depends on both the choice 
and relevance of the descriptors used, the use of solute retention data in the model is 
particularly attractive, because they represent the affinity of a compound in a column 
environment emulating the blood-brain barrier. Such chromatographic strategies are 
compared and evaluated in this work. The following mathematically processed descriptors 
were used, by analogy with a previous MLC study [14]: total molar charge (α), molecular 
weight (MW), molar refractivity (MR), molar volume (MV), parachor (Pr), polarizability, and 
the logarithm of the octanol–water partition coefficient (log P). This set was expanded by 
inclusion of the logarithm of the octanol–water distribution coefficient at pH 7.4 (log D7.4), 
intrinsic aqueous solubility (log WSo), solubility profile at pH 7.4 (WS7.4), plasma protein 
binding (PB), Ames test mutagenic index (MI and MIA), and human intestinal absorption 
(HIA). The α values, which can be positive of negative, were calculated as in Ref. [22].  
All descriptors are listed in Table C-1. In this work, PLS models were constructed by use of 
retention data for 45 solutes for which experimental log BB data are available together with 
the set of molecular descriptors mentioned above. The merits of each model were then 
compared. 
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III.5 Results and discussion 
The set of previously used SDS and Brij35 type of micelles in MLC for log BB prediction 
was expanded by addition of micelles of sodium deoxycholate (SDC), a natural bile acid 
which possibly better emulates lipids in the blood–brain barrier. Because one of the functions 
of bile acids is the processing of fat by the formation of micelles, and because they are 
essentially UV transparent, they were directly applicable as an MLC surfactant in this chapter. 
Because of deoxycholate precipitation in the phosphate-buffered solution, the phosphate 
buffer was replaced by a borate buffer. The retention factors measured with the three MLC 
conditions are given in the left part of Table III-1. It is apparent that some solutes could not be 
detected if Brij35 and, especially, SDC buffer, were used. This could be related to increased 
background absorbance of the SDC buffer combined with loss of sensitivity at high retention 
(except for valproic acid). Note that although MLC is a powerful technique in terms of 
selectivity optimization and for complete elution under aqueous conditions, it is inherently 
hindered by peak-broadening phenomena because of the thick layer of surfactant that covers 
the stationary phase [23] and therefore rarely allows one to achieve theoretical plate heights 
within reasonable analysis times, with reduced S/N ratios and sensitivity as a consequence. 
The logarithms of the retention factors measured by use of DPBS containing 40, 30, or 20 % 
methanol as mobile phase with an IAM.PC.DD2 column are listed in the right part of Table 
III-1. Some solutes were excessively retained when 20 % methanol was used and were, 
therefore, no longer detected under those conditions. As an example, the chromatograms 
obtained for ethylbenzene are shown in Figure III-1. The disadvantages of the SDC buffer, 
namely increased background absorbance and loss of sensitivity, are notable (Figure III-1b). 
The retention data in Table III-1 was also extrapolated to 100 % aqueous phases. The 
rationale was that this enables comparison irrespective of the amount of organic co-solvent 
and avoids fictitious interaction scales because of differences in the order of elution which 
occur for different percentages of co-solvent. 
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Figure III-1: Chromatograms obtained for ethylbenzene by use of MLC (a, b, and c) and IAM liquid 
chromatography (d, e, and f). Chromatogram a was obtained with Brij35 in the mobile phase, b with SDC, and c 
with SDS. Chromatograms d, e, and f were obtained by use of 40 %, 30 %, and 20 % methanol, respectively. 
 
III.5.1 Prediction of log BB 
Partial least-squares (PLS) regression was subsequently performed in Matlab to determine the 
correlation coefficients (R) between experimental log BB values (Table C-1) and log BB 
values predicted by use of log k values together with the other descriptors mentioned in Table 
C-1. The correlation coefficients in Table III-2 enable comparison of the merits of the 
different models. The lowest correlation coefficient was obtained when Brij35 was used as 
surfactant. The highest correlation coefficient (R= 0.9159) was obtained with SDC as 
surfactant, but this micellar mobile phase enabled measurement for 36 out of the 45 
compounds only. This demonstrates the potential of SDC-type micelles but, because the final 
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objective in this type of research is accurate prediction of the log BB value for any drug, not 
only for those drugs that are easy to measure, those conditions which enabled measurement 
for all 45 compounds were considered most interesting. 
 
Table III-2: Correlation coefficients between predicted and experimentally determined log BB values when using 
normal partial least-squares regression (PLS) or using leave-one-out cross-validation (LOOCV). 
 Brij35 SDC SDS IAM IAM IAM IAM SDS + SDS + 
 0.05 M 0.05 M 0.05 M 40 % 30 % 20 % 0 % IAM 40 % IAM 30 % 
    MeOH MeOH MeOH MeOH MeOH MeOH 
# compounds 43 36 45 45 45 39 45 45 45 
R (PLS) 0.8387 0.9159 0.8866 0.8707 0.8737 0.8646 0.8744 0.8972 0.8981 
R (LOOCV) 0.5069 0.6846 0.6962 0.6159 0.6303 0.5837 0.6500 0.6926 0.6933 
 
 
Measurement for all 45 compounds was possible by use of SDS as surfactant on a C18 column 
or by use of the IAM.PC.DD2 column with DPBS buffer containing 30 or 40 % methanol. 
When using the IAM column, the correlation between experimental and predicted log BB 
values was somewhat higher when the mobile phase contained 30% methanol (R= 0.8737) in 
comparison with 40 % methanol (R= 0.8707). Use of PLS models built on extrapolation to 
100 % aqueous somewhat improved the accuracy of prediction (R= 0.8744). These data 
therefore illustrate there is little benefit in retention factor extrapolation to 100 % aqueous 
mobile phase, which is a time-consuming procedure. Direct use of the 30 % or 40 % MeOH 
data enables construction of a suitable model when working with the IAM.PC.DD2 column. 
The highest applicable correlation measured was observed when using SDS as surfactant (R= 
0.8866). The correlation between predicted and experimental log BB values with SDS as 
surfactant for the 45 solutes is shown in Figure III-2a. With the exception of a few outliers, 
the predicted log BB values for most compounds appear satisfactorily close to the 
experimentally determined values. The correlation improved even further when the results of 
MLC with SDS were combined with the IAM results obtained by use of 30 % or 40 % 
MeOH. This is logical, because the more variables available to work with, the better the PLS 
correlation that can be obtained. 
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Figure III-2: Scatter plots comparing predicted log BB values with values determined experimentally by use of 
SDS as surfactant. Predicted log BB values are based on partial-least squares regression (a, c) or leave-one-out 
cross-validation (b, d). C and d were obtained after elimination of several variables from Table C-1. 
 
Overfitting is an inevitable problem when the performance of multivariate calibration models 
is evaluated. An overfitted model usually has much a better regression performance on the 
training data set than on the test data set or the validation data set. To avoid overfitted models, 
crossvalidation methods are often used to detect the robustness of models. These methods 
include k-fold CV, twofold CV, random sub-sampling validation, and leave-one-out 
crossvalidation (LOOCV). 
In this chapter, LOOCV was applied to the dataset. Fortyfour compounds were used as the 
training set and one compound as test sample. This procedure was repeated for each 
compound, enabling the construction of a new scatter plot; this is presented for SDS in Figure 
III-2b. The approach was repeated for each MLC and IAM method; the corresponding 
correlation coefficients are listed in Table III-2. 
A relative large decrease of 0.2407, on average, in regression coefficients R is observed for all 
models when they are assessed in that way. In other words, the equations constructed for log 
BB prediction when the solutes are included, fit the training set in a much better way than is 
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the case when they are not included, which is typically regarded as indicative of overfitting. 
There are at least two major sources of overfitting. The first is related to use of a model which 
is too complex and has inferred too much (e.g. too many variables or other data) from the 
available training samples. Variable selection is one solutions used to solve this problem – 
unrelated variables are removed from the training data set, making the model more 
generalized for both training and test data sets. The second source is related to undersampling 
of the underlying distribution. In other words, the samples presented do not cover the major 
range of the underlying native distribution of samples. In this case, there is little that can be 
done unless more representative data or samples can be added to the model. 
Therefore, variable selection was performed by systematic removal and/or reinsertion of all 
descriptors from the models while monitoring the effect on the LOOCV regression 
coefficients. This process was iteratively improved until maximum correlation was obtained 
for the LOOCV results. The maximum correlation was obtained when eight of the 15 
descriptors, i.e. MW, MR, MV, Pr, log P, log D7.4, MI, and MIA, were removed from the 
model. The correlation coefficients for the simplified models are listed in Table III-3. Further 
descriptor removal led to a decrease in regression coefficients. For instance, when the log k 
descriptor was removed, regression coefficients for Brij35, SDC, and IAM with 20 % MeOH 
dropped to 0.6066, 0.6011, and 0.6494, respectively; for all other models (in which all 45 
compounds were detected) the correlation coefficient dropped to 0.6378. This huge drop in 
regression coefficient illustrates why in vitro measurement of log k has a positive effect on 
experimental log BB prediction.  
 
Table III-3: Correlation coefficients between predicted and experimentally determined log BB values when using 
normal partial least-squares regression (PLS) or using leave-one-out cross-validation (LOOCV) after elimination 
of eight variables (MW, MR, MV, Pr, log P, log D7.4, MI and MIA) from the model. 
 Brij35 SDC SDS IAM IAM IAM IAM SDS + SDS + 
 0.05 M 0.05 M 0.05 M 40 % 30 % 20 % 0 % IAM 40 % IAM 30 % 
    MeOH MeOH MeOH MeOH MeOH MeOH 
# compounds 43 36 45 45 45 39 45 45 45 
R (PLS) 0.787 0.8862 0.8564 0.8602 0.8659 0.8389 0.8621 0.8825 0.8848 
R (LOOCV) 0.662 0.7842 0.7993 0.7533 0.7724 0.7451 0.7831 0.7916 0.7982 
 
 
On study of Table III-2 and III-3, two important differences can be noticed. On the one hand, 
the correlation coefficient of the PLS regression has dropped for each type of analysis. This is 
logical, because the PLS regression tries to fit the data as well as possible to an equation. The 
more variables available to work with, the better the correlations that can be obtained, though 
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this is mainly overfitting. On the other hand, the correlation coefficient after the leave-one-out 
cross-validation has significantly increased, demonstrating that the predictive capabilities of 
the different models have, indeed, been improved by applying this strategy. 
As a result, the average difference between the PLS and LOOCV R values has dropped to 
0.0928 in Table III-3. Compared with the average value of 0.2407 in Table III-2, this indicates 
that the model after variable selection is more generalized across the data sets and, therefore, 
enables more robust prediction. For analysis with IAM liquid chromatography (with 30 % or 
40 % MeOH), the correlation increased from ±0.62 to ±0.76. A consequence is that the 
improved IAM model is now performing almost as well as the SDS-based model, illustrating 
that both approaches are commendable and applicable. 
Note that the correlation coefficients for the other types of analysis (Brij35, SDC, and IAM 
with 20 and 0 % MeOH) are also substantially improved by applying this strategy. The 
correlation coefficient after leave-one-out cross-validation for 0 % MeOH IAM was even 
higher than for 30 % MeOH IAM. The values for 0 % MeOH were, however, obtained by 
extrapolation of the values for IAM with 20, 30, and 40 % MeOH, which means many 
measurements had to be taken to obtain a relatively small increase in the correlation 
coefficient. This is why emphasis in this work was set on the methods enabling 
straightforward detection of all 45 solutes (i.e. SDS MLC and 30 and 40 % MeOH IAM). In 
Figure III-2c, d, the SDS-based correlations between predicted and experimental log BB 
values are presented as scatter plots for the optimized models. Comparison of Figure III-2a, c 
(PLS) with Figure III-2b, d (LOOCV) enables visual assessment of the improvements in 
correlation achieved with the new SDS-based model. Analogous conclusions can be made for 
analysis with Brij35, SDC, or IAM liquid chromatography.  
The coefficients of the equations obtained from PLS regressions that lead to the R values 
listed in Table III-3, are listed in Table III-4. The general equation for Table III-4 is: predicted 
log BB= a + b × α + c × Polarizability + d × log WSo + e × WS7.4 + f × PB + g × HIA + h 
× log k1 (+ i × log k2). 
As is apparent from Figure III-3, there are, inherently, various differences between MLC and 
IAM retention mechanisms. Both approaches emulate the blood–brain barrier in an interesting 
but different way. When a C18 column is used with a surfactant solution above the critical 
micellar concentration, retention of a compound depends both on its interactions with the 
modified reversed stationary phase and with the micelles present in the mobile phase (Figure 
III-3a). 
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Table III-4: Coefficients generated by PLS regression after elimination of several descriptors. The general 
equation for the predicted log BB values is: log BB = a + b × α + c × Polarizability + d × log WSo + e × WS7.4 
+ f × PB + g × HIA + h × log k1 (+ i × log k2). 
 Brij35 SDC SDS IAM IAM IAM IAM SDS +  SDS + 
 0.05 M 0.05 M 0.05 M 40 % 30 % 20 % 0 % IAM 40 % IAM 30 % 
    MeOH MeOH MeOH  MeOH MeOH MeOH 
a -3.666 -3.800 -3.911 -3.039 -2.995 -2.809 -2.859 -3.350 -3.302 
b 0.589 0.241 0.397 0.455 0.495 0.437 0.600 0.324 0.358 
c -0.039 -0.053 -0.050 -0.044 -0.051 -0.053 -0.069 -0.046 -0.051 
d 0.099 0.063 0.080 0.155 0.152 0.146 0.133 0.146 0.144 
e -0.002 -0.003 -0.003 -0.003 -0.002 -0.002 -0.002 -0.003 -0.003 
f 0.007 0.007 0.011 0.003 0.002 0.003 0.004 0.005 0.005 
g 0.044 0.048 0.044 0.047 0.046 0.042 0.042 0.045 0.045 
h 0.530 0.439 0.571 0.709 0.705 0.517 0.604 0.453 0.466 
i - - - - - - - 0.344 0.323 
 
In addition, dynamic adsorption of a time-averaged fixed amount of surfactant monomers on 
the stationary phase also occurs, in this way giving rise to a stable modified column and 
regular retention behavior [24]. By contrast, when the IAM.PC.DD2 column is used, no 
micelles are present in the mobile phase, which means that interactions of compounds can 
only occur with the stationary phase (Figure III-3b). On the IAM.PC.DD2 column, 
phosphatidylcholine is covalently bonded to aminopropyl silica and endcapped with C10 and 
C3 amides [8]. 
 
 
Figure III-3: Schematic representation of drug interactions in MLC (a) and in IAM liquid chromatography (b). 
 
Because interactions on the C18 column and the IAM column are different, the corresponding 
solute retention factors also seem to be significantly different (Table III-1). Because of the 
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acceptable models which could be constructed by use of the individual MLC and IAM data, it 
was interesting to construct a model based on both datasets. Therefore, two extra PLS 
regressions were performed in which the log k values obtained by IAM liquid 
chromatography (with 40 and 30 % methanol) were added to the dataset obtained from MLC 
analysis with SDS.  
It seemed that the corresponding correlation coefficients increased from 0.8564 (SDS, Table 
III-3) to 0.8825 (SDS + 40 % MeOH) and 0.8848 (SDS + 30 % MeOH), respectively, 
demonstrating the interesting potential of combining chromatographic data from orthogonal 
approaches for experimental data prediction. This was, however, not confirmed by leave-one-
out cross-validation, in which correlation coefficients of these combinations decreased from 
0.7993 (SDS, Table III-3) to 0.7916 and 0.7982, respectively. An obvious extra practical 
drawback of this strategy is that the combined approach increases the number of 
measurements required. 
 
III.6 Conclusion 
In this chapter, several in vitro methods for predicting the logarithm of blood–brain 
distribution coefficient (log BB) values were compared. MLC was performed on a C18 column 
with Brij35, SDC, and SDS as surfactants. IAM liquid chromatography was performed with 
methanol as organic modifier. SDS as a surfactant resulted in the best correlation coefficient 
between experimental and predicted log BB values (R = 0.7993), followed closely by IAM 
measurements using 30 % methanol (R = 0.7724). Combination of results from use of 
immobilized artificial membrane LC phases and micellar LC did not improve the accuracy of 
log BB prediction. 
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Chapter IV. Development of the first Sphingomyelin 
biomimetic stationary phase for Immobilized 
Artificial Membrane Liquid Chromatography
5
 
 
IV.1 Summary 
A prototype sphingomyelin stationary phase for Immobilized Artificial Membrane (IAM) 
chromatography was synthesized by an ultra-short, solid-phase inspired methodology, in 
which an oxidative release monitoring strategy played a vital role. Evaluated in a proof-of-
concept model for blood–brain barrier passage, partial least squares regression 
demonstrated its potential as an in vitro prediction tool. 
 
IV.2 Introduction 
As an innovative approach to liquid chromatography in which the stationary phase emulates 
the lipid environment of a cell membrane, the so-called Immobilized Artificial Membrane 
(IAM) technology offers an in vitro HPLC model of in vivo drug partitioning [1,2]. High-
throughput and simple, the practical advantages of this chemical technique over more 
traditional biological methods are, however, affected by oversimplification and structural 
ambiguities in the small range of commercial, ‘phosphatidylcholine-only’ IAM columns such 
as 1 (Figure IV-1). Considering the mechanistic complexity of the in vivo uptake process [3], 
                                                 
5
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chromatography. Chem Commun 48 (8):1162-1164. 
Development of the first sphingomyelin stationary phase for IAMLC 
 
96 
 
alternative and more sophisticated IAM stationary phases are desired, the synthetic aspects 
need up-to-date revision, and assay correlations [4] should accordingly be improved. 
 
 
Figure IV-1: Synthesis and structure of Sphingo-IAM silica 2, as counterpart of the commercial IAM.PC.DD2 
reference 1 (Phosphatidylcholine.Drug Discovery 2nd generation). 
 
The focus in this chapter is the development of a sphingomyelin [5,6] counterpart 2 (Figure 
IV-1) of the columns that are available so far. Useful as such in a broader synthetic context, 
an oxidative release monitoring strategy proved to be essential to achieve a straightforward, 
ultra-short synthesis of the desired silica material, while minimizing the aforementioned 
ambiguities. As such, this chapter provides the development and proof-of-concept evaluation 
of a prototype sphingomyelin stationary phase manufactured through an unprecedented, solid-
phase inspired methodology, susceptible to mixed-phase approaches towards more genuine 
membrane mimics. To the best of our knowledge, neither such material for IAM 
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chromatography in particular nor such methodology for synthesis of dedicated stationary 
phases in general was previously reported. 
 
IV.3 Materials and methods 
IV.3.1 Chemicals 
Test compounds were obtained from several sources: acetaminophen, acetylsalicylic acid, 
aminopyrine, amobarbital, antipyrine, carbamazepine, cimetidine, eserine, ethylbenzene, 
hexobarbital, ibuprofen, N-methyl-2-pyridineethanamine, omeprazole, oxazepam, 
pentobarbital, phenylbutazone, phenytoin, ranitidine, ropinirole, salicylic acid and toluene 
(Sigma–Aldrich, St Louis, MO, USA or Steinheim, Germany); indomethacin (Fluka, St 
Louis, MO, USA), and benzene (Acros, Geel, Belgium). 
Products and solvents used for synthesis (Figure IV-1) were obtained from Sigma-Aldrich, 
except for the silica gel (Chromatorex NH SPS300-10; Fuji Silysia, Tokio, Japan) and 
sphingomyelin (egg source; Avanti Polar Lipids, Alabaster, AL, USA). 
 
IV.3.2 Apparatus 
IAM retention analysis was performed on an Alliance, Waters 2690 chromatograph (Milford, 
MA, USA) with a quaternary pump and an automatic injector. A Waters 2487 dual-
wavelength absorbance detector was used. The detection wavelength was set between 210 nm 
and 300 nm, depending on the compound analyzed. Data acquisition and processing were 
performed with a PeakSimple Chromatography Data System (model 202) and PeakSimple 
software (SRI Instruments, Torrance, CA, USA). For IAM experiments, analysis was 
performed at 25 °C with a flow rate of 1 mL min
−1 
for the Regis IAM.PC.DD2 (10 μm, 150 
mm×4.6 mm; Morton Grove, IL, USA) column, and a flow rate of 0.5 mL min
-1
 for the new 
Sphingo-IAM (150mm×3mm) column. 
LC-MS runs were performed on an Agilent 1100 series HPLC (Agilent Technologies, 
Waldbronn, Germany) connected to an Agilent G1956B single quad Mass Spectrometer with 
ESI-ionization source. Data acquisition and processing were performed with Agilent 
B.01.03.SR2 chemstation software. A Phenomenex Luna C18 column (5 µm, 250 mm × 4.6 
mm; Utrecht, The Netherlands) was used with a flow rate of 1 mL min
-1
 at 35 °C using a 
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gradient run going from 0 to 100 % ACN in 15 minutes and a 5 mM NH4OAc(aq) solution. 
The injection volume was 5 µL. 
 
IV.3.3 Experimental conditions 
In this section, the detailed procedure for the preparation of the Sphingo-IAM column 2 is 
described, which involves coupling of lysosphingomyelin 3 to intermediate material 4, and 
packing of the resulting silica 2 into a column. The intermediate silica material 4 (2.34 g, 
0.137 mmol g
-1
, 0.32 mmol) was weighed into a round-bottomed flask (100 mL), followed by 
the addition of lysosphingomyelin 3 (297.2 mg, 0.64 mmol, 2 eq.) and anhydrous NMP (16 
mL). After complete dissolution of 3 and homogeneity of the silica suspension, the flask was 
flushed with argon and DIC (59.6 µL, 0.385 mmol, 1.2 eq.) was added. The resulting 
orange/yellowish opaque mixture was gently agitated overnight at 50 °C. By successively 
adding reagents and solvent upon evaluation of several Tamao–Kumada samples (see next 
paragraph), a total of 38 equivalents DIC and 6 equivalents lysosphingomyelin were 
eventually reacted in 23 mL of total NMP volume over a period of 2 weeks, yielding complete 
conversion as shown in LC-MS results (Figure IV-2). The resulting silica was isolated and 
purified by filtration over a nylon-66 membrane (0.45 µm pores) under reduced pressure and 
washed with NMP, MeOH and Et2O to give an orange/brownish filtrate. The off-white silica 
was dried for 3 hours at 70 °C and carefully transferred to a round-bottomed flask (100 mL). 
Finally, the material was gently treated overnight at room temperature with a methanolic HCl 
solution (20 mL, 50 mM, pH 2) under an argon atmosphere as described. The above filtration, 
washing (MeOH, ACN, THF, CHCl3 and Et2O) and transfer procedure was repeated to yield 
the white Sphingo-silica 2 (1.8325 g) upon careful drying under high vacuum. This material 
(1.5037 g) was suspended in water (7 mL) and the resulting slurry packed (300 bar) in an 
HPLC column (15 cm × 3 mm) for subsequent proof-of-concept IAM-evaluation (Figure IV-
3).  
Monitoring via Tamao–Kumada oxidative release of silica samples: by means of a glass 
pipette, an aliquot (500 µL) of the above silica suspension was withdrawn from the reaction 
flask. The above filtration, washing (NMP, MeOH, ACN, CHCl3 and Et2O) and transfer 
procedure was repeated to obtain a silica sample in a small pressure tube. Upon adding equal 
volumes (215 µL) of THF, MeOH, NaHCO3 (aq,sat), KF (aq,sat) and H2O2 (35% aq), the 
resulting white, heterogeneous mixture was gently stirred overnight at 60 °C. The tube was 
cautiously opened, followed by the above filtration and washing (MeOH, THF and EtOH) 
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procedure to its content. Collected in a roundbottomed flask (250 mL), the colourless filtrate 
was concentrated under reduced pressure at 40 °C, and the wax-like, opaque/whitish residue 
dried under high vacuum. Upon redissolution in MeOH, a sample was prepared for analysis. 
 
IV.3.4 Data Sources, software, and processing 
A total of 23 values of the logarithm of brain–blood distribution coefficients (log BB) were 
collected [7-9]. The experimental values of log BB ranged between −1.42 and 0.61. Values of 
acidity constants were obtained from Refs. [10,11] or were calculated. The acidity constants 
were used to calculate the total molar charge (α) values at pH 7.4. Structural data (molecular 
weight (MW), molar refractivity (MR), molar volume (MV), parachor (Pr), and polarizability) 
were calculated by use of ACD/Chemsketch software. Other data (log P, log D7.4, intrinsic 
aqueous solubility (log WSo), pH solubility profile (WS7.4), plasma protein binding (PB), 
Ames test mutagenic index (MI and MIA), and human intestinal absorption (HIA)) were 
predicted by use of Chemsilico prediction software (Chemsilico free trial version). The values 
for these can be found in Table C-1 (Appendix C). The experimental retention factors (k) are 
listed in Appendix D. All retention data are averages from triplicate determination. Microsoft 
Excel (Microsoft Corporation, v. 2007) and Matlab (version 7.12) were used to perform 
statistical analysis of the results. 
 
IV.4 Results and discussion 
As depicted in Figure IV-1, target material 2 was assembled on a similar carrier and through 
the same linker chemistry in order to allow direct comparison to state-of-the-art IAM.PC.DD2 
(reference) column 1, pioneered by Pidgeon et al. already more than two decades ago [1,12]. 
In this approach, gram quantities of the precious [13] lysosphingomyelin (D-erythro-
sphingosylphosphorylcholine) building block 3 could be semi-synthetically prepared by 
chemical means through methanolysis of sphingomyelin, adapted from Bittman et al. [14]. 
Through merger of the lysosphingomyelin amine functionality and the immobilized fatty acid 
linker 4 in this N-deacylation/reacylation strategy, the complete sphingomyelin molecule is 
reconstituted while being anchored to the silica particles. 
As such, the aminopropyl silica carrier is regarded from a solid-phase point of view, with its 
typical merits. However, the so-called black-box character of this approach challenged the 
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aim to ensure proper stationary phase integrity, and possible cross-link formation by reacting 
a symmetrical C14-diacid linker prompted a critical evaluation of the coupling outcome. 
Neither qualitative efforts by malachite green colour testing [15] or infrared (HATR, DRIFT, 
2D mapping) measurements, nor quantitative HR-MASNMR experiments provided consistent 
clues [16], let alone conclusive data on the amount of available COOH moieties and/or cross-
linked species. Yet fortunately, Tamao–Kumada (TK) oxidative release of the attached 
molecules from a silica sample, recently disclosed by Komba et al. [17], solved this issue. By 
mild oxidation of the Si–C bond (Figure IV-1), analytical aliquots are readily available for 
standard solution phase evaluation of the generated alcohols, which conveniently increase the 
compatibility of the hydrophobic lipid species with reversed-phase and mass spectrometry 
techniques. This procedure provides reaction monitoring without the need for interfering 
cleavage handles. 
A 42/58 COOH/cross-link ratio was derived from LC-MS data (Figure IV-2a) after standard 
PyBOP-mediated coupling (equimolar, double treatment overnight), with an apparently 
negligible/inconsistent influence of equivalent ratios during further attempts. As N-cap 
moieties with fatty acid character, these inert cross-links resemble features of the 
IAM.PC.DD2 column 1, and allow steps to follow, direct and optimize reaction progress of 
the subsequent coupling as a reference LC-MS signal. 
Demanding because of its inverse nature (activated COOH species on support instead of in 
solution) yet delicate because of its straightforwardness, proper introduction of unprotected 
lysosphingomyelin 3 onto silica intermediate 4 (Figure IV-1) indeed succeeded due to the LC-
MS monitoring, possible through the Tamao–Kumada protocol. Prior stability testing 
confirmed the resistance of the sphingomyelin amide over a phosphatidylcholine ester to 
Tamao-Kumada conditions, the latter one being completely hydrolyzed overnight. Further 
agreeing with the (lyso)sphingomyelin and strategic choice, N-acylation is likewise favoured 
over O-acylation upon proper activation, and quantitative DIC-mediated [18,19] conversion 
was achieved by gradual increase of reagent equivalents upon careful monitoring, as 
confirmed in Figure IV-2b (see section IV.3.3). NMP proved thereby mandatory for 
dissolution of building block 3, despite literature precedents and an initial preference for 
CHCl3 in regard to supposed sidereactions and selectivity [19,20]. Neither the cross-links 
(which are dimensionally expected to form loops) nor the silica carrier prevented diffusion or 
reaction, provided 300 Å material is used, which is in line with the above choices and the 
commercial IAM.PC.DD2 column 1. 
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Figure IV-2: LC-MS (0 – 100 % ACN vs. 5 mM NH4OAc(aq) in 15 min 1 mL/min; C18-100 Å, 25 cm × 4.6 mm; 
214 nm) results for the Tamao–Kumada sample of (a) intermediate material 4, and (b) final Sphingo-IAM silica 
2 (ESI+, Exact mass 761.6 Da). 
 
To correct for remaining traces of unreacted COOH intermediate 4 and the presence of labile 
or miscoupled species, a finishing methylation/methanolysis under mild conditions was felt 
worthwhile in order to further strive for minimal ambiguities. As such, free, O-acylated, 
activated or anhydride linker species are all capped/converted to the corresponding methyl 
ester, whereas possible esters formed during linker coupling are discarded from residual 
silanol groups. Attention should be paid to the shielding effect of such species during 
subsequent lysosphingomyelin reaction, which should conveniently serve as protecting group 
for potentially interfering silanol moieties. The presence of free silanols in the ester-based 
phosphatidylcholine reference column 1 [21], with apparently no further end-capping efforts, 
should be noted. However, both these silanol functionalities and residual aminopropyl groups 
are buried in the bulky surrounding of the immobilized lipids, which tends to minimize 
retention biases as stated in the literature [1,2]. A ninhydrin, TNBS and chloranil [22] 
negative result for the amine moieties after linker/cross-link introduction must thereby further 
be noted. The methylation/methanolysis step should enhance the stability of the 
sphingomyelin amide, column lifetime and reliability. 
min
mAU
12 14 16 18 20 22 24
0
200
400
18.1
12 14 16 18
0
200
400
11.6
12.6
4
m
A
U
Inert cross-link species:
Reference signal for subsequent coupling
(a)
(b)
min20 22 24
m/z100 200 300 400 500 600 700 800
381.8
762.5
763.5
Complete conversion
2
m
A
U
[M + 2H]2+
[M + H]+
Development of the first sphingomyelin stationary phase for IAMLC 
 
102 
 
In a proof-of-concept evaluation through comparative assessment with IAM.PC.DD2 column 
1, the new stationary phase 2 passed exploratory correlation studies as an in vitro prediction 
tool (Figure IV-3; see Appendix D for details). As mentioned above, structural similarities 
between both phases allow for direct comparison and facilitate the investigation of the role of 
the lipid component in the observed tendencies. After in-house slurry packing of the 
synthesized material into an HPLC column, a selection of 23 small molecules relevant in drug 
discovery was eluted under typical isocratic IAM conditions [23], and flow rates adjusted to 
compensate for varying column diameters. The covalently fixed IAM monolayer thereby 
mimicked the phospholipid bilayer to be crossed for uptake, so that chromatographic 
partitioning (expressed by partition coefficient KIAM) corresponded to cellular diffusion. 
Experimental retention factors kIAM were calculated from retention time measurements and 
included as a parameter in a prediction model for in vivo Blood–Brain (BB) passage [10]. 
Similar PLS regression results between the novel Sphingo-IAM prototype 2 and reference 
column 1 form the basis for the profound study in chapter V. 
 
 
Figure IV-3: Proof-of-concept evaluation by PLS regression (see Appendix D for details), correlating in vivo log 
BB data of 23 small molecules with predicted in vitro model values involving experimental retention factors 
kIAM from (a) IAM.PC.DD2 column 1 and (b) Sphingo-IAM column 2. 
 
IV.5 Conclusion 
In this chapter, a new sphingomyelin-based IAM stationary phase was created for which 
proof-of-concept correlation studies were performed; extended correlation studies are 
presented in the next chapter. As an important constituent of eukaryotic plasma membranes 
[5,6] in general, interesting behavior is anticipated for the sphingomyelin lipid. Tuning of the 
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synthetic route should give access to a repertoire of further IAM silicas, combinations thereof 
and mixed-phase materials [24] with enhanced integrity. With some additional effort, 
throughput, reliability and predictability [25] of IAM chromatography could be improved. 
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Chapter V. Evaluation of sphingomyelin, cholester and 
phosphatidylcholine based immobilized artificial 
membrane liquid chromatography to predict drug 
penetration across the blood-brain barrier
6
 
 
V.1 Summary 
In this chapter, the sphingomyelin column created in chapter IV and a cholester column are 
tested towards their ability to predict drug penetration across the blood-brain barrier. Upon 
comparison with the phosphatidylcholine stationary phase, the sphingomyelin and cholester 
based columns depict similar predictive performance. Combining data from the different 
stationary phases did not lead to improvements of the models. 
 
V.2 Introduction 
In general, the BBB restricts the diffusion of both small molecules and larger objects (for 
example bacteria) into the cerebrospinal fluid (CSF). When the blood-brain barrier is studied, 
the extent of BBB-permeation is expressed as the ratio of the steady-state concentration of the 
substance in the brain to the concentration in blood, usually called log (Cbrain/Cblood) or log BB 
[1,2]. 
In vitro chromatographic models have been suggested for modeling of BBB-permeation, since 
they mimic the lipid environment of the barrier by dynamically or covalently immobilizing 
                                                 
6
 Published as: De Vrieze M, Verzele D, Szucs R, Sandra P, Lynen F (2014) Evaluation of sphingomyelin, 
cholester, and phosphatidylcholine-based immobilized artificial membrane liquid chromatography to predict 
drug penetration across the blood-brain barrier. Anal Bioanal Chem 406 (25):6179-6188 
Evaluation of sphingomyelin, cholester and phosphatidylcholine based IAMLC to predict 
drug penetration across the BBB 
 
108 
 
structures on a column. The affinity of the solutes for the immobilized phase is then combined 
with physicochemical data or molecular descriptors for optimal model construction. 
IAMLC is one of the most commonly used in vitro chromatographic models for the prediction 
of log BB values [3,4]. IAMLC follows an approach whereby the lipid environment of a cell 
membrane is mimicked by anchoring synthetic phospholipid analogues at monolayer density 
to silica particles. These particles are subsequently used as column packing material for 
HPLC [3,5,6]. Thanks to the work of Pidgeon et al. [7], this type of stationary phase was 
introduced about 20 years ago. Although some research was conducted towards the use of 
mixed ligands [8], this methodology never really gained foothold. Eventually, only PC-coated 
particles became available in commercial columns. Usually, IAMLC is combined with UV 
detection, analyzing a single compound each run. Therefore, throughput for drug discovery 
applications is not very high. However, the use of a volatile buffer (e.g. ammonium acetate) 
allows coupling with atmospheric pressure ionization mass spectrometry, which provides the 
possibility for simultaneous determination of retention factors and, therefore, an increased 
throughput. 
Methanol and acetonitrile are the most popular co-solvents in HPLC. Their use in the 
extrapolation of log kIAM values has been studied with an IAM.PC.DD2 column [6]. The 
conclusion was that methanol is more appropriate for obtaining the log kIAM values of charged 
compounds, since its solvent properties are closer to the properties of water. Furthermore, 
when acetonitrile is used, mobile phases containing more than 30 % (w/w) must be avoided 
since their microheterogeneity disrupts the structure of water [9]. 
IAMs are interesting because of their capacities for the prediction of drug partitioning into 
biological membranes. Next to a comparative study between MLC and IAMLC [10] (chapter 
III), a new sphingomyelin stationary phase for IAMLC was recently developed [11] (chapter 
IV). In this chapter, a total of 49 compounds with known log BB values were selected for 
comparative in vitro IAMLC measurements. The compounds were analyzed on three different 
lipid-like IAM-columns, namely the commercial IAM.PC.DD2-column (DD2 = drug 
discovery 2
nd
 generation), the in-house synthesized Sphingo-IAM-column [11] (Sphingo = 
sphingomyelin; chapter IV), and an alternative commercial Cholester-column. To the best of 
our knowledge, the last two types of columns have not yet been tested as alternatives for the 
IAM.PC.DD2-column. The aim of this chapter is to obtain a full comparison regarding the 
potential of these IAM phases to predict log BB values. 
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V.3 Materials and methods 
V.3.1 Chemicals 
The analytes were obtained from several sources: 2,2,2-trifluoroethyl vinyl ether, 2,6-
diisopropylphenol, acetaminophen, acetylsalicylic acid, aminopyrine, amitriptyline, 
amobarbital, antipyrine, atenolol, caffeine, carbamazepine, chlorambucil, chlorpromazine, 
cimetidine, clonidine, cotinine, desipramine, domperidone, eserine, ethylbenzene, 
fluphenazine, haloperidol, halothane, hexobarbital, hydroxyzine, ibuprofen, imipramine, 
mianserin, N-methyl-2-pyridineethanamine, omeprazole, oxazepam, pentobarbital, 
phenylbutazone, phenytoin, promazine, propranolol, pyrilamine, quinidine, ranitidine, 
ropinirole, salicylic acid, theobromine, theophylline, toluene, valproic acid, verapamil and 
zidovudine were obtained from Sigma–Aldrich (Steinheim, Germany); indomethacin was 
purchased from Fluka (St Louis, MO, USA), and benzene came from Acros (Geel, Belgium). 
 
V.3.2 Apparatus 
The IAM retention analysis was performed on an Alliance, Waters 2690 chromatograph 
(Milford, MA, USA) with a quaternary pump and an automatic injector. A Waters 2487 dual-
wavelength absorbance detector was used, for which the detection wavelength was set 
between 210 nm and 300 nm, depending on the analyzed compound (the exact wavelengths 
are presented in Table C-2; Appendix C). The data acquisition and processing were performed 
with a PeakSimple Chromatography Data System (model 202) and PeakSimple software (SRI 
Instruments, Torrance, CA, USA). IAM experiments were respectively performed on an 
IAM.PC.DD2 (10 μm, 150 mm×4.6 mm; Regis Technologies, Morton Grove, IL, USA), a 
Cosmosil Cholester (5 µm, 250 mm×4.6 mm; Nacalai Tesque, San Diego, CA, USA) and a 
Sphingo-IAM  (150 mm×3.0 mm; [11]) column. Analysis was performed at 25 °C with a flow 
rate of 1 mL min
-1
, except for the Sphingo-IAM-column, where the flow rate was set to 0.5 
mL min
-1
. 
 
V.3.3 Mobile phase and sample preparation 
The IAM mobile phases consisted of different ratios of methanol (HPLC-grade; Biosolve, 
Valkenswaard, The Netherlands) and Dulbecco’s phosphate-buffered saline (DPBS). 30 
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volume% of methanol was added to the mobile phase when the IAM.PC.DD2- or the 
Sphingo-column was used; the methanol content was increased to 50 volume% using the 
Cholester-column. The DPBS consisted of 2.7 mmol L
-1
 KCl, 1.5 mmol L
-1
 KH2PO4, 137 
mmol L
-1
 NaCl, and 8.1 mmol L
-1
 Na2HPO4 (Sigma-Aldrich). The pH of the mobile phase, 
which was altered by addition of methanol, was adjusted to 7.4 by use of H3PO4 (Sigma-
Aldrich). Before use, all mobile phases were vacuum-filtered through 0.20 μm nylon 
membranes (Grace Davison, Lokeren, Belgium).  
Stock solutions of all drugs were prepared by dissolving 10 mg in 1 mL methanol, except for 
quinidine and theobromine, for which stock concentrations of 1 mg mL
-1
 and 200 μg mL-1 
were used; caffeine and theophylline, which were dissolved in water (10 mg mL
-1
); and 
domperidone, which was dissolved in dimethyl sulfoxide (10 mg mL
-1
). Working solutions 
were prepared by dilution of the stock solutions (to 50 μg mL-1) with mobile phase. 
 
V.3.4 Data sources, software, and processing 
A total of 49 actual (= in vivo determined) log BB values were collected from literature [12-
14]. The actual values of log BB (Table C-2) ranged between −1.70 and 1.51. Values of 
acidity constants (not shown in Table C-2) were obtained from Refs. [15,16] or were 
calculated by ChemSilico prediction software (ChemSilico free trial version). The acidity 
constants were used to calculate the total molar charge (α) values at pH 7.4. These α values, 
which can be positive or negative, were calculated as in Ref. [17]. Structural data (molecular 
weight (MW), molar refractivity (MR), molar volume (MV), parachor (Pr), and polarizability) 
were calculated by use of ACD/Chemsketch software. Other data (log P, log D7.4, intrinsic 
aqueous solubility (log WSo), pH solubility profile (WS7.4), plasma protein binding (PB), 
Ames test mutagenic index (MI and MIA), and human intestinal absorption (HIA)) were 
predicted by use of ChemSilico prediction software. The experimental logarithms of the 
retention factors (log k) are listed in Table V-1. All retention data are averages from triplicate 
determinations. Matlab (version 7.13) was used to perform statistical analysis of the results. 
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Table V-1: Log k values of compounds measured on different IAM columns.
a
 
No. Compound IAM.PC.DD2 Sphingo-IAM Cholester 
  30 % MeOH 30 % MeOH 50 % MeOH 
1 2,2,2-trifluoroethyl vinyl ether 0.095 0.210 0.573 
2 2,6-diisopropylphenol 1.544 1.681 1.785 
3 acetaminophen -0.372 -0.261 -0.519 
4 acetylsalicylic acid -0.664 -0.131 -0.476 
5 aminopyrine -0.206 -0.082 0.011 
6 amitriptyline 1.975 1.657 1.510 
7 amobarbital 0.457 0.617 0.653 
8 antipyrine -0.368 -0.329 -0.273 
9 atenolol -0.206 -0.539 -0.767 
10 benzene 0.338 0.530 0.834 
11 caffeine -0.590 -0.477 -0.262 
12 carbamazepine 0.593 0.772 0.630 
13 chlorambucil 0.793 1.000 1.947 
14 chloropromazine 2.404 2.110 1.946 
15 cimetidine -0.145 -0.091 -0.221 
16 clonidine 0.458 0.135 -0.061 
17 cotinine -0.711 -0.647 -0.644 
18 desipramine 1.864 1.564 1.291 
19 domperidone 2.042 1.837 1.468 
20 eserine 0.355 0.238 0.096 
21 ethylbenzene 0.994 1.139 1.462 
22 fluphenazine 2.596 2.445 2.238 
23 haloperidol 1.844 1.466 1.379 
24 halothane 0.487 0.618 0.956 
25 hexobarbital 0.253 0.433 0.518 
26 hydroxyzine 1.800 1.741 1.693 
27 ibuprofen 0.499 0.884 0.993 
28 imipramine 1.838 1.524 1.403 
29 indomethacin 1.061 1.462 1.372 
30 mianserin 1.843 1.776 1.727 
31 N-methyl-2-pyridineethanamine -0.249 -0.373 -0.773 
32 omeprazole 0.713 0.806 0.723 
33 oxazepam 1.118 1.182 1.307 
34 pentobarbital 0.489 0.647 0.668 
35 phenylbutazone 0.477 0.931 0.678 
36 phenytoin 0.761 0.981 0.635 
37 promazine 2.035 1.708 1.465 
38 propranolol 1.474 1.348 0.857 
39 pyrilamine 1.132 0.974 0.652 
40 quinidine 1.346 1.045 0.909 
41 ranitidine -0.045 -0.204 -0.386 
42 ropinirole 0.385 0.166 0.180 
43 salicylic acid -0.656 -0.086 -0.490 
44 theobromine -0.932 -0.819 -0.744 
45 theophylline -0.621 -0.511 -0.355 
46 toluene 0.683 0.942 1.171 
47 valproic acid  -0.546 -0.112 0.319 
48 verapamil 1.663 1.400 1.208 
49 zidovudine -0.482 -0.325 -0.155 
a
 All log k data are averages from three analyses 
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V.4 Rationale 
The accuracy of prediction of a model depends on the type of model selected, the relevance, 
diversity, orthogonality (independence) of the input variables and on the shortlist of those 
which have been retained after model optimization, the size of the training set, and the 
similarity of the test molecules to those in the training set. 
The processing of QRAR and QSRR studies (whereby chromatographic retention data is used 
as an additional input in a model using mathematically processed descriptors) can be done 
with MLR, PCR, PLS and ANN methodologies.  
Within the multivariate calibration family of algorithms, both MLR and PLS models have 
thus far been proposed for prediction of drug absorption for which mathematically generated 
descriptors are combined with retention data [18,15,19]. The performance of MLR is, 
however, significantly affected by the selected variables when they are strongly correlated. 
This problem is avoided in the PLS method, which finds a linear regression model by 
projecting y and X to a new space, where the projected original variables are transformed as 
latent variables in nomenclature. PLS regression is particularly suitable for problems when the 
number of samples is fewer than the number of independent variables and where there is 
probably a large correlation among X-values. Eventually, an equation of the type y = b0 + b1 
x1 + b2 x2 + … + bn xn is created, where y is the predicted (log BB) value, b0-bn are constants 
and x1-xn are variables (descriptors). Obtaining a suitable equation of this type is important for 
this type of work. 
As the accuracy of the response (in this case log BB) of the model depends on both the choice 
and relevance of the used descriptors, use of solute retention data in the model is particularly 
attractive, because this represents the affinity of a compound in a column environment 
emulating the blood-brain barrier. Such chromatographic strategies are compared and 
evaluated in this chapter. All descriptors used in this chapter are listed in Table C-2. PLS 
models were constructed by use of retention data for 49 solutes for which actual log BB data 
are available together with the set of molecular descriptors mentioned above. The merits of 
each model were then compared. 
 
V.5 Results and discussion 
When an IAM-column is used, an organic modifier is usually added to the mobile phase since 
this is a requisite for solute elution. The logarithms of the retention factors (log k) measured 
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on the different columns by use of DPBS and methanol in the mobile phase are listed in Table 
V-1. On the Cholester-column, some solutes were excessively retained when 30 % methanol 
was used and were no longer detected under those conditions. Therefore, measurements were 
made with 50 % methanol on this column. According to Taillardat-Bertschinger et al. [6], an 
extrapolation to 100 % aqueous phase is required to enable comparison of retention factors 
irrespective of the amount and type of organic co-solvent. Extrapolation also avoids the use of 
fictitious interaction scales because of the differences in the elution order which occur at 
different percentages of co-solvent. However, extrapolations were not performed here since 
Detroyer et al. [20] indicated that extrapolation is not necessary when measurable k-values 
can be obtained for all investigated compounds using only one mobile phase for each column. 
Furthermore, improvement towards log BB prediction that can be achieved when using 
extrapolations to 0 % organic co-solvent have been shown to be close to negligible [10]. 
Figure V-1 illustrates the dissimilarity in retention behavior of compounds on the different 
stationary phases by comparing the chromatograms obtained for clonidine (a, b and c), 
halothane (d, e and f) and ibuprofen (g, h and i).  
 
 
Figure V-1: Chromatograms obtained for clonidine (a, b, and c), halothane (d, e, and f), and ibuprofen (g, h, and 
i). Chromatograms (a, d, and g), (b, e, and h), and (c, f, and i) were, respectively, obtained on the IAM.PC.DD2-
, Sphingo-IAM-, and Cholester-column. 
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The upper chromatograms (a, d and g) were obtained on the IAM.PC.DD2-column, the 
central chromatograms (b, e and h) originate from the Sphingo-IAM-column, and the lower 
chromatograms (c, f and i) were obtained on the Cholester-column. The elution order of the 
compounds varies, indicating the effect of the different stationary phases. 
 
V.5.1 Prediction of log BB 
Partial least-squares (PLS) regression was subsequently performed to determine the 
correlation coefficients (R) between actual log BB values (Table C-2) and log BB values 
predicted by use of log k values together with the other descriptors mentioned in Table C-2. 
The correlation coefficients in Table V-2a enable comparison of the merits of the different 
columns. The lowest correlation coefficient (R = 0.8604) was obtained when the Cholester-
column was used. The highest correlation coefficient (R = 0.8772) was obtained with the 
IAM.PC.DD2-column. The correlation between predicted and actual log BB values on the 
IAM.PC.DD2-column is illustrated in Figure V-2a. Except for a few outliers, the predicted 
log BB values appear sufficiently close to the actually determined values for most 
compounds. 
 
Table V-2: Correlation coefficients between predicted and experimentally determined log BB values when using 
normal partial least-squares regression (PLS) or using leave-one-out cross-validation (LOOCV) (a) and these 
correlation coefficients after elimination of 11 variables (MW, MR, MV, Polarizability, Log P, Log D7.4, Log 
WSo, WS7.4, PB, MI, and MIA) from the model (b) 
  IAM.PC.DD2 Sphingo-IAM Cholester 
a     
 R(PLS) 0.8772 0.8701 0.8604 
 R(LOOCV) 0.6231 0.6064 0.5620 
     
b     
 R(PLS) 0.8542 0.8429 0.8303 
 R(LOOCV) 0.8129 0.7994 0.7750 
 
Overfitting is an inevitable problem when the performance of multivariate calibration models 
is evaluated. To avoid overfitted models, crossvalidation (CV) methods are often used to 
detect the robustness of models. These methods include k-fold CV, twofold CV, random sub-
sampling validation, and leave-one-out crossvalidation (LOOCV) [21]. 
In this chapter, LOOCV was applied to the dataset. In this method, 48 compounds were used 
as the training set and one compound as test sample. This procedure was repeated for each 
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compound, enabling the construction of a new scatter plot; this is presented for the 
IAM.PC.DD2-column in Figure V-2b. The approach was repeated for the two other columns; 
the corresponding correlation coefficients are listed in Table V-2a. 
 
 
Figure V-2: Scatter plots comparing predicted log BB values with in vivo determined values based on retention 
factor measurements with an IAM.PC.DD2-column. Predicted log BB values are based on partial least-squares 
regression (a and c) or leave-one-out cross-validation (b and d); c and d were obtained after elimination of 
eleven descriptors from Table C-2. 
 
A relatively large average decrease of 0.2721 in regression coefficient R is observed for all 
columns when they are assessed in that way. In other words, the equations constructed for log 
BB prediction when the solutes are included, fit the training set in a much better way than is 
the case when they are not included, which is typically regarded as an indication of 
overfitting. There are at least two major sources of overfitting. The first one is related to the 
use of a too complex model (e.g. too many variables or other data). Variable selection is one 
solution used to solve this problem, in which unrelated variables are removed from the 
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training data set. The second source is related to undersampling of the underlying distribution. 
In other words, the samples presented do not cover the major range of the underlying native 
distribution of samples. In this case, more representative data or samples should be added to 
the model. 
In this chapter, variable selection was performed by systematic removal and/or reinsertion of 
all descriptors from the models while monitoring the effect on the LOOCV regression 
coefficients. This process was iteratively improved until maximum correlation was obtained 
for the LOOCV results. The maximum correlation was obtained when eleven out of fifteen 
descriptors, i.e. MW, MR, MV, Polarizability, Log P, Log D7.4, Log WSo, WS7.4, PB, MI 
and MIA were removed from the model. The correlation coefficients for the simplified 
models are listed in Table V-2b. Further descriptor removal led to a decrease in regression 
coefficients. In Figure V-2c, d, the IAM.PC.DD2-based correlations between predicted and 
actual log BB values are presented as scatter plots for the optimized models. Comparison of 
Figure V-2a, c (PLS) with Figure V-2b, d (LOOCV) enables visual assessment of the 
improvements in correlation achieved with the new IAM.PC.DD2-based model. Analogous 
conclusions can be made for analysis on the two other columns. 
To illustrate the importance of the in vitro measurements of log k values by IAMLC, variable 
selection was performed on the same set of descriptors except log k. Eventually, ten out of 
fourteen descriptors were removed from the model; only α, Pr, log P and HIA were retained. 
The obtained regression coefficients (identical for all three columns) dropped to 0.8053 (PLS) 
and 0.7508 (LOOCV). This drop in regression coefficient clearly illustrates that in vitro 
measurement of log k has a positive effect on the prediction of actual log BB values. 
The coefficients of the equations obtained from PLS regressions that lead to the R values 
listed in Table V-2b, are listed in Table V-3. The general equation for Table V-3 is: predicted 
log BB = a + b × α + c × Pr + d × HIA + e × log k. The coefficients obtained for the 
IAM.PC.DD2- and the Sphingo-IAM-column are similar, while these coefficients are 
somewhat different for the Cholester-column. This is an indication that the adsorption of 
compounds to the stationary phase is somewhat comparable for the IAM.PC.DD2- and the 
Sphingo-IAM-column. This makes sense, since both sphingomyelin and phosphatidylcholine 
have a polar phosphocholine headgroup and two apolar alkyl chains. The cholesterol bound at 
the cholester column has a completely different structure, which allows for another adsorption 
profile of the compounds and consequently other coefficients in Table V-3. 
 
Chapter V 
117 
 
Table V-3: Coefficients generated by PLS regression after elimination of eleven variables. The general equation 
for the predicted log BB values is: log BB = a + b × α + c × Pr + d × HIA + e × log k. 
 IAM.PC.DD2 Sphingo-IAM Cholester 
a -2.831 -2.750 -3.374 
b 0.444 0.653 0.735 
c -0.003 -0.003 -0.002 
d 0.042 0.039 0.044 
e 0.703 0.706 0.629 
 
 
When Tables V-2a and V-2b are compared, two important differences can be noticed. On the 
one hand, the correlation coefficient of the PLS regression has dropped for each type of 
analysis. This is logical, because the PLS regression tries to fit the data as well as possible to 
an equation. The more variables available to work with, the better the correlations that can be 
obtained, though this is mainly overfitting. On the other hand, the correlation coefficient of 
the leave-one-out cross-validation has significantly increased, demonstrating that the 
predictive capabilities of the different models have, indeed, been improved a lot by applying 
this strategy. As a result, the average difference between the PLS and LOOCV R values has 
dropped to 0.0467 in Table V-2b. Compared with the average difference of 0.2721 in Table 
V-2a, this indicates that the model after variable selection is more generalized across the data 
sets and, therefore, enables more robust prediction. 
The final correlation coefficients range from 0.7750 to 0.8129 (Table V-2b). These are 
excellent values, taking into account that in vitro HPLC methods only allow for prediction of 
passive permeation of compounds across the BBB. Consequently, all three optimized models 
are now performing very good, illustrating that all three columns are appropriate for this kind 
of measurements. 
Since all measured log k values contributed positively to the final correlation coefficients, the 
question also arose whether the combination of k or log k values could lead to an improved 
correlation coefficient. Therefore, several extra regressions were performed in which the 
obtained k or log k values for all column types (Table V-1) were combined into one new 
model with log k’ values. The results of the PLS- and LOOCV-analyses are presented in 
Table V-4. In Table V-4a, log k’ values were calculated by combining log k values; in Table 
V-4b, log k’ values were calculated by taking the logarithm of combined k values. All 
obtained correlation coefficients are smaller than these of IAM.PC.DD2 in Table V-2b. Also, 
values in Table V-4 increase when the impact of IAM.PC.DD2 is increased and decrease 
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when the impact of Cholester is increased. For this set of columns, no improvement in 
correlation coefficients could be achieved through a combination of (log) k values. 
 
Table V-4: Correlation coefficients between predicted and experimentally determined log BB values when using 
normal partial least-squares regression (PLS) or using leave-one-out cross-validation (LOOCV) after elimination 
of eleven variables from the model. Log k′ values were generated by combining log k values (a) or k values (b) 
as indicated. 
a     
 log k' = I+II+III log k' = 2×I+II+III log k' = I+2×II+III log k' = I+II+2×III 
R(PLS) 0.8485 0.8509 0.8479 0.8457 
R(LOOCV) 0.8043 0.8077 0.8041 0.7994 
I = log k values IAM.PC.DD2, II = log k values Sphingo-IAM, III = log k values Cholester 
b     
 log k' = 
log(IV+V+VI) 
log k' = 
log(2×IV+V+VI) 
log k' = 
log(IV+2×V+VI) 
log k' = 
log(IV+V+2×VI) 
R(PLS) 0.8393 0.8418 0.8396 0.8368 
R(LOOCV) 0.7911 0.7947 0.7925 0.7865 
IV = k values IAM.PC.DD2, V = k values Sphingo-IAM, VI = k values Cholester  
 
V.6 Conclusion 
As illustrated in chapter III, the IAM.PC.DD2 column is interesting for the prediction of drug 
partitioning into biological membranes. In this chapter, three IAM-columns were tested and 
their abilities towards prediction of log BB values were compared. The correlation 
coefficients between actual and predicted log BB values of the three corresponding models 
were very good; all three columns proved to be useful for this kind of prediction. The results 
obtained with the Sphingo-IAM-column proved to be similar to the commercial 
IAM.PC.DD2-column (this was also the case for the proof-of-concept correlation studies in 
chapter IV). As such, the Sphingo-IAM-column is a useful alternative for this kind of 
measurements. The Sphingo-IAM-column might also perform well at other application areas 
for which the IAM.PC.DD2-column is used, but this is a subject for other studies. 
.  
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Chapter VI. Investigation of the lipid composition of 
brain tissue 
 
VI.1 Introduction 
A striking difference regarding the in vitro research with IAM columns and MLC is the 
choice of the molecules used for emulation of the in vivo conditions. On IAM columns, 
phosphatidylcholine, cholesterol and sphingomyelin have been used (as described in chapter 
V) for the mimicking of the biological environment. Note that all these solutes are part of 
what is traditionally considered as the lipid family of molecules. With the MLC approach, 
surfactants – such as SDS, Brij35, CTAB and SDC – proved suitable to allow the prediction 
of in vivo log BB behavior, although they do not belong to the family of lipids. An overview 
of the lipid classes is given in Figure VI-1. 
Although all IAM columns and MLC surfactants described in the previous chapters can be 
used for in vitro log BB prediction, their biological relevance might be disputable. It is well 
known that phospholipids are the main constituents of membranes, but they are certainly not 
the only constituents (e.g. proteins; see Figure II-3). This chapter will focus on the 
measurement of the actual composition of (phospho)lipids in (brain) membranes, which will 
allow a better choice of future MLC and IAM conditions for in vitro log BB prediction. 
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Figure VI-1: Overview of the different lipid classes. Based on [1]. 
  
Practically every class of lipids has its own specific functions, independent of participation in 
membrane formation or use as an energy source. For example, they are involved in the control 
of transcription and translation, cell signaling, and intercellular interactions. The largest 
number of lipids and their greatest diversity are commonly found in the most organized part 
of the body, the brain. This indicates the exceptional importance of these compounds for the 
specific functions of nervous tissue. The total mass of lipids accounts for 45-50 % of the dry 
weight of the adult brain [2,3]. Previous investigations have demonstrated that the total lipid 
content of human brain (on a wet weight basis) increases after birth up to an age of 30-40 
years and slowly decreases in older individuals [4]. 
Membranes of the CNS are characterized by the greatest structural diversity relative to the 
lipid membranes of other organs, which consist primarily of a large number of molecular 
types of phospholipids. In addition to glycerophospholipids, which form the basis of 
biological membranes in all tissues, there are several types of specific lipids in the brain: 
cerebrosides, sulfocerebrosides, globosides, and gangliosides (all types of 
glycosphingolipids), whose quantity and structural diversity are typical only of this tissue. 
Different brain structures may be quite different from each other in their lipid compositions. 
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For example, the content of cholesterol in neuronal membranes is unusually high. The level of 
cholesterol is strictly regulated in the brain; cholesterol participates in the formation of lipid 
rafts and in the synthesis of important signaling molecules [2].  
 
VI.2 Available extraction and identification protocols for the analysis of biological 
tissues 
Based on the need to present a total overview of the lipid composition in membranes, several 
authors have presented methods for the extraction and/or quantification of (brain) lipids. 
Folch et al. [5] provided the first general method for the isolation and purification of lipids 
from animal tissues. In this method, a chloroform-methanol mixture was added to the tissue in 
order to dissolve the lipids. After filtering, water was added and a biphasic system was 
obtained. The lower phase (chloroform) contained almost all lipids and could subsequently be 
analysed. 
Holčapek et al. [6-8] used a modified Folch procedure for the lipidomic profiling of biological 
tissues. A lot of effort was put in the optimization of the separation and quantification of lipid 
classes. Therefore, a comprehensive lipidomic analysis was created which enabled the 
quantification of all lipid classes by separation of the lipid classes in the first dimension – 
using hydrophilic interaction liquid chromatography (HILIC)-HPLC – and identification of 
the individual lipids in the second dimension – using RP-HPLC/MS.  
Matyash et al. [9] developed a methyl-tert-butyl ether (MTBE) protocol and demonstrated that 
it provided similar or better recoveries for all major lipid classes compared to the Folch-
method. In the lipid extraction protocol, methanol, MTBE and water were used. The 
extraction procedure used later in this chapter was based on this method. Since lipids 
dissolved in the upper phase (MTBE), pipetting became easier compared to the traditional 
Folch extraction. After lipid extraction, the lipid profiling was performed by quadrupole time-
of-flight mass spectrometry (TOF-MS). 
Abbott et al. [10] developed a high-throughput lipidomic analysis of human brain samples. 
MTBE was used for extraction with mechanical homogenization using ceramic beads. The 
easy pipetting of the MTBE phase allowed automation of the collection step. Most lipids were 
analyzed via electrospray ionization MS, sterols were analyzed using gas chromatography 
mass spectrometry. This high throughput method was considered to be an improved version 
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of the traditional Folch-method, since the same lipid species were found using the high 
throughput method. MTBE is also less toxic than chloroform. 
 
VI.3 Literature overview of the lipid classes in brain tissue 
The most frequently measured lipid classes in brain tissue are mentioned together with their 
structure in Table VI-1.  
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Table VI-1: Overview of the most frequently measured lipid classes in brain tissue and their structures. The fatty 
acid composition is not fixed, therefore, alkyl chains are indicated by R1 and R2. 
 
Lipid class Abbreviation Structure
Cholesterol C
Phosphatidic acid PA
Phosphatidylcholine PC
Lysophosphatidylcholine LPC
Phosphatidylethanolamine PE
Lysophosphatidylethanolamine LPE
Phosphatidylglycerol PG
Phosphatidylinositol PI
Phosphatidylserine PS
Sphingomyelin SPM
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Table VI-2 shows a comparison of the abundances of different lipid classes in porcine, human 
and rat brain. Despite the differences in analytical methods and brain samples, the abundances 
are similar. According to this table, the two major lipid classes – PE and PC – account for 
more than 70 % of the total lipid fraction. When all porcine organs were compared [8], the 
relative abundance of PC is in the range 32-40 %, PE 26-35 %, SPM 5-19 %, PI up to 20 %, 
PS up to 13 %, LPE up to 8 %, LPC up to 7 %, and PG up to 5 %.  
 
Table VI-2: Comparison of relative abundances (%) of individual lipid classes in the brain (porcine [8], human 
or rat [11]). Based on [8]. 
Lipid class Porcine Human Rat 
 Relative abundance (%) Relative abundance (%) Relative abundance (%) 
PI 5.0 5.3 3.3 
PE 34.3 37.6 37.6 
LPE 2.3 0.0 1.4 
PS 13.1 12.5 12.7 
PC 37.1 37.6 36.9 
SPM 7.3 1.9 4.8 
LPC 0.9 0.0 1.5 
Others 0.0 5.1 1.8 
 
Table VI-3 shows a comparison of lipids present in porcine, mouse, rat, bovine and human 
brain endothelial cells (see Figure II-1).  
 
Table VI-3: Comparison of lipid composition of brain endothelial cells (porcine [12], mouse [13], rat [14], 
bovine and human [15]). Based on [16]. 
Lipid class Porcine Mouse Rat Bovine Human 
 (wt%)
a 
(wt%)
a 
(wt%)
a 
(wt%)
a 
(wt%)
a 
PC 31.7 36.8 31.9 32.1 32.1 
PE 25.2 23.4 24.4 23.9 24.5 
PS 7.5 12.9 9.8 10.6 10.3 
SPM 14.8 18.3 18.1 20.9 17.8 
PI 6.1 8.4 
b 
4.5 4.9 
PA NA NA 0.9 0.7 0.2 
C 12.7 NA NA NA NA 
Others 2.0 0.2 14.9 7.3 10.2 
  
a
 An average MW of 700 for phospholipids was used to convert mol% to wt% 
  
b
 Included in SPM     
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Comparison of Table VI-3 with Table VI-2 is not straightforward, since some other lipid 
classes were measured and the values are expressed in wt%. It is, however, notable that the 
PC/PE ratio is different in these two tables; the SPM-content also seems to be strikingly 
different. 
From the values presented in this Table VI-2 and VI-3, it can be concluded that it is very 
difficult to come up with an exact overview of lipid classes and their concentrations present in 
brain membranes. Differences between different species are obvious, but it is seldom taken 
into account that differences also arise in various sections of the brain (which will be 
illustrated in the next section of this chapter), between individuals and related to age [17]. 
Most authors are not only interested in the lipid classes present in biological tissue; also the 
carbon chain length of the fatty acids bound to these lipids (e.g. to the glycerol backbone in 
phospholipids) is very interesting [6-8,18,9,10]. One of the popular techniques to determine 
this, is a derivatization from the fatty acids to their corresponding fatty acid methyl esters 
(FAMEs), which easily allows their measurement. The obtained fatty acid composition is 
strongly dependent on the source of the lipids. A lot of variation can be found between 
different organs [8]. One general remark however, is that the fatty acids with 16 and 18 
carbon atoms usually represent 70 % or more of the total fatty acid content. 
 
VI.4 Determination of lipid classes in white and grey matter of newborn piglets 
As mentioned in the section VI.3, the presence and concentration of lipid classes in various 
parts of the brain is divergent. Research of this type is normally performed on animals, since 
experimental use of human brain is strictly regulated. Because of the size of the brain, porcine 
and bovine brain tissue are the most convenient to work with. 
The brain can be divided into areas of grey matter and areas of white matter, where grey 
matter has a darker color. Grey matter is involved in muscle control, and sensory perception 
such as seeing and hearing, memory, emotions, speech, decision making, and self-control, 
while white matter provides communication between different areas of grey matter within the 
CNS [19]. In this section, the lipid fractions of porcine white and grey matter are briefly re-
analyzed and discussed. In-house available protocols were used for analysis to assess the 
scope and variability of the published data and to ascertain the relative order of the natural 
prevalence of brain lipid solutes in an experimental way. Only porcine tissue was used during 
experiments due to obvious ethical and availability issues. 
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VI.4.1 Experimental 
VI.4.1.1 Chemicals 
All solvents used were HPLC grade. Hexane was purchased at VWR (Leuven, Belgium). 
Isopropanol, dichloromethane, methanol, MTBE, acetic acid, formic acid, ammoniumacetate, 
triolein, oleic acid, cholesterol, dioleoylglycerol, 1-oleoyl-rac-glycerol, 1,2-dioleoyl-glycero-
3-phosphoethanolamine, L-α-phosphatidylinositol, 1,2-diacyl-glycero-3-phospho-L-serine, 
1,2-dioleoyl-glycero-3-phosphocholine and sphingomyelin were purchased from Sigma-
Aldrich (St. Louis, MO, USA or Steinheim, Germany). Cholesteryloleate and L-α-
lysophosphatidylcholine were respectively from Janssen (Beerse, Belgium) and Avantipolar 
Lipids (Alabaster, AL, USA). 
 
VI.4.1.2 Sample preparation 
Grey and white matter was dissected from the cerebrum of newly born piglets (< 24h). They 
were separately collected in cryotubes and frozen by liquid nitrogen, after which they were 
freeze-dried. Lipids were extracted using a procedure mainly based on Matyash et al. [9].  
Extraction procedure: to a vial with 100 mg of sample, 1.5 mL of methanol was added after 
which the vial was put in an ultrasonic bath for 5 min. Then, 5 mL of MTBE was added and 
the mixture was incubated for 1 h at room temperature in a shaker. Phase separation was 
induced by adding 1.25 mL of water. Upon 10 min of incubation at room temperature, the 
sample was centrifuged at 1000 rpm for 10 min. The upper (organic) phase was collected and 
the lower phase was re-extracted with 3.3 mL MTBE/methanol (10:1, v/v). The combined 
organic phases were dried in an oven at 80 °C. The extracted lipids were dissolved in 8 mL of 
hexane/dichloromethane (3:1, v/v). 
Different standards – including the most prominent lipids in membranes – were dissolved at a 
concentration of 100 µg/mL and subsequently used in the comparative study. Fatty acids (FA) 
were represented by oleic acid. Cholesterol (C) and cholesteryloleate (CO) were chosen as 
sterol lipids. Triolein, dioleoylglycerol, and 1-oleoyl-rac-glycerol represented respectively the 
triacylglycerols (TGs), diacylglycerols (DGs) and monoacylglycerols (MGs). 
Phosphatidylcholines (PCs) were represented by 1,2-dioleoyl-glycero-3-phosphocholine and 
L-α-lysophosphatidylcholine (LPC). Sphingomyelin (SPM) represented the 
phosphosphingolipids. Phosphatidylethanolamines (PEs), phosphatidylinositols (PI) and 
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phosphatidylserines (PSs) were respectively represented by 1,2-dioleoyl-glycero-3-
phosphoethanolamine, L-α-phosphatidylinositol, and 1,2-diacyl-glycero-3-phospho-L-serine.  
 
VI.4.1.3 HPLC conditions 
Analyses were performed on an Alliance, Waters 2690 chromatograph. A Corona CAD-
detector (ESA Analytical, Aylsbury, Buckinghamshire, England) was used for detection using 
a pressure of 35 psi and a detection range of 500 pA. Data acquisition and processing were 
performed with a PeakSimple Chromatography Data System (model 202) and PeakSimple 
software. A Princeton SFC diol column (5 µm, 250 * 4.6 mm) (Princeton, Cranbury, NJ, 
USA) was used for separation. Experiments were performed at room temperature with a flow 
rate of 0.5 mL/min. Injection volume was 20 µL. The mobile phase gradient is presented in 
Table VI-4. 
 
Table VI-4: gradient used for lipid separation. Here, A is hexane/acetic acid (99.5:0.5, v/v); B is 
dichloromethane/isopropanol/acetic acid (49.75:49.75:0.5, v/v/v); C is isopropanol/buffer (20 mM 
ammoniumacetate at pH 3.5) (50:50, v/v); and D is isopropanol. 
Time (min) A B C D 
0 97 3 0 0 
4 97 3 0 0 
29 0 100 0 0 
30 0 80 20 0 
50 0 80 20 0 
65 0 65 35 0 
66 0 0 0 100 
80 0 0 0 100 
81 97 3 0 0 
110 97 3 0 0 
 
VI.4.2 Results and discussion 
Results obtained by analysis of grey and white matter are presented in Figure VI-2. The 
method allows for separation of both ‘neutral’ (until 29 min in Table VI-4) and ‘polar’ (from 
30 till 65 min in Table VI-4) lipid fractions. Although baseline separation was achieved for 
most compounds, PI and PS fractions could not be separated using this method.  
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Figure VI-2: Analysis of white and grey matter using HPLC-CAD. Standards were injected to obtain 
chromatogram A, while B and C were respectively obtained after lipid extraction of the white and grey matter of 
the cerebrum. Experimental conditions, sample preparation and abbreviations are mentioned in section VI.4.1. 
 
 
Several lipid standards (mainly DG, SPM and LPC, to a minor extent PI and PS) exhibit 
several peaks. For dioleoylglycerol (DG), this is explained by a slightly different retention 
profile of 1,2- and 1,3-substituted diglycerides. The other fractions – PI, PS, SPM and LPC – 
can show multiple peaks based on differences in fatty acid carbon chain length. As mentioned 
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in section VI.3, carbon chain lengths with 16 or 18 carbon atoms are the most abundant, 
although minor fractions of longer (and shorter) chains are also present. 
In Figure VI-2 B and C, all the ‘polar’ lipid fractions (PE, PI, PS, PC, SPM and LPC) are 
clearly visible, although peak shapes and heights are not completely similar. This is already a 
first visual indication of differences in various sections of the brain. The PC fraction shows 
several peaks, which illustrates the different fatty acid carbon chain lengths in biological 
samples. The ‘neutral’ lipid fraction (until 29 min) is almost exclusively limited to cholesterol 
in the analysis of grey matter (Figure VI-2 C). The clearest visual indication of differences in 
Figure VI-2 B and C is the number of peaks from 23 to 35 min in Figure VI-2 B (white 
matter). Although peak identification could not be performed due to time constraints, these 
solutes appear in the zone where glycolipids (such as cerebrosides) are expected. 
Next to the peak shapes, the relative peak areas (Table VI-5) were also somewhat divergent 
for lipid fractions of white and grey matter. Of course, this is mainly due to the high 
abundance of lipids between 23 and 35 minutes in the white matter of the brain (probably 
glycolipids; 28.1 %). However, even without considering these lipids, the relative peak areas 
of cholesterol, phosphatidylcholine, sphingomyelin and lysophosphatidylcholine in white 
matter (respectively 15.0, 41.1, 5.0 and 5.7 %) show quite some differences, which also 
illustrates the difference based on sampling area in the brain. In Table VI-5, the relative peak 
areas measured in this section are compared to the relative abundance of lipids in porcine 
brain. Peak areas can, however, not be translated into abundances without performing a 
quantification procedure (not performed due to time constraints), so comparison of the results 
is difficult here. 
 
Table VI-5: Relative abundances (%) of individual lipid classes in porcine brain [8] and relative peak areas (%) 
of individual lipid classes in the white and grey matter of newborn piglets. 
Lipid class Porcine Porcine Porcine 
  White matter Grey matter 
 Relative abundance (%) Relative peak area (%) Relative peak area (%) 
C NA 10.8 19.5 
PE 34.3 12.3 17.5 
PI + PS 18.1 11.5 15.5 
PC 37.1 29.6 36.9 
SPM 7.3 3.6 2.7 
LPC 0.9 4.1 7.9 
Others 2.3 28.1 0.0 
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VI.5 Conclusion 
In this chapter, a limited comparative study was performed with HPLC-CAD to visualize 
differences in the lipid composition of white and grey matter in newborn piglets in order to 
provide a better insight into the local lipid composition of the brain. Although the lipid 
profiles were comparable, several differences (e.g. the assumed presence of glycolipids) were 
found. It is challenging to create an exact overview of lipid classes and their concentrations in 
brain membranes, since differences arise not only between various sections of the brain, but 
also between species, individuals, and related to age.  
Like the lipid classes, the carbon chain lengths of the fatty acid groups in lipids are not fixed. 
Fatty acids with 16 or 18 carbon atoms usually represent 70 % or more of the total fatty acid 
content. Therefore, the most representative examples of natural lipids depict a carbon chain 
length of 16 or 18 carbon atoms. 
When the present lipid classes are compared to the use of MLC and IAMLC for in vitro log 
BB prediction, IAMLC (chapter V: stationary phases with phosphatidylcholine, 
sphingomyelin and cholesterol) is clearly based on a more realistic biomimicking system than 
MLC (chapter III: SDS, Brij35, CTAB, SDC, … as surfactants). The use of lipids in MLC 
would create a more realistic simulation of drug interactions in brain membranes. Therefore, 
this field is explored in more detail in chapter VII. 
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Chapter VII. In vitro prediction of human intestinal 
absorption and blood–brain barrier partitioning: 
development of a lipid analog for micellar liquid 
chromatography
7
 
 
VII.1 Summary  
Over the past decades, several in vitro methods have been tested for their ability to predict 
either human intestinal absorption (HIA) or penetration across the blood–brain barrier 
(BBB) of drugs. Micellar liquid chromatography (MLC) has been a successful approach for 
retention time measurements of drugs to establish models together with other molecular 
descriptors. Thus far, MLC approaches have only made use of commercial surfactants such 
as sodium dodecyl sulfate (SDS) and polyoxyethylene (23) lauryl ether (Brij35), which are not 
representative for the phospholipids present in human membranes. Miltefosine, a 
phosphocholine-based lipid, is presented in this chapter as an alternative surfactant for MLC 
measurements. By using the obtained retention factors and several computed descriptors for a 
set of 48 compounds, two models were constructed: one for the prediction of HIA and another 
for the prediction of penetration across the BBB expressed as log BB. All data were 
correlated to experimental HIA and log BB values, and the performance of the models was 
evaluated. Log BB prediction performed better than HIA prediction, although HIA prediction 
was also improved a lot (from 0.5530 to 0.7175) compared to in silico predicted HIA values. 
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VII.2 Introduction 
In modern drug design, the failure of many compounds in the development stage is caused by 
unfavourable absorption, distribution, metabolism, excretion, and toxicity (ADMET) 
properties. Therefore, a lot of effort is put into the field of ADMET predictions. Among these 
properties, good oral bioavailability is one of the most desirable aspects of a new drug. 
Significant effort is put in the prediction of HIA because the first step for obtaining a high oral 
bioavailability is to achieve a good oral absorption [1]. 
 
VII.3 In vivo behavior and in vitro prediction of human intestinal absorption 
Unfavourable absorption, distribution, metabolism and excretion (ADME) properties have 
been identified as a major cause of failure for candidate molecules in the later stages of drug 
development. Therefore, there is significant interest in the early prediction of ADME 
properties, with the objective of increasing the success rate of compounds reaching the 
development stage [2]. ADME properties are difficult to model for several reasons. The 
quality of experimental data varies enormously and is often limited in quantity and chemical 
diversity. In addition, ADME properties such as oral bioavailability, human intestinal 
absorption (HIA) and metabolic stability arise from multiple physiological mechanisms, 
which make them difficult to model with traditional quantitative structure-activity relationship 
(QSAR) approaches [2]. 
A widely known ADME ‘model’ is Lipinski’s ‘rule of 5’, which is used in the pharmaceutical 
industry to filter out compounds likely to be purely absorbed through the human intestine, 
based on four simple rules related to molecular properties [3]. The ‘rule of 5’ states that – 
except for compound classes that are substrates for biological transporters – poor absorption 
or permeation is more likely when: 
- There are more than 5 H-bond donors (expressed as the sum of OHs and NHs) 
- There are more than 10 H-bond acceptors (expressed as the sum of Ns and Os) 
- The MW is over 500 
- The Log P is over 5 (or MLogP is over 4.15) 
Oral intake is the most commonly used route of drug administration and the most convenient 
for patients resulting in high therapy compliance. Orally administered drug compounds should 
possess biopharmaceutical properties that enable them to achieve therapeutic concentrations 
at their site of action. The absorption of orally administered drugs is complex and depends not 
Chapter VII 
137 
 
only on drug properties (e.g. aqueous solubility, molecular size, charge, dosage form, 
absorption enhancers, …), but also on physiological aspects (e.g. intestinal pH, disease state) 
and biochemical parameters (e.g. metabolism, efflux/uptake transporters) of the 
gastrointestinal tract [4]. Based on the fact that the majority of drugs are administered via the 
oral route, and that the first step for obtaining a high oral bioavailability is to achieve a good 
oral absorption, HIA is the most studied form of biological permeation, and significant effort 
is put in its prediction [1]. 
It is well known that the major absorption barrier to drugs taken orally is the intestinal mucosa 
membrane [5]. Some of the most important intestinal drug absorption processes are depicted 
in Figure VII-1. Molecules cross the intestinal epithelium by four main pathways. Firstly, by 
passive (transcellular) diffusion across the cell membranes, which involves mainly lipophilic 
compounds. Diffusion across the cell membranes and transcellular permeation through the 
cells constitute the most important mechanisms by which drugs cross biological membranes. 
Secondly, by carrier mediated transcellular transport (e.g. of ions, glucose, and amino acids). 
This is known as active transport and requires two sets of transport proteins in the plasma 
membrane. One on the apical side of the cells to transport molecules from the gut into the cell. 
The other in the basolateral surfaces of the cells to facilitate diffusion into the extracellular 
fluid. Active transport processes require specific binding of the drug to the transporter protein; 
some proteins (e.g. P-glycoprotein [6]) can cause efflux of a drug. The third mode of transport 
is a transcytosis (of high-molecular-weight substances, such as proteins), which could be 
apically taken into the cell by endocytosis, intracellularly transported to the other side of the 
cell via the transcytotic vesicles and then released to the basolateral space by exocytosis. 
Finally, the fourth mode of absorption is passive diffusion between adjacent cells, also called 
paracellular transport, mainly applicable to water-soluble low molecular weight compounds. 
Paracellular permeation is mainly governed by the size and the number of the pores between 
the cells, as well as the size and charge of the drug [7,8]. 
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Figure VII-1: Schematic representation of the four main transport mechanisms of intestinal drug absorption. 
Hydrophobic substances can penetrate cell membranes and might be transported via the cells interior by passive 
(transcellular) diffusion (a); specific transporters mediate the transport of specific nutrients (= carrier-
mediated transport) (b); macromolecules can be transported across the cells by transcytosis (c); and 
paracellular transport is associated with passive diffusion through the space between neighbouring cells of 
water soluble lowmolecular substances (d) (based on [4,8]). 
 
The most important strategy of pharmaceutical industry to overcome its productivity crisis in 
drug discovery is to integrate early ADME profiling with toxicity (T) optimization in parallel 
with efficacy. Drug candidates with high potency at a single target and good ADMET profiles 
are widely recognised as having further opportunity for enhanced success in clinical trials [9]. 
To improve the prediction of human intestinal absorption, several in vivo [10,11], ex vivo 
(e.g. intestinal perfusion; everted gut sac experiments) and in situ (e.g. Loc-I-Gut, intestinal 
perfusion) approaches have been created [12,13]. Research towards factors that govern the 
intestinal absorption of compounds has been conducted for a long time, since understanding 
this would provide a useful guideline for the prediction of the degree and speed of absorption 
of a new drug. Schanker et al. [14] tested the absorption of a large number of acidic and basic 
compounds by the rat small intestine (in situ). Their results supported the concept that drugs 
are passively absorbed in the unionized form. Cheaper and faster (in silico and in vitro) 
methods were also created and are nowadays used for the prediction of HIA. 
An important remark is that HIA prediction models are in essence supported by in vivo 
absorption in rats. However, it has been shown that evaluation of in vivo absorption in rats 
can be used as an alternative method (because of strong correlation between the values) to 
predict the extent of HIA following oral administration [15]. 
Although the in silico approach is very attractive, its accuracy is not overwhelming [16]. 
Nevertheless, in silico models provide an inexpensive and fast way to assess the ADME 
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properties of a molecule before synthesis and they enable prioritization of molecules for in 
vitro and in vivo studies. Therefore, these models are also very interesting [17-19]. 
A variety of cellular and noncellular in vitro permeability models have been developed and 
are available for use during the preclinical ADME phase. The created models include 
PAMPA [16,20]; BAMPA [21]; RPLC, MLC, ILC and IAM [22-24]; MDCK, HT29 and 
Caco-2 cell line [9,25-28]. There is however no consensus with respect to the better model 
choice. 
 
VII.4 Limitations of current log BB predictive approaches 
Furthermore, an important question is whether or not a new pharmaceutical compound will 
have an effect on the central nervous system (CNS). This effect can be desired or can be an 
(un)fortunate side effect of a drug targeting another place in the human body. Barriers at three 
interfaces separate the blood from the brain interstitial fluid. The BBB, with the largest 
surface area (12– 18 m2 for the average human adult) and shortest diffusion distances 
(typically < 10–15 μm) to neurons, is the most important in regulating drug permeability to 
the brain. Therefore, a high degree of transportation across the BBB is often used as a 
measure for effect on the CNS [29,30]. 
Endothelial cells provide a crucial interface between blood and tissue environments. The free 
diffusion of chemicals across endothelia is prevented by endothelial tight junctions, of which 
the permeability varies considerably depending on tissue and conditions. In peripheral tissues 
(e.g., intestine, kidney, and salivary gland), these cell barriers depict fenestration enabling 
almost free exchange of water and solutes. The endothelial barrier separating the blood from 
the CNS is, however, characterized by tight junctions of severely limited permeability 
(excluding molecules with a diameter larger than 10–15 Å), no fenestrae, and an attenuated 
pinocytosis. The tight junctions significantly reduce permeation of polar (hydrophilic) solutes 
through paracellular diffusional pathways between the endothelial cells from the blood plasma 
to the brain extracellular fluid [31]. This forces molecular traffic to take a largely transcellular 
route across the brain endothelium [32-34]. The transcellular routes include passive diffusion, 
carrier-mediated, and vesicular transport mechanisms. A schematic representation of the 
various pathways involved in the BBB permeability is shown in Figure II-5. 
Most of the currently used active drug substances cross cells by passive permeation. In this 
process, a substance dissolved in the membrane lipid bilayer permeates through the membrane 
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and enters into the cytoplasm of the cell. To establish an adequate concentration gradient for 
passive permeation, the substance must not only be soluble in lipids but it must also be 
sufficiently soluble in water due to the aqueous nature of the extracellular and intracellular 
spaces. Therefore, lipid/water partitioning is an important factor governing a substance’s 
ability to diffuse through cell membranes [23]. A common measure of the degree of BBB 
permeation is the ratio of the steady-state concentration of the drug molecule in the brain to 
concentration in the blood, usually expressed as log (Cbrain/Cblood) or log BB [35,36]. 
In an attempt to avoid the time-consuming and expensive in vivo log BB determinations, the 
modeling of BBB permeation has gained in popularity. Both in silico and in vitro models have 
been proposed for this [36-38]. Contrary to the in silico models whereby no experiments are 
performed, in the in vitro chromatographic models, the lipid environment of the barrier is 
mimicked by dynamically or covalently immobilizing lipids on a column. The affinity of the 
solutes for the immobilized phase is then combined with physicochemical parameters or 
molecular descriptors for optimal model construction. 
In quantitative structure-activity relationship (QSAR) methods, the biological activity of 
solutes or their ability to penetrate the different hydrophobic barriers (membranes) is related 
to their physicochemical properties. One of the main drawbacks is that many biologically 
active compounds of interest in QSAR studies are ionic at physiological pH, and ionic organic 
compounds are not or only weakly retained in reversed-phase liquid chromatography (RPLC) 
[39]. 
A possible way to circumvent this problem is the use of MLC, which has been a popular 
technique in high-performance liquid chromatography (HPLC) to model drug behavior. MLC 
is a mode of RPLC which uses a surfactant solution above the critical micellar concentration 
(CMC) as mobile phase [37,40]. Neutral polyoxyethylene (23) lauryl ether is the most widely 
used surfactant for BBB permeation modeling, but anionic sodium dodecyl sulfate and 
cationic cetyltrimethylammonium bromide have also been used frequently [37,41]. Above the 
CMC, a change in surfactant concentration is translated in an increase in the concentration of 
micelles in the solution, whereas the number of monomers of surfactant in the mobile phase 
remains constant. Adsorption of an approximately fixed amount of surfactant monomers on 
the stationary phase is also produced, giving rise to a stable modified column and regular 
retention behavior. MLC is a fascinating example of the benefits of secondary equilibrium in 
RPLC (see Figure VII-2). The primary equilibrium is solute partitioning between bulk solvent 
and the stationary phase. A secondary equilibrium is established with the micelles in the 
mobile phase. Both equilibria are affected by a variety of factors, such as the nature and 
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concentration of the surfactant and additives (e.g., salts), temperature, ionic strength, and pH. 
This added complexity of MLC compared to conventional RPLC [41,42] also allows 
improved mimicking of the BBB environment. 
 
 
Figure VII-2: Schematic representation of drug interactions in MLC. When a surfactant is used above the CMC, 
retention depends on interactions with the modified stationary phase and with the micelles present in the mobile 
phase. A regular retention behavior is achieved based on a fixed amount of surfactant monomers bound to the 
stationary phase. Modified from [43]. 
 
The main chromatographic advantages of MLC are: (i) simultaneous separation of charged 
and uncharged compounds, (ii) direct on-column injection of physiological fluids, (iii) unique 
separation selectivity (Figure VII-2; different types of surfactants are possible), (iv) low cost 
and toxicity, (v) enhanced luminescence detection, and (vi) the biodegradability of the 
solvents used [44-46]. However, MLC is not a very popular technique due to poor column 
efficiency and the weak solvent strength of micellar eluents. The two main approaches that 
have been used to enhance efficiency in MLC are to increase the temperature and to add low 
amounts of organic modifier to the mobile phase, although some caution should be taken 
concerning the compounds for which to use an additional organic modifier and the total 
percentage of modifier [39,42]. 
Micellar mobile phases have been used for all kinds of purposes in RPLC. The surfactants can 
be charged positive or negative or can be neutral. The retention of a compound in MLC 
depends on the type of interaction (electrostatic and/or hydrophobic) with the micelles and 
with the surfactant-modified stationary phase. Non-ionic solutes are supposed to be only 
affected by hydrophobic interactions, and charged solutes can be subject to hydrophobic 
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and/or electrostatic interactions [39]. When the net charge is the same for structurally related 
compounds, differences in retention arise from differences in hydrophobicity. 
A general disadvantage of MLC is that only passive diffusion (see Figure II-5) can be 
accounted for when using this technique. MLC does not consider the potential role of 
paracellular transport, carrier-mediated transport, vesicular transport, or drug metabolism on 
permeability. Although passive diffusion is assumed to be the major factor in drug absorption, 
overlooking the possible influence of all these other factors can be dangerous and may 
provide a very limited view of the true absorption potential of a compound [27]. Therefore, it 
is relevant to mimick the biological structure of cell membranes as much as possible via the 
use of micelles with high biosimilarity. 
 
VII.5 Miltefosine as a new lipid-like surfactant for improved HIA and log BB prediction 
Phospholipids are the major components of cell membranes. These structures – with a 
hydrophilic ‘head’ and a hydrophobic ‘tail’ – could therefore serve as good surfactants for 
MLC. Thus far, they have not been used as surfactants in MLC, probably as a consequence of 
cost and solubility issues of many natural phospholipids. However, various synthesis routes 
have been described for phospholipids [47-49], lysophospholipids [50], and 
alkylphosphocholines [51-57]. Miltefosine, an alkylphosphocholine, is an antitumor drug 
[48,52,55,58] which has also been tested for the oral treatment of visceral leishmaniasis 
[49,59] and for its antifungal and antimicrobial activity [53-57]. 
Considering the chemical analogy with the other linear synthetic micelformers, and the 
relatively simple composition allowing bulk synthesis and cheap MLC, it is highly relevant to 
investigate the use of miltefosine (and of its structural variants) as surfactant in MLC for the 
prediction of biological behavior. The achievable model quality with input from various 
descriptors is evaluated in this contribution using 48 pharmaceutical drugs with known log 
BB values and a subset of 36 drugs with known HIA values. The corresponding models were 
constructed by partial least squares regressions (PLS) and the added value of the retention 
factor was investigated. 
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VII.6 Materials and methods 
VII.6.1 Chemicals 
The solutes were obtained from several sources: 2,2,2- trifluoroethyl vinyl ether, 2,6-
diisopropylphenol, acetaminophen, acetylsalicylic acid, aminopyrine, amitriptyline, 
amobarbital, antipyrine, atenolol, caffeine, carbamazepine, chlorambucil, chlorpromazine, 
cimetidine, clonidine, cotinine, desipramine, domperidone, eserine, ethylbenzene, 
fluphenazine, halothane, haloperidol, hexobarbital, hydroxyzine, ibuprofen, imipramine, 
mianserin, N-methyl-2-pyridineethanamine, omeprazole, oxazepam, pentobarbital, 
phenylbutazone, phenytoin, promazine, propranolol, pyrilamine, quinidine, ranitidine, 
ropinirole, salicylic acid, theobromine, theophylline, toluene, valproic acid, verapamil 
(Sigma-Aldrich, St. Louis, MO, USA or Steinheim, Germany), indomethacin (Fluka, St. 
Louis, MO, USA), and benzene (Acros, Geel, Belgium). 
 
VII.6.2 Apparatus 
Compound structure verification was achieved using NMR. NMR measurements were 
performed on a Bruker Avance 300 MHz Ultrashield spectrometer. Synthesis products were 
dissolved in CD3OD before analysis. Data was processed with ACDLABS 12.0 1 D NMR 
processor software.  
An Agilent HPLC 1290 system (Agilent Technologies, Waldbronn, Germany) consisting of a 
binary pump, a diode array detector with a micro flow cell (volume: 1 μL, pathlength: 10 
mm), and a 6230 time-of-flight mass spectrometer (TOF-MS) equipped with a Jetstream 
Electrospray Ionization source was used for the mass determination during synthesis. The 
system was operated with the Agilent Masshunter software for instrument control and data 
acquisition. The injection volume was 2 μL, and all experiments were conducted at a 
temperature of 20 °C. TOF-MS detection was performed in the positive ionization mode. 
Mass was scanned in the range from 100 to 1000 amu. 
Fluorescence spectra and intensities were obtained at room temperature with waters 474 
scanning fluorescence detector coupled to an Alliance, Waters 2690 chromatograph (Milford, 
MA, USA) with a quaternary pump and an automatic injector. The flow rate was set at 0.5 
mL/min, and 20 μL was injected for each run. The excitation and emission wavelengths for 8-
anilino-1-naphthalenesulfonic acid magnesium salt (ANS, TCI Europe, Zwijndrecht, 
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Belgium) were, respectively, set at 370 and 470 nm. Data acquisition and processing were 
performed with a PeakSimple Chromatography Data System (model 202) and PeakSimple 
software (SRI Instruments, Torrance, CA, USA). 
MLC retention analyses were performed on an Alliance, Waters 2690 chromatograph. A 
Waters 2487 dual wavelength absorbance detector (Milford, MA, USA) was used. The 
detection wavelength was set between 210 and 300 nm, depending on the analyzed compound 
(the exact wavelengths are presented in Table VII-1). Data acquisition and processing were 
performed with a PeakSimple Chromatography Data System (model 202) and PeakSimple 
software. MLC experiments were performed on a Grace GraceSmart C18 (3 μm, 150×2.1 mm) 
(Deerfield, IL, USA) column at 37 °C with a flow rate of 0.2 mL/min.  
 
VII.6.3 Synthesis  
For the synthesis of hexadecylphosphocholine, the following products were used: cetyl 
alcohol and triethylamine (Acros, Geel, Belgium), toluene (Sigma-Aldrich, St. Louis, MO, 
USA or Steinheim, Germany), trimethylamine, and 2-chloro-1,3,2-dioxaphospholane-2-oxide 
(TCI Europe, Zwijndrecht, Belgium).  
 
VII.6.4 Testing of the critical micellar concentration 
A stock solution of 450 μM ANS (= 8-Anilino-1-naphthalenesulfonic acid) in water was 
prepared for the fluorescent tests. During fluorescence measurements, the ANS concentration 
was diluted to 15 μM. Fluorescence tests were performed by several additions of small 
aliquots of the surfactant to the solution of ANS. Reported values are averages of triplicate 
injections. The emission intensity was recorded 2 h after preparation of the samples to allow 
them to reach an equilibrium. 
 
VII.6.5 Mobile phase and sample preparation 
The mobile phase used in MLC was composed of an aqueous solution of 0.01 M miltefosine. 
The pH was adjusted with a phosphate buffer at pH 7.4, prepared with 0.05 M disodium 
hydrogen phosphate (Sigma-Aldrich) and potassium dihydrogen phosphate (Sigma-Aldrich). 
In order to reproduce the osmotic pressure of biological fluids, NaCl (9.20 g/L) (Sigma-
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Aldrich) was added to the micellar mobile phase. The mobile phase was vacuum-filtered 
before use through a 0.45-μm nylon membrane (Grace, Lokeren, Belgium).  
 
Table VII-1: List of selected compounds and their detection wavelengths. Experimentally determined log BB 
and HIA
a
 values are presented, as well as the log k values of these compounds measured by MLC. 
No. Compound UV (nm) log BB HIA (%) log k 
1 2,2,2-trifluoroethyl vinyl ether 210 0.13  1.75 
2 2,6-diisopropylphenol 210 0.48  2.30 
3 acetaminophen 254 -0.31 83 0.55 
4 acetylsalicylic acid 230 -0.50 88 0.41 
5 aminopyrine 254 0.00 100 0.64 
6 amitriptyline 254 0.98 72 2.67 
7 amobarbital 210 0.04  1.47 
8 antipyrine 240 -0.10 98 0.39 
9 atenolol 270 -1.42 51 0.76 
10 benzene 210 0.37 97 1.49 
11 caffeine 210 -0.05 100 0.21 
12 carbamazepine 210 0.00 89 1.75 
13 chlorambucil 254 -1.70 94 1.87 
14 chloropromazine 254 1.06 87 2.57 
15 cimetidine 210 -1.42 75 0.74 
16 clonidine 270 0.11 96 1.21 
17 cotinine 260 -0.32  1.90 
18 desipramine 254 1.20 99 2.29 
19 domperidone 270 -0.78 93 2.43 
20 eserine 240 0.08  1.23 
21 ethylbenzene 210 0.20 82 1.61 
22 fluphenazine 263 1.51  2.54 
23 haloperidol 254 1.34 70 2.11 
24 halothane 210 0.35  1.53 
25 hexobarbital 254 0.10 95 1.28 
26 hydroxyzine 210 0.39  1.88 
27 ibuprofen 270 -0.18 97 1.68 
28 imipramine 240 1.06 99 2.42 
29 indomethacin 210 -1.26 100 1.69 
30 mianserin 280 0.99  2.81 
31 N-methyl-2-pyridineethanamine 254 -0.30 100 0.81 
32 omeprazole 300 -0.82 80 1.99 
33 oxazepam 230 0.61 92 1.96 
34 pentobarbital 210 0.12  1.55 
35 phenylbutazone 240 -0.52 94 1.45 
36 phenytoin 210 -0.04 90 2.17 
37 promazine 254 1.23 40 2.37 
38 propranolol 290 0.64 94 2.46 
39 pyrilamine 300 0.49  2.22 
40 quinidine 254 -0.46 81 1.92 
41 ranitidine 230 -1.23 55 0.42 
42 ropinirole 254 0.25 100 1.44 
43 salicylic acid 300 -1.10 100 0.16 
44 theobromine 270 -0.28  -0.10 
45 theophylline 270 -0.29 99 0.13 
46 toluene 210 0.37 100 1.60 
47 valproic acid  210 -0.22 100 0.18 
48 verapamil 210 -0.70 90 2.34 
a
 Empty boxes in the table indicate that in vivo HIA values were not available 
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The stock solutions of all drugs were prepared by dissolving 10 mg in 1 ml of methanol 
except for quinidine and theobromine where stock concentrations of 1 mg/ml and 200 μg/ml 
were used, caffeine and theophylline which were dissolved in water (10 mg/ml), and 
domperidone which was dissolved in dimethyl sulfoxide (10 mg/ml). Stock solutions were 
stored at 5 °C, except for atenolol, which was stored at -20 °C. Working solutions were 
prepared by dilution of the stock solutions (to 50 μg/ml) with mobile phase. 
 
VII.6.6 Data sources, software, and processing 
A total of 48 values of logarithm of brain–blood distribution coefficients (= log BB) were 
collected from a number of sources [60-62]. Also, for 36 of these compounds, experimental 
HIA values (ranging between 40 and 100 %, see Table VII-1) were found in literature [1,63-
73,19,74-76]. The experimental values of log BB (Table VII-1) range between -1.70 and 1.51. 
The values of the acidity constants (not shown in Table C-3; Appendix C) were obtained from 
references [77,78] or were calculated. The acidity constants were used to calculate the total 
molar charge (α) values at pH 7.4. Structural parameters (molar refractivity (MR), molar 
volume (MV), parachor (Pr), and polarizability) were calculated using the ACD/Chemsketch 
software. Other parameters (log P, log D7.4, intrinsic aqueous solubility (log WSo), pH 
solubility profile (WS7.4), plasma protein binding (PB), Ames test mutagenic index (MI and 
MIA), and human intestinal absorption (HIA)) were predicted with Chemsilico prediction 
software (Chemsilico free trial version). The values for polar surface area (PSA) and 
molecular surface area (MSA) were collected from Chemicalize.org [79]. Hydrogen bond 
donor (HBD) and hydrogen bond acceptor (HBA) values were achieved from Chemspider 
[80]. The values for these parameters are presented in Table C-3. The experimental logarithms 
of the retention factors (log k) are listed in Table VII-1. All retention data are averages of 
minimally duplicate determinations. Relative standard deviations ranged between 0.01 and 
17.82 %; the largest (>10 %) deviations were found for compounds with low retention (log k 
< 0.6) and were partially caused by fluctuations in t0. Microsoft Excel (Microsoft Corporation, 
v. 2007) and Matlab (version 8.1) were used to perform statistical analysis of the results. 
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VII.7 Rationale 
VII.7.1 Synthesis 
Synthesis of alkylphosphocholines has been described by several authors [51-59,81,82]. Our 
synthesis route was slightly modified from a previously reported procedure by Zhang et al. 
[54]. A mixture of cetyl alcohol (100 mg, 0.41 mmol) and Et3N (288 μL, 2.06 mmol) in 
anhydrous toluene (8.25 mL, 77.90 mmol) was cooled to 0 °C. To this solution, 100 μL (1.08 
mmol) of 2-chloro-1,3,2-dioxaphospholane-2-oxide was added dropwise while stirring. The 
solution was kept at 0 °C for 15 min, warmed to room temperature, and stirred for an 
additional 4 h. The precipitation formed during the reaction was removed through filtration, 
and the filtrate was concentrated in vacuo yielding an oily residue 1 (Figure VII-3). 
 
 
Figure VII-3: Synthesis route for hexadecylphosphocholine (miltefosine). The individual steps are described in 
the text. 
 
For the synthesis of hexadecylphosphocholine, NMe3 (9 mL, 18 mmol, 2 M in anhydrous 
THF) was added to the oily residue in a pressure tube. The mixture was heated to 70 °C for 48 
h, subsequently quenched with MeOH and concentrated in vacuo. MeOH/CH3CN (1.3 mL, 
10/90, v/v) was added, and all solids were removed through filtration. A final recrystallization 
from acetone of the concentrated filtrate afforded the target compound. 
 
VII.7.2 Testing of the critical micellar concentration  
After obtaining the target compound, its CMC was determined. Several methods exist for the 
estimation of the CMC of surfactants. These methods include the use of fluorimetric titrations 
of ANS or rhodamine 6G [54,83,84] and the variation of surface tension [56,85-87]. 
Fluorescent probes are particularly useful to detect changes in physicochemical properties of 
the compounds kept in solution even at very low concentrations. Mast and Haynes [88] 
reported that an enhancement of fluorescence of the anionic ANS was observed with 
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nonionic, anionic, and zwitterionic surfactants. The anionic dye, ANS, is almost 
nonfluorescent in water, but becomes highly fluorescent in organic solvents or when bound to 
most macromolecules. Rhodamine 6G has also proven to be effective with either zwitterionic, 
cationic, or nonionic surfactants. This dye is strongly fluorescent in water, and its 
fluorescence is usually quenched upon binding. The use of ANS or rhodamine 6G with a 
surfactant of opposite charge may lead to interactions when the surfactant is at concentrations 
below the CMC, leading to less reliable results. When considering a zwitterionic surfactant, 
both ANS and rhodamine 6G show a good response [83]. 
 
VII.7.3 Prediction of HIA and log BB 
The accuracy of prediction of a model is dependent on the type of model which is selected, 
the relevance, diversity, and orthogonality (independency) of the input variables used therein 
and on the shortlist of those which have been retained after model optimization, the size of the 
training set, and on the similarity of the test molecules versus the training set.  
Next to in silico strategies, applying only mathematically processed descriptors [36,60,89,90], 
the approach whereby chromatographic retention data is used as additional in vitro input in 
these models is labeled by the terminology quantitative retention activity relationships 
(QRAR) or quantitative structure retention relationships (QSRR). The latter have been well 
reviewed by Héberger [91]. This type of multivariate problem is typically solved by the 
algorithm family of multivariate calibrations, such as the multiple linear regression (MLR), 
principle component regression (PCR), and partial least squares (PLS) methodology.  
Considering multivariate calibrations, both MLR and PLS models have been proposed for 
drug absorption predictions whereby mathematically generated descriptors are combined with 
retention data [23,77,18]. In this chapter, PLS was chosen as regression model. All the above 
mentioned methods from the family of multivariate calibrations can provide an equation of 
the type y = b0 + b1 x1 + b2 x2 + … + bn xn, where y is the predicted (HIA or log BB) value, b0 
until bn are constants, and x1 until xn are variables (descriptors). Obtaining a suitable (and 
preferably simple) equation of this type is one of the main goals in this chapter. 
As the accuracy of the response (in this case HIA or log BB) of the model depends both on 
the choice and on the relevance of the used descriptors, the use of solute retention data in the 
model is particularly attractive since it represents the affinity of a compound in a column 
environment emulating the physiology of a membrane. 
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Following mathematically processed descriptors were used in analogy with a previous MLC 
study [77]: total molar charge (α), molecular weight (MW), molar refractivity (MR), molar 
volume (MV), parachor (Pr), polarizability, and the logarithm of octanol-water partition 
coefficients (log P). This set was expanded by inclusion of the logarithm of octanol–water 
distribution coefficients at pH 7.4 (log D7.4), intrinsic aqueous solubility (log WSo), 
solubility profile at pH 7.4 (WS7.4), plasma protein binding (PB), Ames test mutagenic index 
(MI and MIA), human intestinal absorption (HIA), polar surface area (PSA), hydrogen bond 
acceptor and donor (HBA and HBD), and molecular surface area (MSA). The α values, which 
can be positive of negative, were calculated as in reference [92]. 
All calculated descriptors are presented in Table C-3. In this chapter, PLS models are 
constructed based on the retention data of 36 (or 48) solutes for which experimental HIA (or 
log BB) data are available together with the set of molecular descriptors mentioned above. 
The merits of the models are evaluated. 
 
VII.8 Results and discussion 
In this section, the results for the synthesis of miltefosine are presented. Afterwards, the CMC 
of miltefosine is determined, providing a good base for its use as a surfactant in MLC. Finally, 
the results of the chromatographic runs with miltefosine as surfactant are used together with 
other descriptors for the prediction of HIA and log BB values. 
 
VII.8.1 Synthesis of hexadecylphosphocholine (= miltefosine).  
The synthesis procedure can be found in the “Rationale”. After the first step of the synthesis, 
HPLC-TOF-MS was used to check the oily residue (1 in Figure VII-3). This molecule, with a 
molecular weight of 348.2429 Da, provided the major m/z peak of 349.2463 (Figure VII-4a). 
The peaks with m/z 697.4892 and 719.4757 are the (2M+H)
+
 and the (2M+Na)
+
 fragments. 
Miltefosine (= hexadecylphosphocholine), a white-brownish solid with a molecular weight of 
407.3164 Da, was evaluated with HPLC-TOF-MS (Figure VII-4b), and with 
1
H- and 
13
C-
NMR (results at end of this paragraph). In Figure VII-4b, the peaks at m/z 408.3198 and 
815.6362 are provided by miltefosine, clearly illustrating a good purity of the product. The 
overall yield of the reaction was 58 %. 
1
H-NMR (300 MHz, MeOD-d4) δ ppm 4.25–4.36 (m, 
2 H), 3.85–3.95 (m, 2 H), 3.64–3.73 (m, 2 H), 3.21–3.29 (m, 9 H), 1.64 (m, J= 7.00 Hz, 2 H), 
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1.17–1.47 (m, 26 H), 0.83–0.97 (m, 3 H). 13C-NMR (75 MHz, MeOD-d4) δ ppm 67.59 (CH2), 
67.48 (CH2), 60.74 (CH2), 54.84 (CH3), 33.22 (CH2), 32.02 (CH2), 30.95 (CH2), 30.63 (CH2), 
27.04 (CH2), 23.88 (CH2), 14.63 (CH3). 
 
 
Figure VII-4: TOF-MS spectra, conditions as mentioned in “Materials and methods”. The molecular weight of 
the molecule in a is 348.2429 Da. In b, the mass spectrum of miltefosine is shown. This molecule has a 
molecular weight of 407.3164 Da. 
 
VII.8.2 Testing of the CMC  
Since the choice of appropriate MLC conditions is important, initial knowledge of the CMC 
of miltefosine was crucial. After miltefosine was obtained, its CMC was determined using an 
online flow injection system with a fluorescence detector. According to literature [56,86,87], 
miltefosine has a CMC of around 0.012 mM. Based on the report of De Vendittis [83], this 
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should be measurable by fluorescence with both the anionic ANS and the cationic rhodamine 
6G since both fluorescent molecules were proven to be effective with zwitterionic surfactants. 
Here, tests were performed with 15 μM ANS solutions and miltefosine concentrations ranging 
from 3 to 45 μM. The average areas (after subtracting the blank peak areas) obtained with 
miltefosine concentrations of 3, 6, 9, 12, 15, 21, 30, and 45 μM were, respectively, 12, 11, 18, 
17, 20, 39, 61 and 93. These values are represented in Figure VII-5. The CMC is defined as 
the breakpoint in the plot of peak area vs concentration. As can be seen in Figure VII-5, two 
separate trendlines can be drawn, giving rise to an intersection somewhere between 12 and 15 
μM, very close to the imposed CMC of 12 μM. 
 
 
Figure VII-5: Critical micellar concentration of miltefosine in H2O with 15 μM ANS. Results based on 20 μL 
injections with a flow rate of 0.5 mL/min at 25 °C. The excitation and the emission wavelengths were, 
respectively, 370 and 470 nm. All values are averages of triplicate injections. Standard deviations of each point 
are indicated in the figure. 
 
Compared to more common surfactants, like sodium dodecyl sulfate (8.2 mM), 
cetyltrimethylammonium bromide (0.92 to 1 mM), and polyoxyethylene (23) lauryl ether (91 
μM), the CMC of miltefosine is very low. This implies that MLC could be performed with 
miltefosine at lower concentrations than when other surfactants are used. A rather high 
surfactant concentration is however pleasant since retention time decreases when the micelle 
concentration increases.  
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VII.8.3 The use of miltefosine as surfactant 
A concentration of 10 mM miltefosine was chosen for MLC. One of the major advantages of 
MLC is the possibility to use a purely aqueous mobile phase. Although organic solvents can 
be used, they are preferentially avoided since a high concentration can lead to a change or a 
disruption of the micelles. Elution times can be decreased by increasing the temperature, the 
surfactant concentration, or the amount of organic solvent. In Figure VII-6, the obtained 
chromatograms for some of the measured compounds are given. The peak shapes were 
usually nice, although the efficiency for this type of runs was not very high (quite broad 
peaks), and some compounds (e.g., atenolol) were subject to some tailing. The 
chromatographic efficiency is, however, comparable to what is obtained in conventional MLC 
on this type of column.  
 
 
Figure VII-6: Chromatograms obtained for acetaminophen, acetylsalicylic acid, amobarbital, atenolol, halothane, 
ibuprofen, indomethacin, pentobarbital, and phenylbutazone. HPLC and solvent conditions can be found under 
“Materials and methods”. 
 
The logarithms of the retention factors (log k) measured in this chapter using 10 mM of 
miltefosine as surfactant in a purely aqueous buffer are listed in Table VII-1. As can be seen, 
14 out of the 48 compounds have a log k value > 2, indicating a very long elution time. 
However, in this case, there would only be one interesting option to decrease these elution 
times. Increasing the temperature is no option since 37 °C is the most relevant for mimicking 
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the body temperature. Since it was not easy to solubilize miltefosine in a phosphate buffer at a 
concentration of 10 mM, increasing the surfactant concentration does not seem to be the best 
choice. The final option, i.e., the addition of organic modifier (methanol or acetonitrile), 
would therefore be the most promising alternative to reduce the log k values, providing the 
amount of modifier is limited. 
 
VII.8.4 Prediction of HIA and log BB  
Partial least-squares (PLS) regression was performed to determine the correlation coefficients 
(R) between actual HIA or log BB values (Table VII-1) and those values predicted by use of 
log k (Table VII-1) values together with the descriptors mentioned in Table C-3. The 
correlation coefficients in Table VII-2a give an indication of the performance of the model. 
The correlation coefficient for the 36 compounds with experimental HIA values (R = 0.8237) 
was substantially lower than for the 48 compounds with experimental log BB values (R = 
0.8827).  
 
Table VII-2: Correlation coefficients between predicted and actual HIA and log BB values when using partial 
least-squares regression (PLS) or using leave-one-out cross-validation (LOOCV) (a) and these correlation 
coefficients after elimination of 12 (for HIA) or 11 (for log BB) variables from the model (b). 
  HIA log BB 
a    
 R(PLS) 0.8237 0.8827 
 R(LOOCV) 0.3666 0.5298 
b    
 R(PLS) 0.7991 0.8484 
 R(LOOCV) 0.7175 0.7849 
 
Overfitting is an inevitable problem when the performance of multivariate calibration models 
is evaluated. To avoid overfitted models, cross-validation (CV) methods are often used to 
detect the robustness of models. These methods include k-fold CV, 2-fold CV, random 
subsampling validation, and leave-one-out cross-validation (LOOCV) [93]. 
In this chapter, LOOCV was applied to the data set. In this method, 35 (or 47 for log BB) 
compounds were used as the training set and one compound as test sample. This procedure 
was repeated for each compound. The correlations between predicted and actual values by 
LOOCV are illustrated by a scatter plot in Figure VII-7a (HIA values) and VII-7b (log BB 
values). The corresponding correlation coefficients (0.3666 and 0.5298) can also be found in 
Table VII-2a. A large difference between R values from PLS and LOOCV regressions is 
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observed, which is a clear indication for overfitting. In other words, the equations constructed 
for HIA and log BB prediction, when the test sample is included, fit the training set in a much 
better way than is the case when it is not included, which is typically regarded as an indication 
of overfitting.  
 
 
Figure VII-7: Scatter plots comparing predicted leave-one-out cross-validation HIA values (a and c) or log BB 
values (b and d) with actual values. Predicted values are calculated using several descriptors and log k values 
from MLC with 10 mM miltefosine. Predicted R values based on LOOCV were calculated before (a and b) and 
after (c and d) optimization (elimination) of several descriptors from Table C-3. 
 
There are two major sources of overfitting. The first source is related to the use of a too 
complex model (e.g., too many variables or other data). This problem can be solved by 
variable selection – unrelated variables are removed from the training data set, making the 
model more generalized for both training and test data sets. The second source is related to 
undersampling of the underlying distribution. In other words, the samples presented do not 
cover the major range of the underlying native distribution of samples. In this case, there is 
little that can be done unless more representative data or samples can be added to the model. 
Therefore, variable selection was performed by systematic removal and/or reinsertion of all 
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descriptors from the models while monitoring the effect on the LOOCV regression 
coefficients. This process was iteratively improved until maximum correlation was obtained 
for the LOOCV results. 
The maximum correlation was obtained when 12 (for HIA) or 11 (for log BB) out of 19 
descriptors were removed from the model. The correlation coefficients for the simplified 
models are listed in Table VII-2b. Further descriptor removal led to a decrease in LOOCV 
regression coefficients. In Figure VII-7c, d, the correlations between the predicted and actual 
values are presented as scatter plots for the optimized LOOCV models. Comparison of Figure 
VII-7a, b with c and d enables visual assessment of the improvements in correlation achieved 
by optimizing the model. 
The coefficients of the equations obtained from PLS regressions that lead to the R values 
listed in Table VII-2b are listed in Table VII-3. The equations indicated by Table VII-3 are: 
 Predicted HIA = a + b × log k + c × α + d × MW+ e × Pr + g × log WSo + j × HIA 
+ m × MSA 
 Predicted log BB = a + b × log k + c × α + f × polarizability + h × WS7.4 + i × PB 
+ j × HIA + k × PSA + l × HBA  
 
Table VII-3: Coefficients generated by PLS regression after elimination of variables. The general equation for 
the predicted values is: x = a + b × log k + c × α + d × MW + e × Pr + f × polarizability + g × log WSo + h × 
WS7.4 + i × PB + j × HIA + k × PSA + l × HBA + m × MSA 
 HIA log BB 
a -5.350 -2.669 
b 12.349 0.234 
c -8.390 0.699 
d 0.115 - 
e -0.243 - 
f - -0.048 
g 6.532 - 
h - -0.002 
i - 0.009 
j 1.117 0.034 
k - -0.017 
l - 0.167 
m 0.267 - 
 
The descriptors that are withheld in the final models are almost completely different for both 
models. This is nice since there is a large difference in the physiology of the intestinal 
membranes and the BBB. These two models thus indicate that descriptor selection cannot be 
generalized and should be performed for each case separately. In both models, log k is 
retained, which indicates that this experimentally measured value gives additional input that is 
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not provided by the selected descriptors. For the prediction of HIA values, one of the retained 
descriptors is HIA, which was predicted by the Chemsilico prediction software. Although this 
descriptor provides quite some information on its own (R(PLS) = 0.5992 and R(LOOCV) = 
0.5530), these values are not sufficient. The increase for R(LOOCV) to 0.7175 in Table VII-
2b indicates that the other descriptors also contribute to a large extent in providing a better 
prediction model. 
When Table VII-2a, b is compared, two important differences can be noticed. On the one 
hand, the correlation coefficient of the PLS regression has dropped for each type of analysis. 
This is logical because the PLS regression tries to fit the data as well as possible to an 
equation. The more variables available to work with, the better the correlations which can be 
obtained, though this is mainly overfitting. On the other hand, the correlation coefficient of 
the leave-one-out cross-validation has significantly increased, demonstrating that the 
predictive capabilities of the different models have, indeed, been improved a lot by applying 
this strategy. As a result, the average difference between the PLS and LOOCV R values has 
dropped to 0.0725 in Table VII-2b. Compared with the average difference of 0.4050 in Table 
VII-2a, this indicates that the model after variable selection is more generalized across the 
data sets and, therefore, enables more robust prediction. 
The final correlation coefficients in Table VII-2b, 0.7175 and 0.7849, indicate that the log BB 
values are predicted in a better way than what is possible for the HIA values. The 
comparatively lower correlation observed for the HIA prediction can probably partially be 
attributed to the choice of sample set. As can be seen in Table VII-1, 23 compounds (out of 
36) have a HIA value ≥ 90, and 30 compounds have a HIA value ≥ 80. Since the chosen 
compounds do not homogeniously cover the range from 0 to 100 %, and the focus is placed 
on compounds with high HIA values, it is more difficult to model for compounds with a low 
HIA value, as can be seen clearly for promazine (HIA = 40 %). Nevertheless, the final 
correlation coefficient for log BB (0.7849) is a satisfactory value, taking into account that in 
vitro HPLC methods only allow for prediction of passive permeation (b in Figure II-5) of 
compounds across the BBB. Miltefosine can thus be considered to be an alternative surfactant 
for MLC in predicting log BB values. The prediction of HIA values could probably be 
improved if a more diverse set of compounds and descriptors would be selected, but the 
approach shows potential as an alternative or complementary MLC strategy for the prediction 
of in vivo behavior. 
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VII.9 Conclusion 
In this chapter, miltefosine was synthesized and evaluated as a possible surfactant in MLC. 
Retention of compounds proved to be shorter compared to a purely aqueous mobile phase, 
indicating that the principle of MLC also works with miltefosine-based micelles. Since a 
phosphocholine-based lipid is structurally more similar to biological membranes than 
common surfactants, retention data was used for in vitro predictions of HIA and log BB 
values. The optimized model for HIA prediction on a compound set of 36 compounds 
provided a correlation coefficient of 0.7175, while a value of 0.7849 was reached for log BB 
prediction with 48 compounds. For both predictions, data provided by MLC with miltefosine 
proved to contribute in a positive way.  
Since biological membranes are composed of several types of (phospho)lipids, additional 
research, in which a variety of (phospho)lipids are combined as surfactants for MLC, might 
prove to be very interesting for this type of work.  
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Chapter VIII. Critical assessment of the developed, 
existing and combined MLC and IAMLC methods 
 
In the previous chapters, several MLC and IAMLC methods were presented. Several points of 
concern have, however, not been addressed so far. Firstly, although combinations of MLC and 
IAMLC methods were performed in chapters III and V, the combination of a micellar phase 
in an IAM-column has not been tested. This setup could lead to a significant difference in 
retention times, since surfactant interactions with the stationary phase should be totally 
different compared to MLC. Secondly, the results of all different methods were not compared 
yet, although this type of comparison would allow the selection of the most appropriate 
method. Thirdly, no additional information has been provided so far concerning the effect of 
performing another regression method or the usefulness of the descriptors, while these points 
are actually critical to obtain a good overall in vitro correlation. These issues are treated in 
this chapter.  
 
VIII.1 Investigation of the use of MLC conditions on an IAM column for the prediction 
of log BB and HIA values 
VIII.1.1 Introduction 
Historically, MLC has mostly been performed on C18 columns, although C8 and cyanopropyl 
columns have also been used [1,2]. C18 stationary phases are particularly interesting, since the 
long C18 carbon chains of the stationary phase can interact with the hydrophobic part of a 
surfactant molecule. This results in the adsorption of an approximately fixed amount of 
surfactant monomers on the stationary phase, and therefore a stable modified column and 
regular retention behavior [2,3]. The use of MLC allows for the presence of micelles in the 
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mobile phase and creates a secondary equilibrium in RPLC (explained in section VII-4 and 
illustrated in Figure VII-2). One of the advantages of this technique is that the use of an 
organic modifier can be avoided. 
This is not the case in IAMLC, where the use of an organic modifier is necessary for 
lipophilic drugs. The types of stationary phases in IAM columns are, however, mimicking the 
biological conditions in a better way than MLC with C18, C8 and cyanopropyl columns. Since 
the evaluation of several IAM columns in chapter V indicated that these column types are also 
interesting for in vitro predictions of log BB values, the question arose whether the use of a 
mobile phase similar to those used in MLC would have a positive effect on retention in 
IAMLC. This was investigated in section VIII.1. 
 
VIII.1.2 Materials and methods 
VIII.1.2.1 Chemicals 
Except for indomethacin (Fluka, St. Louis, MO, USA) and benzene (Acros, Geel, Belgium), 
all analytes were obtained from Sigma-Aldrich (Steinheim, Germany). 
 
VIII.1.2.2 Apparatus 
The IAM retention analysis was performed on an Alliance, Waters 2690 chromatograph 
(Milford, MA, USA) with a quaternary pump and an automatic injector. A Waters 2487 dual 
wavelength absorbance detector was used, for which the detection wavelength was set 
between 210 and 300 nm, depending on the analyzed compound (the exact wavelengths are 
presented in Table VIII-1). Experiments were performed on an IAM.PC.DD2 (10 μm, 150 
mm× 4.6 mm; Regis Technologies, Morton Grove, IL, USA) column. Data acquisition and 
processing were performed with a PeakSimple Chromatography Data System (model 202) 
and PeakSimple software (SRI Instruments, Torrance, CA, USA). Analysis was performed at 
25 °C with a flow rate of 1 mL min
−1
. 
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Table VIII-1: Complete set of compounds with their corresponding in vivo log BB and HIA
a
 values, together 
with their log k values measured on an IAM.PC.DD2 column with a DPBS buffer and 20 mmol L
-1
 SDS in the 
mobile phase.
b
 
No. Compound UV (nm) log BB HIA (%) log k 
1 2,2,2-trifluoroethyl vinyl ether 210 0.13  0.72 
2 2,6-diisopropylphenol 210 0.48  1.79 
3 acetaminophen 254 -0.31 83 0.20 
4 acetylsalicylic acid 230 -0.50 88 -0.44 
5 aminopyrine 254 0.00 100 0.83 
6 amitriptyline 254 0.98 72 1.75 
7 amobarbital 210 0.04  1.01 
8 antipyrine 240 -0.10 98 0.58 
9 atenolol 270 -1.42 51 0.92 
10 benzene 210 0.37 97 0.99 
11 caffeine 210 -0.05 100 0.21 
12 carbamazepine 210 0.00 89 0.98 
13 chlorambucil 254 -1.70 94 1.62 
14 chloropromazine 254 1.06 87 1.80 
15 cimetidine 210 -1.42 75 0.99 
16 clonidine 270 0.11 96 1.80 
17 cotinine 260 -0.32  0.34 
18 desipramine 254 1.20 99 1.69 
19 domperidone 270 -0.78 93 1.56 
20 eserine 240 0.08  1.30 
21 ethylbenzene 210 0.20 82 1.40 
22 fluphenazine 263 1.51  1.73 
23 haloperidol 254 1.34 70 2.05 
24 halothane 210 0.35  1.14 
25 hexobarbital 254 0.10 95 0.87 
26 hydroxyzine 210 0.39  1.73 
27 ibuprofen 270 -0.18 97 0.39 
28 imipramine 240 1.06 99 1.76 
29 indomethacin 210 -1.26 100 0.76 
30 mianserin 280 0.99  1.62 
31 N-methyl-2-pyridineethanamine 254 -0.30 100 1.24 
32 omeprazole 300 -0.82 80 1.18 
33 oxazepam 230 0.61 92 1.12 
34 pentobarbital 210 0.12  1.05 
35 phenylbutazone 240 -0.52 94 0.30 
36 phenytoin 210 -0.04 90 1.38 
37 promazine 254 1.23 40 1.75 
38 propranolol 290 0.64 94 1.65 
39 pyrilamine 300 0.49  1.56 
40 quinidine 254 -0.46 81 1.91 
41 ranitidine 230 -1.23 55 1.05 
42 ropinirole 254 0.25 100 1.38 
43 salicylic acid 300 -1.10 100 -0.45 
44 theobromine 270 -0.28  -0.10 
45 theophylline 270 -0.29 99 0.02 
46 toluene 210 0.37 100 1.27 
47 valproic acid  210 -0.22 100 -0.28 
48 verapamil 210 -0.70 90 1.79 
49 zidovudine 270 -0.72 100 0.17 
                                       a Empty boxes in the table indicate that in vivo HIA values were not available 
                                       b All log k data are averages from three analyses 
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VIII.1.2.3 Mobile phase and sample preparation 
The mobile phase was prepared similar to mobile phases in chapter V, only replacing 
methanol with sodium dodecyl sulfate (SDS). The mobile phase was again based on the 
Dulbecco’s phosphate-buffered saline (DPBS). The DPBS consisted of 2.7 mmol L−1 KCl, 1.5 
mmol L
−1
 KH2PO4, 137 mmol L
−1
 NaCl, and 8.1 mmol L
−1
 Na2HPO4 (Sigma-Aldrich). After 
addition of 20 mmol L
-1
 SDS, the pH of the mobile phase was adjusted to 7.4 by use of acetic 
acid (Sigma-Aldrich). Before use, the mobile phase was vacuum-filtered through a 0.20 μm 
nylon membrane (Grace Davison, Lokeren, Belgium).  
Stock solutions of all drugs were prepared by dissolving 10 mg in 1 mL methanol, except for 
quinidine and theobromine, for which stock concentrations of 1 mg mL
−1
 and 200 μg mL−1 
were used; caffeine and theophylline, which were dissolved in water (10 mg mL
−1
); and 
domperidone, which was dissolved in dimethyl sulfoxide (10 mg mL
−1
). Working solutions 
were prepared by dilution of the stock solutions (to 50 μg mL−1) with mobile phase. 
 
VIII.1.2.4 Data sources, software, and processing 
The descriptors in Table C-4 (Appendix C) are the same as those mentioned in section 
VII.4.6; only zidovudine was added to the dataset. The experimental logarithms of the 
retention factors (log k) are listed in Table VIII-1. All retention data are averages from 
triplicate determinations. Matlab (ver. 8.1) was used to perform statistical analysis of the 
results. 
 
VIII.1.3 Results and discussion 
As can be seen in Table VIII-1, all compounds eluted without the use of an organic modifier 
in a reasonable amount of time (average t0 = 1.32 min). This indicates that the micelles 
formed by the addition of SDS give rise to a secondary equilibrium. Similar to MLC, a solute 
in the bulk solvent can now interact both with the stationary phase (phosphatidylcholine) and 
the micelles (SDS). Because of the interaction with SDS micelles, compounds are retained for 
a shorter amount of time on the stationary phase and elution is expedited. Therefore, organic 
solvents are no longer required when micellar mobile phases are used with this type of 
columns. 
PLS regression was subsequently performed to determine the correlation coefficients between 
actual HIA or log BB values (Table VIII-1) and their values predicted by use of log k values 
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together with the descriptors mentioned in Table C-4. The correlation coefficients are 
presented in Table VIII-2a. As in the previous chapters, overfitting can cause problems, and 
cross-validation (CV) methods can be used to detect the robustness of the model. Therefore, 
LOOCV was applied to the dataset. The correlation coefficients are presented in Table VIII-
2a and illustrated in Figure VIII-1a,b. 
 
Table VIII-2: Correlation coefficients between predicted and actual HIA and log BB values when using partial 
least-squares regression (PLS) or using leave-one-out cross-validation (LOOCV) (a) and these correlation 
coefficients after elimination of 11 (for HIA) or 13 (for log BB) variables from the models (b). 
  HIA Log BB 
Number of compounds 37 49 
a    
 R(PLS) 0.7987 0.8873 
 R(LOOCV) -0.0747 0.4189 
b    
 R(PLS) 0.7706 0.8452 
 R(LOOCV) 0.6694 0.7863 
 
In Table VIII-2a, a very large average decrease of 0.6709 is found when the difference 
between R(PLS) and R(LOOCV) is calculated. This is again a typical indication for 
overfitting. 
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Figure VIII-1: Scatter plots comparing predicted leave-one-out cross-validation HIA values (a and c) or log BB 
values (b and d) with actual values. Predicted values are calculated using several descriptors and log k values. 
Predicted R-values based on LOOCV were calculated before (a and b) and after (c and d) optimization 
(elimination) of superfluous descriptors. 
 
If the overfitting is caused by the use of a too complex model, the model should perform 
much better after variable selection, in which the unrelated variables are removed from the 
training set. If the overfitting is related to undersampling of the sample distribution, more 
representative samples should be added to the model to overcome this problem, which is 
sometimes very difficult. Therefore, variable selection was performed by systematic removal 
and/or reinsertion of all descriptors from the models while monitoring the effect on the 
LOOCV regression coefficients. This process was iteratively improved until maximum 
correlation was obtained for the LOOCV results. 
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For the HIA model, 12 out of 19 descriptors were removed this way, while for the log BB 
model 13 descriptors were removed. The correlation coefficients for the simplified models are 
listed in Table VIII-2b. After optimization of the models, the difference in correlation 
coefficients between the PLS and the LOOCV values for HIA and log BB prediction have 
respectively dropped to 0.1012 and 0.0589. The difference for the HIA model is still 
significant, which means that undersampling might be a problem here. Since 24 (out of 37) 
compounds have a HIA value ≥ 90, and 31 compounds have a HIA value ≥ 80, it is safe to 
assume that this is not an optimal sample distribution. Therefore, the use of an additional set 
of compounds with in vivo HIA values ranging between 0 and 80 would lead to a better 
sample distribution and would eliminate the problem of undersampling. This was, however, 
not tested due to time limitations. 
In Figure VIII-1c,d, the correlations between predicted and in vivo values are presented as 
scatter plots for the optimized models. Since HIA-values of the chosen compounds do not 
homogeniously cover the range from 0 to 100 %, and the focus is placed on compounds with 
high HIA-values, it is more difficult to model for compounds with a low HIA value, as can be 
seen clearly for promazine (HIA = 40 %). Also, as can be seen from the initial models (Figure 
VIII-1a,b), one compound is not fitting the model at all and might be an outlier. Based on the 
log BB value (-0.72), this compound was easily identified as zidovudine. There are two 
possible reasons for this compound to be wrongly predicted: (i) the predicted value of one or 
more descriptors is causing a problem; (ii) the azide functionality of this compound causes 
diverging characteristics or retention behavior, which leads to a wrong prediction. All 
structural formulas are presented in Appendix B; zidovudine is the only compound with an 
azide-group. As can be seen in Figure VIII-1c,d, zidovudine is no longer causing a problem 
after optimization of the model. Therefore, zidovudine was not deleted from the model. Also, 
correlation coefficients for the optimized models without using zidovudine (HIA R(LOOCV) 
= 0.6704; Log BB R(LOOCV) = 0.7841) are not so different compared to the correlation 
coefficients in Table VIII-2, which indicates that zidovudine itself may not really be an 
outlier. 
The coefficients of the equations obtained from PLS regressions that lead to the R values 
listed in Table VIII-2b, are listed in Table VIII-3. The equations indicated by Table VIII-3 
are: 
 Predicted HIA = a + c × MW + d × MV + e × Pr + f × log D7.4 + g × log WSo + h 
× PB + i × HIA 
 Predicted log BB = a + b × α + e × Pr + f × log D7.4 + h × PB + i × HIA + j × PSA 
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The descriptors that are withheld in the final models are almost completely different for both 
models. This appears relevant, since there is a large difference in the physiology of the 
intestinal membranes and the BBB. A very important remark here, is that log k has not been 
retained for the construction of the final log BB and HIA model. This means that the 
experimentally measured values did not provide additional input compared to the selected 
descriptors for the construction of the log BB and HIA model. 
 
Table VIII-3: Coefficients generated by PLS regression after elimination of variables. The general equation for 
the predicted values is: x = a + b × α + c × MW + d × MV + e × Pr + f × log D7.4 + g × log WSo + h × PB + 
i × HIA + j × PSA. 
 HIA log BB 
a 22.5956 -2.8602 
b - 0.6132 
c 0.1887 - 
d 0.4710 - 
e -0.2689 -0.0016 
f 1.8587 0.1723 
g 8.8444 - 
h 0.2670 0.0072 
i 0.8159 0.0357 
j - -0.0069 
 
Although the log k values were not retained for both models – illustrating that the 
chromatographic runs did not provide additional prediction power compared to a pure in silico 
method – the conclusion that can be drawn from this experimental work is very important, 
since the use of MLC conditions with SDS on an IAM.PC.DD2 column was – to our 
knowledge – not yet documented. The use of MLC conditions provided the ability to avoid 
the use of organic modifiers on the IAM column, which was previously not possible. 
An enhanced prediction of HIA values is probably possible by the selection of a more diverse 
set of compounds and descriptors, which could also allow the log k values to gain in 
importance. The correlation coefficient of 0.6694 is however substantially lower than what 
was obtained in chapter VII (R(LOOCV) = 0.7175), which indicates that the use of 
surfactants in the mobile phase on an IAM column may not be an improvement compared to 
the use of conventional MLC for the prediction of in vivo behavior. 
 
VIII.1.4 Conclusion 
In this section, the use of MLC conditions on an IAM column has been studied for the 
prediction of log BB and HIA values. SDS was selected as surfactant, since this provided the 
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best results in chapter III. Based on the performance of the different IAM columns (chapter 
V), the IAM.PC.DD2 column was selected.  
The correlation coefficients based on LOOCV in this section (both for log BB and HIA) were 
created without the log k values and were lower than the values obtained in the previous 
chapters. Also, since IAM columns are more expensive than conventional C18-columns and 
the mobile phase described in this section could facilitate column blockage, it can be 
concluded that conventional C18-columns are more appropriate for MLC studies.  
 
VIII.2 Extended comparison of MLC and IAMLC methods 
A qualitative comparison of the performance of MLC and IAMLC methods towards the 
prediction of in vivo behavior based on results in literature is nearly impossible because of the 
discrepancy between different studies. Differences between studies can be due to the selected 
compounds, the column type and dimensions, the mobile phase composition, the selected 
descriptors, computational processing, etc. These differences impede the selection of the best 
suited in vitro method. 
Since comparison of the selected methods has been one of the goals throughout this thesis, 
differences have been eliminated as much as possible by using identical compounds, columns 
(for MLC), equipment, descriptors and data treatment. Based on these similarities, methods 
that were studied in chapters III, V, VII and VIII.1 are compared in this section in terms of 
their capability to predict both log BB and HIA behavior. 
 
VIII.2.1 Overview of the methods 
An overview of the log k values for the selected methods is given in Table VIII-4. As in 
chapter III, MLC methods with Brij35, SDC and SDS were selected. The models were created 
based on 43 log k values for Brij35 and 36 values for SDC out of 45 compounds measured 
(see chapter III). For SDS, an additional 4 compounds (chloropromazine, haloperidol, 
halothane and promazine) were measured (extension of chapter III). As mentioned in chapter 
III, the IAM.PC.DD2-column provided better results when more (30 or 40 % MeOH) organic 
modifier was used in the mobile phase. Therefore, the method with only 20 % MeOH and the 
extrapolation to 0 % were not selected for additional research towards HIA-prediction. Log k 
values for the sphingomyelin and cholester columns were taken from chapter V.  
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 Table VIII-4: Overview of the selected methods and the log k values obtained for these methods
a
. 
N° Brij35 SDC SDS IAM IAM SM-IAM Cholester Miltefosine IAM.PC + 
 0.05 M 0.05 M 0.05 M 40% MeOH 30% MeOH 30% MeOH 50% MeOH 0.01 M SDS 0.02 M 
1 0.928 0.694 1.080 -0.089 0.095 0.210 0.573 1.746 0.725 
2 1.254 1.598 1.750 1.156 1.544 1.681 1.785 2.305 1.785 
3 0.261 -0.231 -0.095 -0.657 -0.372 -0.261 -0.519 0.550 0.197 
4 -0.498 -1.004 -0.688 -0.964 -0.664 -0.131 -0.476 0.407 -0.445 
5 0.474 1.438 1.527 -0.547 -0.206 -0.082 0.011 0.636 0.832 
6 2.386  2.123 1.519 1.975 1.657 1.510 2.669 1.754 
7 0.936 0.693 1.249 0.112 0.457 0.617 0.653 1.468 1.008 
8 0.268 0.964 1.053 -0.694 -0.368 -0.329 -0.273 0.386 0.576 
9 -0.093 1.253 1.189 -0.436 -0.206 -0.539 -0.767 0.756 0.917 
10 1.039 1.120 1.207 0.155 0.338 0.530 0.834 1.490 0.990 
11 0.073 0.485 0.767 -0.948 -0.590 -0.477 -0.262 0.208 0.207 
12 0.799 1.236 1.226 0.202 0.593 0.772 0.630 1.752 0.979 
13 1.530 0.261 -0.889 0.397 0.793 1.000 1.947 1.870 1.622 
14 NA NA 2.069 1.851 2.404 2.110 1.946 2.566 1.800 
15 0.301 0.934 1.031 -0.491 -0.145 -0.091 -0.221 0.739 0.986 
16 0.584 1.877 1.500 0.227 0.458 0.135 -0.061 1.212 1.798 
17 0.194 1.100 1.110 -1.139 -0.711 -0.647 -0.644 1.902 0.340 
18 1.704  1.991 1.462 1.864 1.564 1.291 2.290 1.691 
19 0.984 1.891 1.924 1.461 2.042 1.837 1.468 2.432 1.560 
20 0.987 2.074 1.547 0.014 0.355 0.238 0.096 1.229 1.301 
21 1.233 1.476 1.636 0.718 0.994 1.139 1.462 1.605 1.401 
22 1.553  2.046 2.022 2.596 2.445 2.238 2.541 1.727 
23 NA NA 2.188 1.330 1.844 1.466 1.379 2.107 2.048 
24 NA NA 1.237 0.247 0.487 0.618 0.956 1.527 1.143 
25 0.789 0.769 1.260 -0.064 0.253 0.433 0.518 1.276 0.866 
26 1.271  2.010 1.276 1.800 1.741 1.693 1.881 1.729 
27 0.693 0.194 0.565 0.123 0.499 0.884 0.993 1.685 0.392 
28   2.096 1.409 1.838 1.524 1.403 2.422 1.755 
29 0.730 0.291 0.738 0.541 1.061 1.462 1.372 1.693 0.759 
30 1.940  2.173 1.439 1.843 1.776 1.727 2.811 1.625 
31 0.454 1.977 1.560 -0.419 -0.249 -0.373 -0.773 0.808 1.239 
32 0.974 1.562 1.764 0.223 0.713 0.806 0.723 1.989 1.178 
33 0.945 1.244 1.439 0.702 1.118 1.182 1.307 1.962 1.120 
34 0.932 0.739 1.274 0.150 0.489 0.647 0.668 1.548 1.054 
35 0.701 -0.179 0.594 0.041 0.477 0.931 0.678 1.446 0.297 
36 0.933 0.898 1.349 0.392 0.761 0.981 0.635 2.172 1.378 
37 NA NA 1.964 1.490 2.035 1.708 1.465 2.373 1.754 
38 1.326 2.270 1.936 1.119 1.474 1.348 0.857 2.460 1.645 
39   2.001 0.747 1.132 0.974 0.652 2.221 1.563 
40 1.282 1.408 1.590 0.937 1.346 1.045 0.909 1.925 1.909 
41 0.283 1.756 1.191 -0.331 -0.045 -0.204 -0.386 0.424 1.045 
42 0.936 1.938 1.636 0.102 0.385 0.166 0.180 1.438 1.379 
43 0.179 -0.998 -0.672 -1.057 -0.656 -0.086 -0.490 0.159 -0.453 
44 -0.191 -0.076 0.275 -1.334 -0.932 -0.819 -0.744 -0.103 -0.103 
45 0.011 -0.091 0.312 -0.945 -0.621 -0.511 -0.355 0.131 0.017 
46 1.260 1.395 1.511 0.450 0.683 0.942 1.171 1.601 1.267 
47 -0.098  -0.135 -0.689 -0.546 -0.112 0.319 0.177 -0.279 
48 1.652  2.197 1.055 1.663 1.400 1.208 2.340 1.791 
49 0.085 -0.252 0.303 -0.670 -0.482 -0.325 -0.155 0.221 0.166 
a
 Empty boxes in the table indicate that log k values were not obtained, mostly because of too long elution times 
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The log k values based on the MLC runs with miltefosine on a normal C18 column and with 
SDS on the IAM column were respectively taken from chapters VII and VIII. Except for 
Brij35 and SDC, all methods presented in Table VIII-4 provide log k values for 49 
compounds. 
 
VIII.2.2 Results and discussion 
As in chapter VII and in section VIII.1, the log k values were used in combination with a set 
of descriptors (Table C-4) to predict log BB and HIA values (for which in vivo values are 
presented in Table VIII-1). The data was processed as in chapter VII using a PLS regression 
in Matlab, and LOOCV was performed to check the robustness of the models. The correlation 
coefficients of the initial models and the optimized models (after elimination of superfluous 
descriptors) are presented in Table VIII-5. 
 
Table VIII-5: Correlation coefficients between predicted and actual HIA and log BB values when using partial 
least-squares regression (PLS) and leave-one-out cross-validation (LOOCV) and the optimized coefficients after 
elimination of superfluous variables from the models. Values indicated in orange indicate that log k values were 
not selected in the optimized model. 
Log BB prediction Brij35 SDC SDS IAM.PC IAM.PC SM-IAM Cholester Miltefosine IAM.PC + 
 0.05 M 0.05 M 0.05 M 40 % MeOH 30 % MeOH 30 % MeOH 50 % MeOH 0.01 M SDS 0.02 M 
# compounds 43 36 49 49 49 49 49 49 49 
Initial model          
R(PLS) 0.8668 0.9222 0.9026 0.8865 0.8905 0.8900 0.8832 0.8830 0.8873 
R(LOOCV) 0.2279 0.4097 0.2598 0.3659 0.4334 0.4800 0.3304 0.3107 0.4189 
Optimized model          
R(PLS) 0.8358 0.8970 0.8886 0.8470 0.8543 0.8509 0.8452 0.8487 0.8452 
R(LOOCV) 0.7409 0.8200 0.8228 0.8036 0.8131 0.8032 0.7863 0.7879 0.7863 
HIA prediction Brij35 SDC SDS IAM.PC IAM.PC SM-IAM Cholester Miltefosine IAM.PC + 
 0.05 M 0.05 M 0.05 M 40 % MeOH 30 % MeOH 30 % MeOH 50 % MeOH 0.01 M SDS 0.02 M 
# compounds 33 29 37 37 37 37 37 37 37 
Initial model          
R(PLS) 0.9202 0.9274 0.8027 0.7994 0.7967 0.8025 0.8063 0.8165 0.7987 
R(LOOCV) 0.2270 0.1873 -0.0838 -0.0650 -0.0672 -0.0540 -0.0676 -0.0598 -0.0747 
Optimized model          
R(PLS) 0.9093 0.9014 0.7706 0.7706 0.7706 0.7746 0.7811 0.7821 0.7706 
R(LOOCV) 0.8216 0.7756 0.6694 0.6694 0.6694 0.6727 0.6987 0.7002 0.6694 
 
 
As mentioned in VIII.2.1, log BB prediction was performed on a set of 49 compounds for all 
methods except those with Brij35 (43 compounds) and SDC (36 compounds). For HIA 
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prediction, the amount of compounds for the Brij35 and SDC model was again lower than for 
the other models. 
Concerning log BB prediction, several conclusions can be made. For some of the models 
(Brij35, Cholester and IAM.PC+SDS), the log BB prediction was only ameliorated to some 
extent or not ameliorated at all when the log k values were added to the model, leading to the 
elimination of log k values (together with other descriptors) in the optimized model. These 
values are presented in orange in Table VIII-5. The R(LOOCV) value of 0.7863 is also quite 
close to the value for the miltefosine-model (0.7879), which indicates that the use of 
miltefosine as a surfactant in MLC does not provide a much better model compared to the 
model without log k values. All other R(LOOCV)-values are > 0.80, which illustrates that the 
log k values of these models contribute much more to the log BB prediction. The SDS, SDC 
and IAM.PC 30 % MeOH models provided the highest predictive values, favouring these 
setups. The SDC model was, however, created using only 36 compounds, while 49 
compounds were used for the other models. Therefore, the two other models may be 
considered as more reliable. The R(PLS) values are all around 0.85, except for the higher 
values for the SDS (0.88) and SDC (0.89) models. The difference between R(PLS) and 
R(LOOCV) values in the log BB prediction is always < 0.10, indicating that the models are 
quite robust and that overfitting is limited.  
Several conclusions can also be drawn from the HIA prediction in Table VIII-5. Most of the 
models (SDC, SDS, IAM.PC (30 an 40 % MeOH) and IAM.PC+SDS) were not improved 
towards HIA prediction when the log k values were added to the model. Therefore, the log k 
values were not retained in the optimized models. The orange values in Table VIII-5 indicate 
the models for which the log k values were not selected in the final model. The R(LOOCV) 
value of 0.6694 is also quite close to the value for the sphingomyelin-IAM-model (0.6727), 
which indicates that the sphingomyelin column does not provide a much better model 
compared to the model without log k values (even though the results of the sphingomyelin 
column were good for log BB prediction). The other R(LOOCV)-values are higher, which 
illustrates that the log k values of these models contribute much more to the HIA prediction. 
The correlation coefficients of the cholester and miltefosine model are similar, although these 
two models are based on a completely different method. The Brij35 model provides very high 
PLS and LOOCV correlation coefficients (0.9093 and 0.8216), but these high values are 
mainly caused by the advantage that only 33 compounds were used to create the model. When 
the same 33 compounds and the same descriptors were selected for the cholester and 
miltefosine models, their PLS correlation coefficients respectively increased to 0.9046 and 
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0.9122 and their LOOCV correlation coefficients to 0.8005 and 0.8229. This indicates that the 
choice of compounds in the data set is also important and that a rather small change in 
selection (e.g. elimination of 4 compounds) may lead to a phenomenal increase in correlation 
coefficients. In contrast to what might be expected from Table VIII-5, the Brij35 model is not 
better than the miltefosine model (value of 0.8229 in adapted model). This indicates that the 
miltefosine model is actually the best choice of the presented models towards the prediction 
of HIA values. 
When the log BB and HIA predictions are compared in Table VIII-5, one might conclude that 
the techniques that lead to a good log BB prediction are not really interesting for HIA 
prediction and vice versa. None of the presented models was able to perform really well for 
both types of predictions. This indicates that method selection is sometimes crucial for in vitro 
prediction studies. 
Table VIII-6 shows the coefficients that were obtained based on the log BB and HIA 
predictions for all optimized models presented in Table VIII-5. In the optimized models for 
log BB prediction, the descriptors MW, log WSo, MI and MSA were not relevant for any of 
the models; for HIA prediction, α, MR, log P, HBD and MSA were not retained in the final 
models. Both for log BB and HIA prediction, several descriptors are (almost) always present 
in the optimized models; while the descriptors of the log BB models are to a great extent 
different than those of the HIA models. 
 
VIII.2.3 Conclusion 
In section VIII.2, most previously used methods were compared towards both log BB and 
HIA prediction. Methods with a relatively good log BB prediction generally showed a rather 
poor (no improvement based on the log k values) HIA prediction capability and vice versa. 
Therefore, the type of in vitro method that should be selected actually depends on the type of 
in vivo behavior that should be modeled. There was no clear indication that any of the MLC 
or IAMLC methods could be claimed as ‘the best’ general method. The SDS model provided 
the highest LOOCV value for log BB prediction, whereas the miltefosine model provided the 
highest LOOCV value for HIA prediction (even compared to Brij35 in an adapted model). 
The model in which the IAM.PC.DD2 column was used with the addition of 20 mM of SDS 
in the mobile phase was – based on the LOOCV values – the least relevant model presented 
here. 
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Table VIII-6: Coefficients for log BB and HIA prediction generated by PLS regression after elimination of 
variables. 
Log BB Brij35 SDC SDS IAM IAM SM-IAM Cholester Miltefosine IAM.PC + 
 0.05 M 0.05 M 0.05 M 40% MeOH 30% MeOH 30% MeOH 50% MeOH 0.01 M SDS 0.02 M 
Constant -2.784 -3.584 -4.437 -2.849 -2.831 -2.626 -2.860 -2.657 -2.860 
α 0.573  0.284 0.413 0.444 0.590 0.613 0.640 0.613 
MR -0.017  -0.013   -0.015    
MV  0.014        
Pr  -0.008  -0.002 -0.003  -0.002  -0.002 
Polarizability        -0.043  
Log P  -0.228 0.155       
Log D7.4  0.127     0.172  0.172 
WS7.4 -0.003 -0.002 -0.002     -0.002  
PB 0.010 0.008     0.007 0.008 0.007 
MIA   0.376       
HIA 0.038 0.043 0.051 0.043 0.042 0.037 0.036 0.034 0.036 
PSA -0.034  -0.007   -0.005 -0.007 -0.017 -0.007 
HBA 0.293       0.147  
HBD 0.225         
Log k  0.413 0.467 0.719 0.702 0.583  0.237  
HIA Brij35 SDC SDS IAM IAM SM-IAM Cholester Miltefosine IAM.PC + 
 0.05 M 0.05 M 0.05 M 40% MeOH 30% MeOH 30% MeOH 50% MeOH 0.01 M SDS 0.02 M 
Constant 26.172 56.711 22.596 22.596 22.596 19.922 10.413 6.607 22.596 
MW 0.314 0.204 0.189 0.189 0.189 0.190   0.189 
MV 0.421 0.348 0.471 0.471 0.471 0.186 0.336 0.446 0.471 
Pr -0.214 -0.186 -0.269 -0.269 -0.269  -0.152 -0.209 -0.269 
Polarizability -1.909 -1.713    -3.227    
Log D7.4   1.859 1.859 1.859    1.859 
Log WSo 7.385  8.844 8.844 8.844 8.193 7.507 7.932 8.844 
WS7.4  0.044        
PB 0.231 0.265 0.267 0.267 0.267 0.149 0.195 0.248 0.267 
MI  3.431        
MIA -4.291     -3.840    
HIA 0.757 0.430 0.816 0.816 0.816 0.910 0.955 0.933 0.816 
PSA  -0.620        
HBA  8.454     2.768 3.633  
Log k 8.715     8.692 7.631 8.944  
  
VIII.3 Study of the correlation of the used descriptors 
Based on the previously obtained results, overfitting seems to be a recurring issue. A major 
improvement is obtained when the complexity of the model is reduced by variable selection. 
During variable selection, most parameters that are irrelevant for the requested prediction or 
very similar to other parameters, are deleted from the model. In this section, the documented 
descriptors are analyzed and are compared to each other and to the log BB and HIA values. 
Based on the analysis and comparison of the descriptors, it is – to some extent – possible to 
evaluate how important a descriptor is and, therefore, some conclusions can be drawn. All 
figures and tables in this section were created based on calculations with RStudio (R version 
3.1.0) software. 
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VIII.3.1 Analysis and comparison of the descriptors 
VIII.3.1.1 Individual descriptors 
First, all descriptors used for model construction were analyzed. A histogram was made for 
each descriptor (Figure VIII-2), illustrating that for some descriptors (e.g. log D7.4 and log 
WSo), the distribution along the x-axis follows roughly a normal distribution. Then, a 
histogram was also created for the experimental log k values and the in vivo log BB and HIA 
values (Figure VIII-2).  
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Figure VIII-2: Histograms for all descriptors (exact values are presented in Table C-4; Appendix C), log k values 
(Table VIII-4) and in vivo values (Table VIII-1) used for model constructions. 
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Also, for each of these possibilities, the minimum, maximum, 1
st
 and 3
rd
 quartile, median and 
mean were calculated. These values are presented in Table VIII-7. It should be noted that – 
aside from ‘log k Brij35’, ‘log k SDC’ and ‘in vivo HIA’ – all histograms and statistics were 
based on the compound set with 49 compounds. 
 
Table VIII-7: Statistical overview of all descriptors, log k values and in vivo values used for model 
constructions. 
 α MW MR MV Pr Polarizabil. Log P Log D7.4 LogWSo WS7.4 
Min. -1.00 78.11 22.50 89.40 207.20 8.92 -0.50 -1.93 -5.19 0.02 
1st Qu. -0.05 180.16 49.38 153.10 370.90 19.57 1.11 0.25 -3.68 0.24 
Median 0.00 252.34 69.68 209.10 531.30 27.62 1.99 1.83 -2.92 1.92 
Mean 0.20 248.17 69.07 209.00 540.70 27.36 2.11 1.39 -2.79 18.89 
3rd Qu. 0.95 286.71 87.85 257.70 677.30 34.82 3.18 2.49 -1.93 10.20 
Max. 1.00 454.60 131.86 429.30 1063.90 52.27 5.01 4.17 -0.17 377.00 
         Log k Log k 
 PB MI MIA HIA PSA HBA HBD MSA Brij35 SDC 
Min. 7.66 0.00 0.00 64.30 0.00 0.00 0.00 135.90 -0.50 -1.00 
1st Qu. 34.75 0.00 0.00 87.60 23.55 2.00 0.00 272.90 0.28 0.28 
Median 72.02 0.00 0.00 91.00 40.54 3.00 1.00 367.90 0.93 1.03 
Mean 64.54 0.20 0.27 89.49 42.15 3.51 1.00 373.60 0.79 0.91 
3rd Qu. 92.66 0.00 1.00 93.10 63.95 5.00 2.00 459.70 1.24 1.50 
Max. 99.93 1.00 1.00 96.70 108.30 8.00 4.00 782.00 2.39 2.27 
NA's         6 13 
 Log k Log k Log k Log k Log k Log k Log k In vivo In vivo  
 SDS IAM 40 IAM 30 SM-IAM Cholester Milt IAM.PC + Log BB HIA  
       SDS 0.02 M    
Min. -0.89 -1.33 -0.93 -0.82 -0.77 -0.10 -0.45 -1.70 40.00  
1st Qu. 1.03 -0.44 -0.21 -0.09 -0.16 0.76 0.73 -0.46 83.00  
Median 1.35 0.20 0.49 0.77 0.67 1.61 1.14 0.00 94.00  
Mean 1.24 0.28 0.65 0.67 0.64 1.50 1.06 -0.01 88.65  
3rd Qu. 1.92 1.06 1.47 1.40 1.37 2.17 1.65 0.39 99.00  
Max. 2.20 2.02 2.60 2.45 2.24 2.81 2.05 1.51 100.00  
 
 
Some conclusions can be drawn from Figure VIII-2 and Table VIII-7. Concerning WS7.4, 
there is clearly an outlier in the dataset (N-methyl-2-pyridineethanamine). For MI and MIA, 
far more compounds have value 0 (= not mutagenic); PB and in vivo HIA values between 90 
and 100 are abundantly present (which explains why PB was always retained in the optimized 
HIA models in Table VIII-6). When the median is compared to the mean in Table VIII-7, 
these values are mostly similar. However, for log D7.4, the median (1.83) is rather high 
compared to the mean (1.39); for WS7.4, the mean (18.89) is much higher than the median 
(1.92), which is partially explained by the outlier in this dataset.  
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VIII.3.1.2 Correlations between the descriptors 
During model optimization, similar parameters are deleted from the model. Figure VIII-3 
illustrates the correlation between different descriptors and the log k values based on MLC 
with SDS. Although the scatter plots are quite small, it is still easy to see that the correlation 
between some of the descriptors is very high (e.g. between MR and polarizability; MV and Pr; 
Pr and MSA); while other correlations are very low (e.g. between HBA and log WSo; PB and 
HIA; MI and log k SDS). A visual confirmation of (in)dependence of descriptors is nice, but 
it is easier to check the actual correlation coefficients. These are presented in Table VIII-8. 
High values (e.g. > 0.80) indicate that the descriptors are highly correlated, meaning that it’s 
probable that one of them will be eliminated during model optimization. For example, MW, 
MR, MV, Pr and Polarizability are clearly highly correlated. In Table VIII-6, only one model 
uses two of these descriptors after log BB model optimization. This is not the case for HIA 
model optimization because Table VIII-8 is based on the dataset with 49 compounds, not the 
limited dataset of 37 compounds used for HIA prediction.  
When the correlation coefficient between the descriptors and the log k values of MLC with 
SDS as surfactant are evaluated, the highest correlations are found with α (R = 0.70) and log 
D7.4 (R = 0.68). This indicates that these descriptors show (to a certain extent) similar 
behavior to the experimental data of SDS. Similar scatter plots and tables can be obtained for 
all other MLC and IAMLC setups, but this is not illustrated here. 
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Figure VIII-3: Scatter plots of correlations between all descriptors and log k values for MLC with SDS. 
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Table VIII-8: Correlation coefficients between all descriptors and log k values for MLC with SDS. 
       Log Log Log WS         log k 
 α MW MR MV Pr Polar
. 
P D7.4 WSo 7.4 PB MI MIA HIA PSA HBA HBD MSA SDS 
α 1.00 0.34 0.42 0.43 0.41 0.42 0.13 0.26 -0.25 0.07 -0.05 0.06 0.06 -0.09 -0.17 0.00 -0.04 0.41 0.70 
MW 0.34 1.00 0.96 0.94 0.96 0.96 0.45 0.41 -0.65 -0.29 0.57 0.17 0.13 -0.01 0.28 0.49 0.12 0.94 0.43 
MR 0.42 0.96 1.00 0.97 0.99 1.00 0.52 0.44 -0.70 -0.26 0.62 0.14 0.03 0.07 0.16 0.39 0.05 0.98 0.52 
MV 0.43 0.94 0.97 1.00 0.99 0.97 0.54 0.45 -0.69 -0.25 0.60 0.12 0.06 0.04 0.17 0.36 0.04 0.99 0.52 
Pr 0.41 0.96 0.99 0.99 1.00 0.99 0.51 0.42 -0.68 -0.25 0.60 0.15 0.05 0.05 0.21 0.41 0.07 0.99 0.50 
Polar. 0.42 0.96 1.00 0.97 0.99 1.00 0.52 0.44 -0.70 -0.25 0.62 0.13 0.02 0.07 0.16 0.38 0.05 0.98 0.53 
Log P 0.13 0.45 0.52 0.54 0.51 0.52 1.00 0.78 -0.81 -0.37 0.84 -0.03 -0.19 0.02 -0.45 -0.39 -0.27 0.49 0.48 
Log D7.4 0.26 0.41 0.44 0.45 0.42 0.44 0.78 1.00 -0.66 -0.37 0.57 0.02 -0.18 0.00 -0.43 -0.30 -0.30 0.40 0.68 
Log WSo -0.25 -0.65 -0.70 -0.69 -0.68 -0.70 -0.81 -0.66 1.00 0.52 -0.79 -0.10 0.00 0.04 0.10 0.07 0.02 -0.66 -0.47 
WS7.4 0.07 -0.29 -0.26 -0.25 -0.25 -0.25 -0.37 -0.37 0.52 1.00 -0.43 -0.13 -0.11 0.14 -0.06 -0.07 -0.05 -0.24 -0.08 
PB -0.05 0.57 0.62 0.60 0.60 0.62 0.84 0.57 -0.79 -0.43 1.00 0.17 -0.07 0.16 -0.17 -0.12 -0.10 0.58 0.28 
MI 0.06 0.17 0.14 0.12 0.15 0.13 -0.03 0.02 -0.10 -0.13 0.17 1.00 0.38 0.01 0.25 0.18 0.27 0.13 -0.08 
MIA 0.06 0.13 0.03 0.06 0.05 0.02 -0.19 -0.18 0.00 -0.11 -0.07 0.38 1.00 -0.31 0.32 0.25 0.35 0.05 -0.19 
HIA -0.09 -0.01 0.07 0.04 0.05 0.07 0.02 0.00 0.04 0.14 0.16 0.01 -0.31 1.00 -0.14 -0.01 -0.38 0.04 -0.02 
PSA -0.17 0.28 0.16 0.17 0.21 0.16 -0.45 -0.43 0.10 -0.06 -0.17 0.25 0.32 -0.14 1.00 0.90 0.71 0.20 -0.37 
HBA 0.00 0.49 0.39 0.36 0.41 0.38 -0.39 -0.30 0.07 -0.07 -0.12 0.18 0.25 -0.01 0.90 1.00 0.47 0.41 -0.16 
HBD -0.04 0.12 0.05 0.04 0.07 0.05 -0.27 -0.30 0.02 -0.05 -0.10 0.27 0.35 -0.38 0.71 0.47 1.00 0.06 -0.23 
MSA 0.41 0.94 0.98 0.99 0.99 0.98 0.49 0.40 -0.66 -0.24 0.58 0.13 0.05 0.04 0.20 0.41 0.06 1.00 0.50 
log k SDS 0.70 0.43 0.52 0.52 0.50 0.53 0.48 0.68 -0.47 -0.08 0.28 -0.08 -0.19 -0.02 -0.37 -0.16 -0.23 0.50 1.00 
 
VIII.3.2 Specific relations with log BB and HIA 
In this section, the correlation coefficients of the individual descriptors and the experimental 
log k values are compared to the log BB and HIA values (Table VIII-9). Correlations with 
HIA were calculated based on the compound set of 37 compounds. Both for log BB and HIA, 
the number of compounds was lower (see Table VIII-5) for Brij35 and SDC correlations. As 
can be seen in Table VIII-9, the correlation coefficients compared to log BB are mostly 
positive. Also, most of the correlations with log k values are > 0.50; while only few 
descriptors can reach this value. This indicates that the performed experiments show some 
potential towards log BB prediction. 
 
Table VIII-9: Correlation coefficients of all descriptors and the experimental log k values compared to the log 
BB and HIA values. 
 Log BB HIA  Log BB HIA  Log BB HIA 
α 0.432 -0.377 WS7.4 -0.147 0.202 Brij35 0.520 0.002 
MW 0.027 -0.282 PB 0.291 -0.002 SDC 0.339 -0.198 
MR 0.109 -0.318 MI -0.036 0.022 SDS 0.621 -0.251 
MV 0.103 -0.292 MIA -0.115 -0.202 IAM 40 % MeOH 0.609 -0.226 
Pr 0.069 -0.311 HIA 0.305 0.586 IAM 30 % MeOH 0.587 -0.234 
Polarizability 0.110 -0.319 PSA -0.656 -0.099 SM-IAM 0.543 -0.117 
Log P 0.477 -0.130 HBA -0.505 -0.056 Cholester 0.506 -0.029 
Log D7.4 0.563 -0.099 HBD -0.446 -0.249 Miltefosine 0.539 -0.163 
Log WSo -0.307 0.378 MSA 0.065 -0.304 IAM.PC + SDS 0.02 M 0.471 -0.295 
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When we look into the correlations with HIA, it is obvious that most of the correlation 
coefficients are negative. There is only one descriptor with a correlation coefficient > 0.40. 
Also in absolute values, all correlation coefficients comparing HIA with log k values are (a 
lot) lower. Generally, we could conclude here that the experimental log k values are initially 
(not eventually; see section VIII.2.2) more relevant towards log BB prediction.  
The scatter plots in Figure VIII-4 show the correlations between log BB and log k values as 
presented in Table VIII-9. Due to the poor correlation coefficients, the scatter plots of 
correlations between HIA and log k values are not shown. 
 
 
Figure VIII-4: Scatter plots illustrating the correlations between log BB and log k values. 
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As can be seen in Figure VIII-4, for most compounds a low log k value was obtained for a 
low log BB value and vice versa. However, for some compounds a low log BB value resulted 
in a high log k value, which would allow to create a parabolic correlation for a subset of 
compounds (when high log BB / high log k compounds are not taken into account).  
 
VIII.4 Choice of the computational model 
As mentioned in section II.4, several computational models can be applied for the intended 
purposes. In this work, emphasis has been set on the partial least squares (PLS) regression 
approach. Multiple linear regression (MLR) can, however, offer quite equivalent results as 
can be obtained by PLS (see II.4). In order to assess the performance of both approaches, the 
results of the PLS regression using Matlab are compared to the results of MLR performed 
with RStudio (R version 3.1.0) software in this section. 
Correlation coefficients for log BB and HIA prediction using MLR are calculated as in Table 
VIII-5 and are displayed in Table VIII-10. Model optimization was not again performed here; 
the same descriptors as in section VIII.2 were kept in the optimized model. 
 
Table VIII-10: Correlation coefficients between predicted and actual HIA and log BB values when using 
multiple linear regression (MLR) and the optimized coefficients after elimination of superfluous variables from 
the models. Values indicated in orange indicate that log k values were not selected in the optimized model. 
Log BB prediction Brij35 SDC SDS IAM.PC IAM.PC SM-IAM Cholester Miltefosine IAM.PC + 
 0.05 M 0.05 M 0.05 M 40 % MeOH 30 % MeOH 30 % MeOH 50 % MeOH 0.01 M SDS 0.02 M 
# compounds 43 36 49 49 49 49 49 49 49 
Initial model          
R(MLR) 0.8668 0.9222 0.9027 0.8865 0.8905 0.8900 0.8832 0.8829 0.8873 
Optimized model          
R(MLR) 0.8358 0.8970 0.8886 0.8471 0.8543 0.8509 0.8452 0.8486 0.8452 
HIA prediction Brij35 SDC SDS IAM.PC IAM.PC SM-IAM Cholester Miltefosine IAM.PC + 
 0.05 M 0.05 M 0.05 M 40 % MeOH 30 % MeOH 30 % MeOH 50 % MeOH 0.01 M SDS 0.02 M 
# compounds 33 29 37 37 37 37 37 37 37 
Initial model          
R(MLR) 0.9202 0.9274 0.8027 0.7994 0.7967 0.8024 0.8063 0.8165 0.7987 
Optimized model          
R(MLR) 0.9093 0.9014 0.7706 0.7706 0.7706 0.7747 0.7811 0.7820 0.7706 
 
When the values from Tables VIII-5 and VIII-10 are compared, it can be seen that the results 
of MLR and PLS regression are almost identical for this (limited) dataset. The coefficients for 
the corresponding equations are also identical to those in Table VIII-6 and are not displayed 
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here. Therefore, it can be concluded that the choice between PLS and MLR as computational 
model was not relevant in this work.  
Critical assessment of the developed, existing and combined MLC and IAMLC methods 
 
190 
 
VIII.5 References 
1. McCormick TJ, Foley JP, Riley CM, Lloyd DK (2000) The effect of stationary-phase pore 
size on retention behavior in micellar liquid chromatography. Anal Chem 72 (2):294-301. 
2. Ruiz-Angel MJ, Carda-Broch S, Torres-Lapasio JR, Garcia-Alvarez-Coque MC (2009) 
Retention mechanisms in micellar liquid chromatography. J Chromatogr A 1216 (10):1798-
1814. 
3. Quinones-Torrelo C, Martin-Biosca Y, Martinez-Pla JJ, Sagrado S, Villanueva-Camanas 
RM, Medina-Hernandez MJ (2002) QRAR Models for Central Nervous System Drugs using 
Biopartitioning Micellar Chromatography. Mini-Rev Med Chem 2 (2):145-161. 
 
 
 
  
Chapter IX 
191 
 
 
 
 
 
Chapter IX. Summary and general conclusions 
 
IX.1 Summary 
In contemporary drug design, significant effort is put in the prediction of drug delivery at the 
biological location of interest. The rationale behind this, is that the sooner one can establish if 
drug leads pose problems in terms of drug delivery, the sooner they can be eliminated from 
the expensive development process. Therefore, a broad variety of methods have been created 
to establish approaches for predictive modeling. Since all of these in silico or in vitro methods 
possess certain advantages and drawbacks, so far no golden standard has been developed to 
accomplish this task. This work focused on the development of in vitro HPLC methods using 
micellar liquid chromatography and immobilized artificial membrane liquid chromatography 
for the prediction of drug delivery in the brain and also through the intestinal system. A 
comparison of existing techniques and several extensions on available approaches are 
provided. 
 
In chapter II, an overview of the typical methods used for the prediction of transport across 
the BBB is provided. The functions, structure and transport across the BBB are thereby 
illustrated. Subsequently, the most relevant known delivery systems across the BBB are 
mentioned, followed by an overview of existing in vivo, in vitro and in silico methods for the 
prediction of transport across the BBB. Finally, information is provided concerning the 
possible computational methods which can be used in this type of predictions. 
 
In chapter III, several in vitro methods for the prediction of the logarithm of blood–brain 
distribution coefficient (log BB) values were compared. MLC was performed on a C18 column 
with Brij35, SDC, and SDS as surfactants. IAMLC was performed with methanol as organic 
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modifier. SDS as a surfactant resulted in the best correlation coefficient between experimental 
and predicted log BB values (R = 0.7993), followed closely by IAM measurements using 30 
% methanol (R = 0.7724). During data treatment, the combination of the results from IAMLC 
phases and MLC appeared not to improve the accuracy of log BB predictions. 
 
In chapter IV, a novel type of stationary phase was manufactured as an alternative to the 
commercially available immobilized artificial membrane columns. Sphingomyelin was 
chosen to be processed into the new stationary phase because interesting behavior was 
anticipated for this lipid, since it is an important constituent of eukaryotic plasma membranes 
in general. Based on the provided proof-of-concept correlation studies, the sphingomyelin 
phase was considered to be a promising alternative phase in IAMLC. Scalable, short and 
modular tuning of the synthetic route should give access to the development of a further 
repertoire of the novel IAM phases. 
 
In chapter V, the abilities of three different types of IAM-columns towards predicting log BB 
values were compared. The correlation coefficients between actual and predicted log BB 
values of the three corresponding models appeared very good as all three columns proved 
useful for this kind of prediction. The results obtained with the sphingomyelin column proved 
similar to the commercial phosphatidylcholine column. As such, the sphingomyelin column 
was considered to be a useful alternative for this type of measurements. Since the correlation 
coefficients based on the results with the cholester column were slightly less promising than 
those of the other two columns, this column was considered to be a somewhat less interesting 
option for this type of work.  
 
Methods for extraction, identification and quantification of the main lipid classes (in brain 
membranes) were presented in chapter VI. Phosphatidylcholine and –ethanolamine are the 
most prominent lipids in brain membranes, while the relative concentrations of other lipid 
classes have been reported to be divergent in literature. It is therefore challenging to create an 
exact overview of lipid classes and their concentrations in brain membranes. Differences arise 
not only between species, but also between individuals, in various sections of the brain, and 
related to age. A limited comparative study was performed to visualize differences in the lipid 
composition of white and grey matter in newborn piglets. Although the major lipid classes 
provided a similar lipid profile, several differences were observable, confirming that 
significant differences in lipid composition exist between various sections of the brain. 
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Based on the results in chapter VI, the suggestion was made that the use of lipids in MLC 
would create a more realistic simulation of drug interactions in brain membranes. Therefore, 
this field has been explored in chapter VII. Based on the findings that phosphatidylcholine 
and phosphatidylethanolamine are the two most prominent phospholipids in membranes, and 
the fatty acid groups in lipids typically have a carbon chain length of 16 or 18 carbon atoms, 
miltefosine was selected for evaluation as a possible surfactant in MLC. Retention of 
compounds proved to be shorter compared to a purely aqueous mobile phase, indicating that 
the principle of MLC also works with miltefosine-based micelles. Since this phosphocholine-
based lipid is structurally more similar to biological membranes than common surfactants, 
retention data was used for in vitro predictions of HIA and log BB values. The optimized 
model for HIA prediction on a compound set of 36 compounds provided a correlation 
coefficient of 0.7175, while a value of 0.7849 was reached for log BB prediction with 48 
compounds.  
 
In the first part of chapter VIII, the use of MLC conditions on an IAM column has been 
studied for the prediction of log BB and HIA values. SDS was chosen as a surfactant for 
analyses on the IAM.PC.DD2 column, in this way combining experimentally the principles of 
MLC and IAMLC. However, the correlation coefficients based on LOOCV (both for log BB 
and HIA) were lower than the values obtained in the previous chapters, proving that the 
prediction capability of the approach is limited. Also, since the IAM columns are expensive 
and as the micellar mobile phase could more easily lead to column blockage, the conclusion 
was made that conventional C18-columns are more appropriate for MLC studies. 
In the second part of chapter VIII, the most interesting previously developed methods were 
compared in an unambiguous way for their capability to predict log BB and HIA values. It 
appeared that methods with a relatively good log BB prediction generally showed a rather bad 
HIA prediction and vice versa. Therefore, the type of in vitro method that should be selected 
actually depends on the type of in vivo behavior that should be modeled. Both for log BB and 
HIA prediction, several MLC and IAMLC methods could be selected for prediction purposes. 
In the third section of chapter VIII, the degree of correlation of the used descriptors is shown 
in more detail. First, the individual descriptors were statistically processed, then the 
correlation between all descriptors was evaluated. Finally, the relations with log BB and HIA 
values were also shown. The results indicated that the correlation between some of the 
Summary and general conclusions 
 
194 
 
descriptors is very high, which increases their probability towards elimination during model 
optimization.   
In the final section of chapter VIII, results of the partial least squares regression were 
compared to those of multiple linear regression. For this limited set of compounds and 
descriptors, the results of the two methods appeared to be identical. Therefore, the specific 
choice of regression model was considered to be less important in this work. 
 
IX.2 General conclusions 
Introducing a new therapeutic agent on the market is a time-consuming (typically 10 – 15 
years) and expensive (ranging from hundreds of millions to several billion euro) process. The 
overall attrition rate in drug development is very high (> 99%), since most new compounds do 
not pass the broad range of tests during the consecutive stages of the development process. In 
contemporary drug design, significant effort is put in the prediction of drug delivery at the 
biological location of interest, since a faster assessment of lead compounds (or problematic 
compounds) allows to reduce the total cost of drug development. 
In vitro and in silico methods have been developed for the prediction of drug delivery. HPLC-
based methods are an important subset of in vitro-based assays to predict drug penetration. 
This thesis focused on the development and use of micellar liquid chromatography and 
immobilized artificial membrane liquid chromatography methods in an attempt to improve the 
prediction of drug delivery. 
A problem related to micellar liquid chromatography, is that, although classical surfactants – 
such as sodium dodecyl sulfate – provide a reasonable prediction of drug delivery, they do not 
present a realistic mimic of membranes. Therefore, a phosphocholine-based lipid was used as 
a surfactant in an attempt to create a better simulation of the interaction with membranes. 
Since biological membranes are composed of several types of (phospho)lipids, additional 
research, in which a variety of (phospho)lipids are combined as surfactants for MLC, might 
prove to be very interesting. However, the solubility of phospholipids in water might create 
problems for this type of mixed micelles. 
For immobilized artificial membrane liquid chromatography, research was until now only 
performed on phosphatidylcholine-coated particles (which allowed proper prediction of drug 
delivery). Here, the synthesis of sphingomyelin-coated particles was presented and this new 
type of column was evaluated. Based on the results obtained with this column, we could 
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assume that other IAM-phases provide alternative interactions with compounds. Therefore, 
the creation of a mixed stationary phase (which could be created by the coupling of different 
column segments, by mixing several stationary phases into one column, or by linking several 
lipids to aminopropyl silica particles) with a selected composition, should in principal provide 
the best possible mimic of the biological membrane of interest and could therefore provide an 
improvement of the prediction of drug delivery. However, as mentioned in chapter II, 
technical limitations with concerns about column consistency and quality control might cause 
problems for mixed stationary phases. 
Throughput is a major issue for in vitro predictions. Although no attention was paid to this 
point in the thesis, it should be mentioned that throughput could be increased at least by factor 
10 when shorter columns should be selected and higher flow rates would be used. The only 
drawback here is that the efficiency of the chromatographic runs would decrease. Another 
way to increase throughput would be to use an MS-compatible buffer. MS measurements 
would allow to measure multiple components simultaneously, which would greatly benefit the 
total analysis time for a set of compounds. 
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Samenvatting en algemene conclusies 
 
Samenvatting 
Bij de hedendaagse ontwikkeling van geneesmiddelen wordt er veel aandacht besteed aan het 
voorspellen van het afleveren van die geneesmiddelen op de daarvoor bedoelde plaats in het 
lichaam. De reden hiervoor is dat geneesmiddelen sneller verwijderd kunnen worden uit het 
dure ontwikkelingsproces als men sneller te weten komt dat de aflevering in het lichaam 
problemen met zich meebrengt. Daarom is er een brede waaier aan methodes ontwikkeld om 
voorspellingen te kunnen maken. Aangezien al deze in silico en in vitro methodes bepaalde 
voor- en nadelen hebben, is er voorlopig nog geen gulden regel om voorspellingen te maken. 
In dit werk is de focus gelegd op het ontwikkelen van in vitro hoge performantie 
vloeistofchromatografie (HPLC) methodes waarbij gebruik gemaakt wordt van micellaire 
vloeistofchromatografie (MLC) en geïmmobilizeerd artificiëel membraan 
vloeistofchromatografie (IAMLC) voor het voorspellen van het afleveren van geneesmiddelen 
in de hersenen alsook doorheen het darmsysteem. Een vergelijking van bestaande technieken 
en verschillende uitbreidingen op de beschikbare methodes worden besproken. 
 
In hoofdstuk II werd een overzicht gegeven van de typische methodes die gebruikt worden 
voor het voorspellen van transport doorheen de bloed-hersenbarrière (BBB). De functies, 
structuur en transport doorheen de BBB werden hierbij toegelicht. Vervolgens werden de 
belangrijkste gekende afleveringssystemen doorheen de BBB opgelijst, gevolgd door een 
overzicht van bestaande in vivo, in vitro en in silico methodes voor het voorspellen van 
transport doorheen de BBB. Tenslotte werden enkele mogelijke computationele methodes 
aangehaald die gebruikt kunnen worden bij dit type voorspellingen. 
 
In hoofdstuk III werden enkele in vitro systemen voor het voorspellen van het logaritme van 
de bloed-hersen verdelingscoëfficiënt (log BB) vergeleken. MLC werd uitgevoerd op een C18 
kolom met Brij35, natrium deoxycholaat (SDC) en natriumdodecylsulfaat (SDS) als 
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surfactanten. IAMLC werd uitgevoerd met methanol als organisch solvent. SDS leverde de 
beste correlatiecoëfficiënt tussen experimentele en voorspelde log BB waarden (R = 0,7993), 
gevolgd door de geïmmobilizeerd artificiëel membraan (IAM) metingen met 30 % methanol 
(R = 0,7724). Bij het verwerken van de data leverde het combineren van de resultaten van 
IAMLC en MLC geen verbetering voor het voorspellen van log BB waarden. 
 
In hoofdstuk IV werd een nieuw type stationaire fase aangemaakt, dat als een alternatief kan 
gebruikt worden voor de commercieel beschikbare IAM kolommen. Sfingomyeline werd 
gekozen om in de nieuwe stationaire fase te verwerken aangezien interessante kenmerken 
voorzien werden voor dit lipide omdat het een belangrijk bestanddeel is van het 
plasmamembraan bij eukaryoten. Afgaande op de initiële correlatiestudies werd de 
sfingomyeline fase beschouwd als een veelbelovende alternatieve IAMLC fase. De 
synthesemethode, die opschaalbaar, kort en modulair is, zou toegang moeten geven tot het 
ontwikkelen van een nieuwe set IAM fases. 
 
In hoofdstuk V werden de mogelijkheden van drie verschillende types IAM kolommen 
vergeleken op vlak van het voorspellen van log BB waarden. De correlatiecoëfficiënten tussen 
de actuele en voorspelde log BB waarden van de drie overeenkomstige modellen bleken zeer 
goed, de drie kolommen werden dus allen geschikt bevonden voor dit type voorspellingen. De 
resultaten die bekomen werden met de sfingomyeline kolom waren gelijkaardig aan die van 
de commerciële fosfatidylcholine kolom. Zodoende werd de sfingomyeline kolom beschouwd 
als een goed alternatief voor dit type metingen. Aangezien de correlatiecoëfficiënten 
gebaseerd op de resultaten met de cholester kolom minder goed waren dan deze van de andere 
twee kolommen, werd deze kolom beschouwd als een minder interessante optie voor dit type 
metingen. 
 
Methodes voor extractie, identificatie en kwantificatie van de belangrijkste lipidenklassen (in 
hersenmembranen) werden voorgesteld in hoofdstuk VI. Fosfatidylcholine en –ethanolamine 
zijn de meest voorkomende lipiden in hersenmembranen; de relatieve concentraties van 
andere lipidenklassen zijn volgens de literatuur uiteenlopend. Daarom is het zeer moeilijk om 
een exact overzicht te geven van lipidenklassen en hun concentraties in hersenmembranen. 
Verschillen ontstaan niet enkel tussen soorten, maar ook tussen individuen, in verschillende 
delen van de hersenen en afhankelijk van de leeftijd. Een beperkte vergelijkende studie werd 
uitgevoerd om verschillen in lipidensamenstelling te visualiseren tussen witte en grijze stof in 
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pasgeboren biggetjes. Alhoewel de belangrijkste lipidenklassen een gelijkaardig lipidenprofiel 
vertoonden, waren er ook enkele duidelijke verschillen, hetgeen bevestigde dat er significante 
verschillen zijn op vlak van lipidensamenstelling in verschillende secties van de hersenen. 
 
Afgaande op de resultaten van hoofdstuk VI, werd er gesuggereerd dat het gebruik van lipiden 
in MLC zou leiden tot een meer realistische simulatie van interacties van geneesmiddelen in 
hersenmembranen. Bijgevolg werd dit studiegebied verkend in hoofdstuk VII. Gebaseerd op 
de bevindingen dat fosfatidylcholine en –ethanolamine de twee meest prominente fosfolipiden 
in membranen zijn, en dat de vetzuurgroepen in lipiden typisch een koolstofketen met 16 of 
18 koolstofatomen hebben, werd miltefosine geselecteerd voor evaluatie als een mogelijk 
surfactant in MLC. De retentie van componenten was korter in vergelijking met een puur 
waterig systeem, wat aangeeft dat het principe van MLC ook werkt met micellen gebaseerd 
op miltefosine. Aangezien dit fosfocholine-gebaseerd lipide qua structuur beter aanleunt bij 
biologische membranen in vergelijking met gewone surfactanten, werd de retentiedata 
gebruikt voor in vitro voorspellingen van menselijke intestinale absorptie (HIA) en log BB 
waarden. Het geöptimaliseerde model voor HIA voorspellingen met een set van 36 
componenten leverde een correlatiecoëfficiënt van 0,7175; een waarde van 0,7849 werd 
bereikt voor log BB voorspellingen op basis van 48 componenten. 
 
In het eerste gedeelte van hoofdstuk VIII werd het gebruik van MLC condities op een IAM 
kolom bestudeerd voor het voorspellen van log BB en HIA waarden. SDS werd gekozen als 
surfactant voor metingen op een IAM.PC.DD2 kolom; zodat de principes van MLC en 
IAMLC op deze manier experimenteel gecombineerd werden. Niettemin waren de 
correlatiecoëfficiënten zowel voor de predictie van log BB als van HIA lager dan de waarden 
die in de vorige hoofdstukken bereikt werden, wat aangeeft dat de mogelijkheden op vlak van 
voorspellen via deze methode beperkt zijn. Aangezien het ook zo is dat IAM kolommen duur 
zijn en een micellaire mobiele fase gemakkelijker kan zorgen voor blokkage van de kolom, 
was de conclusie dat conventionele C18 kolommen meer geschikt zijn voor MLC studies. 
In het tweede gedeelte van hoofdstuk VIII werden de meest interessante methodes uit deze 
thesis vergeleken naar hun mogelijkheden om log BB en HIA waarden te voorspellen. Het 
leek er op dat methodes met een relatief goede log BB voorspelling algemeen gezien eerder 
slecht presteerden op vlak van HIA-voorspelling (en omgekeerd). Daarom lijkt het belangrijk 
om te weten welk type in vivo gedrag gemodelleerd moet worden vooraleer het type in vitro 
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methode gekozen wordt. Zowel voor log BB als voor HIA voorspelling zijn er enkele MLC 
en IAMLC methodes die geselecteerd kunnen worden om voorspellingen te maken. 
In de derde sectie van hoofdstuk VIII werd de correlatie van de gebruikte descriptoren in meer 
detail getoond. Eerst werden de individuele descriptoren statistisch verwerkt, waarna de 
correlatie tussen alle descriptoren werd geëvalueerd. Tenslotte werden de verbanden met log 
BB en HIA ook getoond. De resultaten gaven aan dat de correlatie tussen enkele van 
descriptoren zeer hoog is, wat de kans op eliminatie tijdens het optimaliseren van een model 
doet toenemen. 
In het laatste deel van hoofdstuk VIII werden de resulaten van de PLS regressie vergeleken 
met deze van meervoudige lineaire regressie (MLR). Voor deze beperkte set van 
componenten en descriptoren bleken de resultaten van de twee methodes identiek. Hierdoor 
konden we stellen dat de keuze van regressiemodel minder relevant was in dit werk. 
 
Algemene conclusies 
De invoering van een nieuw geneesmiddel is een tijdrovend (typisch 10 tot 15 jaar) en duur 
(enkele honderden miljoenen to enkele miljarden euro) proces. Bij het ontwikkelingsproces 
gaat gewoonlijk meer dan 99 % van de geneesmiddelen verloren aangezien de meeste nieuwe 
componenten niet slagen voor de grote waaier aan testen tijdens de opeenvolgende stappen in 
de ontwikkeling. Bij het huidige ontwikkelingsproces van geneesmiddelen wordt er veel 
aandacht besteed aan het voorspellen van het afleveren van die geneesmiddelen op de 
daarvoor bedoelde plaats in het lichaam, aangezien een snellere toewijzing van interessante 
(of problematische) componenten toelaat om de totale kost van de 
geneesmiddelenontwikkeling te verminderen. 
In vitro en in silico methodes werden ontwikkeld voor het voorspellen van het afleveren van 
geneesmiddelen. HPLC-gebaseerde methodes omvatten een belangrijk deel van de in vitro 
onderzoeken om de doorlaatbaarheid van geneesmiddelen te voorspellen. In deze thesis werd 
de nadruk gelegd op de ontwikkeling en het gebruik van micellaire vloeistofchromatografie 
(MLC) en geïmmobilizeerd artificiëel membraan vloeistofchromatografie (IAMLC) 
methodes, met als doel om de aflevering van geneesmiddelen beter te kunnen voorspellen. 
Een probleem met betrekking tot MLC is dat, alhoewel klassieke surfactanten – zoals 
natriumdodecylsulfaat – een redelijke voorspelling bewerkstelligen, ze geen realistisch beeld 
van membranen geven. Daarom werd een fosfocholine-gebaseerd lipide gebruikt als 
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surfactant in een poging om een betere simulatie van de interactie met membranen te 
bekomen. Aangezien biologische membranen bestaan uit meerdere types (fosfo)lipiden, zou 
extra onderzoek, waarbij meerdere (fosfo)lipiden gecombineerd worden als surfactanten bij 
MLC, zeer interessant kunnen zijn. De oplosbaarheid van fosfolipiden in water zou echter 
voor problemen kunnen zorgen bij dit type van gemengde micellen. 
Voor IAMLC werd onderzoek tot nog toe enkel uitgevoerd op deeltjes gecoat met 
fosfatidylcholine (die een redelijke voorspelling van het afleveren van geneesmiddelen 
toelieten). Hier werd de synthese van deeltjes gecoat met sfingomyeline voorgesteld en dit 
nieuw type kolom werd geëvalueerd. Gebaseerd op de resultaten die met deze kolom 
bekomen werden, konden we aannemen dat andere IAM fases andere interacties met de 
componenten aan zouden kunnen gaan. Daarom zou de ontwikkeling van een gemengde 
stationaire fase (die bekomen zou kunnen worden door het aaneenkoppelen van verschillende 
kolomsegmenten, door het mengen van verschillende stationaire fases in één kolom, of door 
het linken van verschillende lipiden op aminopropyl silica deeltjes) met een gekozen 
samenstelling in principe de best mogelijke nabootsing van het biologisch membraan van 
interesse kunnen leveren en bijgevolg ook een verbetering van de voorspelling van het 
afleveren van geneesmiddelen. Zoals reeds werd aangehaald in hoofdstuk II zouden 
technische limitaties en zorgen om kolom consistentie en kwaliteitscontrole problemen 
kunnen veroorzaken bij gemengde stationaire fases. 
Snelheid is een belangrijk aspect bij in vitro voorspellingen. Alhoewel er in deze thesis geen 
aandacht werd besteed aan dit punt, is het belangrijk om te vermelden dat de snelheid van de 
metingen ten minste met een factor 10 verhoogd kan worden door het gebruik van kortere 
kolommen en hogere vloeistofdebieten. Het enige nadeel hierbij is dat de efficiëntie van de 
chromatografische metingen zou afnemen. Een andere manier om de snelheid te verhogen is 
het gebruik van een massaspectrometrie (MS)-compatibele buffer. MS metingen zouden 
toelaten om meerdere componenten tegelijkertijd te meten, wat de totale analysetijd voor een 
reeks componenten enorm zou verminderen. 
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Appendix A. Overview of experimental log BB values 
 
The Table in this section gives an overview of compounds with in vivo determined log BB 
values present in literature [1-24]. When multiple log BB values were found, the average 
value was calculated. Compounds indicated in grey were experimentally used in this thesis; 
the structural formula of these compounds is presented in Appendix B. The Table also 
provides a limited overview of drug usage for these compounds. 
As can be seen in the Table below, various drug applications are mentioned, of which most 
are recurrent. The discussion of all applications lies beyond the scope of this research. 
However, a brief explanation is provided here for some of the more frequently used 
applications: 
 Analgesic: this type of drug is used to relieve the pain (= painkiller). 
 Anesthetic: a drug that causes a temporal loss of sensation. 
 Anticonvulsant: mainly used in the treatment of epileptic seizures (= antiepileptic). 
 Antiemetic: an effective drug against vomiting and nausea. 
 Antihistamine: can be used to treat gastric acid conditions or to suppress allergic 
reactions. 
 Antipsychotic: a drug used primarily to manage psychosis, particularly schizophrenia 
and bipolar disorder (= neuroleptic). 
 Anxiolytic: reduces or inhibits anxiety. 
 Benzodiazepine: enhances the effect of a neurotransmitter, which results in sedative, 
muscle relaxant, hypnotic, anxiolytic and anticonvulsant properties. 
 Beta-blocker: a drug particularly used to manage cardiac arrhythmias, to protect the 
heart from a second heart attack, and sometimes for hypertension. 
 Stimulant: induce temporary improvements in mental and/or physical functions (e.g. 
caffeine and nicotine). 
 Some other drugs are specifically used for the treatment of diseases like Alzheimer’s 
and Parkinson’s. 
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 CAS Name Possible drug use Log BB References 
1 630-20-6 1,1,1,2-Tetrachloroethane - 0.33 14,15 
2  71-55-6 1,1,1-Trichloroethane Insecticide 0.28 1,6,8,10,11,14,15,16,20,21,22,23,24 
3 75-88-7 1,1,1-Trifluoro-2-chloroethane - -0.12 1,6,8,16,24 
4  79-00-5 1,1,2-Trichloroethane - -0.10 14,15 
5  75-34-3 1,1-Dichloroethane Inhalational anesthetic -0.28 14,15 
6 635-46-1 1,2,3,4-Tetrahydroquinoline - 0.65 16 
7 95-63-6 1,2,4-Trimethylbenzene (Pseudocumene) - 0.16 14,15 
8  2234-75-5 1,2,4-Trimethylcyclohexane - 1.02 14,15 
9 107-06-2 1,2-Dichloroethane - -0.14 14,15 
10  583-57-3 1,2-Dimethylcyclohexane - 1.07 14,15 
11  106-99-0 1,3-Butadiene - -0.17 14,15 
12 92817-10-2 16a-Fluoroestradiol (estradiol-16a-fluoro) PET imaging agent -0.30 14,15 
13  106-94-5 1-Bromopropane - 0.31 14,15 
14  71-36-3 1-Butanol - -0.02 14,15 
15 6336-01-2 1-Butyl-3-phenylthiourea - 0.04 6,12 
16 872-05-9 1-Decene - 0.96 14,15 
17 59468-90-5 1-Hydroxymidazolam Benzodiazepine -0.07 1,6,10,12,14,15,16,17 
18 124-11-8 1-Nonene - 0.86 14,15 
19 111-66-0 1-Octene - 0.74 14,15 
20 71-41-0 1-Pentanol - 0.20 14,15 
21 71-23-8 1-Propanol - -0.13 1,6,8,10,11,12,14,15,16,19,20,21,22,23,24 
22 406-90-6 2,2,2-Trifluoroethyl vinyl ether (Fluroxene) Inhalational anesthetic 0.13 1,6,8,10,11,14,15,16,20,21,23,24 
23 75-83-2 2,2-Dimethylbutane - 1.04 1,6,8,10,11,12,14,15,16,20,21,22,23,24 
24 132235-73-5 2',3'-Dideoxy-3'-hydroxymethylcytidine Antiviral -0.79 17 
25  2078-54-8  2,6-diisopropylphenol (Propofol)  Anesthetic 0.59 6,12,14,15 
26 75-26-3 2-Bromopropane - 0.56 14,15 
27 78-93-3 2-Butanone (Methyl ethyl ketone) - -0.10 1,6,8,10,11,12,14,15,16,20,21,22,23,24 
28 592-27-8 2-Methyl heptane - 0.86 14,15 
29 871-83-0 2-Methyl nonane - 1.05 14,15 
30 3221-61-2 2-Methyl octane - 0.98 14,15 
31 78-83-1 2-Methyl-1-propanol (Isobutanol) - -0.16 6,8,10,11,12,14,15,16,20,21,22,23,24 
32 43133-95-5 2-Methylpentane - 0.97 1,6,8,10,11,12,14,15,16,20,21,22,23,24 
33 107-87-9 2-Pentanone - -0.01 14,15 
34 67-63-0 2-Propanol (Isopropanol) Antiseptic -0.14 1,6,8,10,11,12,14,15,16,20,21,22,23,24 
35  6304-27-4 2-Pyridine-ethanamine-n-n-dimethyl Antihistamine -0.61 12,14,15,16,17,18,20,21,23 
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36 123-51-3 3-Methyl-1-butanol (Isopentanol) - 0.04 14,15 
37 589-34-4 3-Methylhexane - 0.90 1,6,8,10,11,12,14,15,16,20,21,23,24 
38 96-14-0 3-Methylpentane - 1.01 1,6,8,10,11,12,14,15,16,20,21,22,23,24 
39 98-56-6 4-Chlorobenzotrifluoride - 0.17 14,15 
40 5400-60-2 4-Fluoroantipyrine Blood flow tracer -0.05 14,15 
41 30896-57-2 4-Hydroxyalprazolam Benzodiazepine -1.48 16 
42  59468-85-8  4-Hydroxymidazolam Benzodiazepine -0.20 1,6,10,12,14,15,16,17 
43 201-019-9 5-Butyl-5-ethyl barbituric acid (Butethal) Barbiturate 0.19 14,15 
44 27653-63-0 5-Methyl-5-ethyl barbituric acid Barbiturate 0.00 14,15 
45 144598-75-4  9-Hydroxy-Risperidone Antipsychotic -0.67 1,4,10,12,14,15,16,18 
46 37517-30-9 Acebutolol Beta-blocker -0.15 17 
47 103-90-2  Acetaminophen (paracetamol) Analgesic -0.37 1,2,5,7,8,9,10,11,12,13,14,15,16,17,19,20,21,24 
48 67-64-1 Acetone (Propanone) - -0.16 1,6,8,10,11,12,14,15,16,20,21,22,23,24 
49  50-78-2 Acetylsalicylic Acid (aspirin) Analgesic/ NSAID -0.59 1,2,5,6,8,9,10,11,12,13,16,17,18,19,20,21,24 
50  107-13-1 Acrylonitrile - -0.40 14,15 
51  59277-89-3  Acyclovir Antiviral -0.84 22 
52 178307-42-1 AI-9 (Revaprazan hydrochloride) Anticancer drugs 0.21 14,15 
53 52-43-7 Allobarbital Barbiturate -0.22 17 
54 25526-93-6 Alovudine Antiviral -0.59 1,14,15 
55 28981-97-7 Alprazolam Benzodiazepine/ Anxiolytic 0.03 1,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,24 
56 13655-52-2 Alprenolol Beta-blocker -0.23 17 
57 58-15-1 Aminopyrine Analgesic 0.00 1,5,6,7,10,12,13,14,15,16 
58 50-48-6 Amitriptyline (Triptanol) Antidepressant 0.90 4,5,6,7,12,13,14,15,16,17,18,19,20,21,23 
59 57-43-2 Amobarbital Barbiturate/ Hypnotic 0.04 1,5,6,7,10,12,13,14,15,16,19 
60 300-62-9 Amphetamine Stimulant 0.93 16 
61 161814-49-9 Amprenavir Antiviral -0.56 17 
62 75-85-4 Amylene-hydrate (tertiary-amyl alcohol) Anesthetic 0.07 14,15 
63  60-80-0 Antipyrine (Phenazone) Analgesic -0.11 1,2,5,6,8,9,10,11,12,13,14,15,16,18,19,20,21,22,24 
64 151581-23-6 Apaxifylline Neuroprotective agent -1.40 17 
65 7440-37-1 Argon - 0.03 10,11,15,16 
66  29122-68-7 Atenolol Beta-blocker -1.12 1,3,5,7,10,12,13,14,15,16,17,19 
67 51-55-8 Atropine Anticholinergic -0.06 5,13,16 
68  57-44-3 Barbital (5-Ethyl-5-ethyl barbituric acid) Barbiturate -0.14 14,15 
69 150146-06-8 Beloxepin Analgesic 0.82 14,15,17,18 
70 55-21-0 Benzamide - -0.24 6 
Overview of experimental log BB values 
 
206 
 
 CAS Name Possible drug use Log BB References 
71 71-43-2 Benzene - 0.32 1,2,5,6,8,10,11,12,14,15,16,19,20,21,22,23,24 
72 63659-18-7 Betaxolol Beta-blocker 0.39 17 
73 514-65-8 Biperiden Anticholinergic 0.85 14,15 
74  80-05-7  Bisphenol A - -0.12 14,15 
75  84379-13-5 Bretazenil Anxiolytic -0.09 1,6,10,12,14,15,17 
76 25614-03-3 Bromocriptine Dopamine agonist -1.10 13,16 
77  10457-90-6 Bromperidol Antipsychotic 1.38 1,10,12,13,16,17,19 
78 34915-68-9 Bunitrolol Beta-blocker 0.38 22 
79 34841-39-9 Bupropion (Zyban) Antidepressant 1.40 17 
80 36505-84-7 Buspirone Anxiolytic 0.48 16 
81  94-25-7 Butyl 4-aminobenzoate Anesthetic 0.42 14,15 
82 123-86-4 Butyl acetate - 0.28 14,15 
83  58-08-2 Caffeine Stimulant -0.04 1,2,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,24 
84  298-46-4  Carbamazepine Anticonvulsant -0.07 1,4,5,6,7,12,13,14,15,16,18,19,20,21,23 
85  36507-30-9 Carbamazepine-10,11-Epoxide Anticonvulsant -0.34 1,4,6,12,13,14,15,16,18,19,20,21,23 
86 75-15-0 Carbon Disulfide - 0.60 6,10,11,14,15,16,21 
87 154-93-8 Carmustine (BCNU) Anticancer drugs -0.52 1,6,8,11,12,13,14,15,16,18,20,21,24 
88 51781-06-7 Carteolol Beta-blocker -0.40 14,15 
89 69712-56-7 Cefotetan Antibiotic -1.89 16 
90 83881-51-0 Cetirizine Antihistamine -2.15 17 
91  305-03-3 Chlorambucil Chemotherapy -1.70 1,8,11,12,18,20,24 
92 67-66-3 Chloroform (Trichloromethane) Inhalational anesthetic 0.25 1,10,11,12,14,15,16 
93 50-53-3 Chlorpromazine Antipsychotic 1.02 1,3,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,24 
94  51481-61-9 Cimetidine (Y-G1) Antihistamine/ Peptic ulcer -1.42 1,3,4,6,7,9,10,11,12,13,16,17,18,19,20,21,23 
95 156-59-2 Cis 1,2-dichloroethene - -0.13 14,15 
96  22316-47-8 Clobazam Benzodiazepine/ Anxiolytic 0.35 1,10,12,13,14,15,16,17,19 
97 4205-90-7 Clonidine (SKB6) Adrenergic 0.13 1,3,4,5,6,7,9,10,11,12,14,15,16,17,18,19,20,21,23 
98 50-36-2 Cocaine Local anesthetic 0.60 14,15 
99  76-57-3  Codeine Analgesic 0.38 1,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,24 
100  486-56-6 Cotinine Antidepressant -0.28 6,12,14,15,17 
101 52-31-3 Cyclobarbital Barbiturate -0.30 17 
102 110-82-7 Cyclohexane - 1.00 10,12,14,15,16 
103 75-19-4 Cyclopropane Inhalational anesthetic 0.04 10,14,15,16 
104 59865-13-3  Cyclosporine A Immunosuppressant -0.78 22 
105  485-35-8  Cytisine Nicotinic -1.09 17 
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106 486-66-8 Daidzein Isoflavones -0.15 14,15 
107 133099-04-4 Darifenacin Urinary incontinence -0.62 17 
108 124-18-5 Decane - 0.67 14,15 
109 57041-67-5 Desflurane Anesthetic 0.11 16 
110 50-47-5 Desipramine Antidepressant 1.11 1,4,8,9,10,11,12,13,14,15,16,17,18,19,20,21,24 
111  22316-55-8  Desmethylclobazam Benzodiazepine 0.31 1,6,10,12,13,14,15,16,17 
112 2095-20-7 Desmonomethylpromazine (Monodesmethylpro.) Antipsychotic 0.59 1,6,10,12,14,15,16,17 
113  439-14-5  Diazepam Benzodiazepine/ Anxiolytic 0.45 1,2,5,6,7,10,12,13,14,15,16,17,19 
114 75-09-2 Dichloromethane  - -0.23 10,14,15,16 
115 69655-05-6 Didanosine Anti-HIV -1.03 1,6,8,10,11,14,15,16,17,18,20,21,22,24 
116 2095-95-6 Didesipramine (Desmethyldesipramine) Antidepressant 1.04 1,6,10,13,14,15,16,17 
117 60-29-7 Diethyl ether Anesthetic 0.00 1,6,8,10,11,12,14,15,16,20,21,22,23,24 
118  20830-75-5 Digoxin Cardiac glycoside -1.23 22 
119 58-73-1 Diphenhydramine Antihistamine 1.26 14,15 
120 109-93-3 Divinyl ether (vinyl ether) Inhalational anesthetic 0.12 10,12,14,15,16 
121  57808-66-9 Domperidone Antiemetic -0.83 1,4,12,14,15,18 
122 120014-06-4 Donepezil (Aricept) Treatment of Alzheimer's 0.89 17 
123 23214-92-8 Doxorubicin Chemotherapy -0.83 22 
124 469-21-6 Doxylamine Antihistamine 0.64 14,15 
125 13838-16-9 Enflurane Inhalational anesthetic 0.21 1,6,8,10,11,14,15,16,20,21,22,23,24 
126  57-47-6  Eserine (Physostigmine) Glaucoma 0.08 1,5,6,7,8,11,12,13,14,15,16,18,20,21,24 
127 64-17-5 Ethanol - -0.15 1,6,8,10,11,12,14,15,16,19,20,21,22,23,24 
128  938-73-8  Ethenzamide (o-Ethoxybenzamide and AI-5) Analgesic -0.05 14,15 
129 94-09-7  Ethyl 4-aminobenzoate Anesthetic 0.27 14,15 
130 141-78-6 Ethyl acetate - 0.00 14,15 
131 637-92-3 Ethyl t-butyl ether  - 0.22 14,15 
132 100-41-4 Ethylbenzene - 0.22 5,10,14,15,16 
133 74-85-1 Ethylene (ethene) Anesthetic 0.31 14,15 
134 75-21-8 Ethylene Oxide - 0.01 14,15 
135 33419-42-0  Etoposide Anticancer drugs -2.00 16 
136 437-38-7 Fentanyl Opioid analgesic 0.58 14,15 
137 83799-24-0 Fexofenadine (Allegra) Antihistamine -0.98 17 
138 98206-10-1 Flesinoxan Antidepressant/ Anxiolitic -0.45 22 
139 86386-73-4 Fluconazole Antifungal -0.22 17 
140  78755-81-4  Flumazenil Antidote for benzodiazepines -0.29 1,2,6,10,12,14,15,17 
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141  1622-62-4 Flunitrazepam Benzodiazepine / Hypnotic 0.06 1,6,10,12,13,14,15,16,17,19 
142 54910-89-3 Fluoxetine Antidepressant 0.72 14,15,17 
143 69-23-8 Fluphenazine (Triflumethazine) Neuroleptic/ Antipsychotic 1.51 1,6,7,10,12,13,16,17,19 
144 54739-18-3 Fluvoxamine Obsessive-Compulsive Disorder 0.79 17 
145 357-70-0 Galantamine Alzheimer's disease 0.32 17 
146 490-79-9  Gentisic acid - 0.08 16 
147  471-53-4  Glycyrrhetinic acid Peptic ulcer -1.40 14,15 
148 109889-09-0 Granisetron Antiemetic -0.69 1 
149 52-86-8 Haloperidol Antipsychotic 1.34 1,3,5,7,10,12,13,16,17,19 
150 151-67-7 Halothane Anesthetic 0.27 1,6,8,10,11,14,15,16,20,21,22,23,24 
151 5579-03-3 HEPP (3-hydroxy-3-phenylpentanamide) Anticonvulsant 0.04 14,15 
152 142-82-5 Heptane - 0.69 1,6,8,10,11,12,14,15,16,20,21,22,23,24 
153 110-54-3 Hexane - 0.74 1,6,8,10,11,12,14,15,16,20,21,22,23,24 
154  56-29-1 Hexobarbital  Barbiturate/Hypnotic 0.04 1,6,10,12,13,14,15,16,17,19 
155 68-88-2 Hydroxyzine Antihistamine 0.34 1,6,8,9,10,11,12,13,14,15,16,17,18,19,20,21,24 
156 15687-27-1 Ibuprofen Analgesic/ NSAID -0.18 1,2,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,24 
157 71351-79-6 Icotidine Antihistamine -2.00 1,4,6,11,12,16,17,18,20,21,23 
158 50-49-7 Imipramine (SKB8) Antidepressant 1.03 1,3,4,5,6,7,9,10,11,12,13,14,15,16,17,18,19,20,21,23 
159 150378-17-9 Indinavir Aids -0.74 1,6,10,14,15,16,17,21,22 
160  53-86-1  Indomethacin Analgesic/ NSAID -1.26 1,2,6,7,8,9,10,11,12,13,14,15,16,18,19,20,21,24 
161 110-19-0 Isobutyl acetate - 0.45 14,15 
162 26675-46-7 Isoflurane Inhalational anesthetic 0.36 1,6,8,10,11,14,15,16,20,21,22,23,24 
163 123-92-2 Isopentylacetate  Honey bee pheromone 0.55 14,15 
164 108-21-4 Isopropyl acetate - 0.40 14,15 
165  4759-48-2  Isotretinoin (13-cis-Retinoic Acid) Anti-acne -0.49 22 
166 65277-42-1 Ketoconazole Antifungal -0.63 17 
167 7439-90-9 Krypton - -0.16 10,15,16 
168  84057-84-1 Lamotrigine Antiepileptic 0.29 1,14,15 
169 59-92-7  Levodopa Dopamine-agonist/ Parkinson's -0.77 13,16 
170 77-07-6 Levorphanol Opioid analgesic 0.00 13,16 
171  137-58-6 Lidocaine Local anesthetic 0.34 14,15 
172 53179-11-6 Loperamide Anti-diarrheal 0.77 17 
173  846-49-1 Lorazepam Anxiolytic/ Hypnotic 0.44 14,15 
174 83903-06-4 Lupitidine Antiulcer -1.06 1,4,6,11,14,15,16,17,18,20,21,23 
175 69-65-8  Mannitol Osmotherapy -1.60 14,15 
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176 53230-10-7 Mefloquine (AI-8) Anti-malaria 0.63 14,15 
177 5588-33-0 Mesoridazine Neuroleptic/ Antipsychotic -0.31 1,6,10,12,13,16,17 
178 33817-09-3 Methamphetamine ADHD 0.93 14,15,16 
179 74-82-8 Methane - 0.04 6,10,11,14,15,16,21,23 
180 67-56-1 Methanol - 0.02 14,15 
181  151-83-7  Methohexital Anesthetic -0.06 1,6,10,12,14,15,16,17 
182 59-05-2 Methotrexate Anticancer drugs -1.52 13,16 
183 76-38-0 Methoxyflurane Inhalational anesthetic 0.21 1,10,11,14,15,16 
184 79-20-9 Methyl acetate - -0.13 14,15 
185 1634-04-4 Methyl t-butyl ether  - 0.36 14,15 
186 108-87-2 Methylcyclohexane - 0.96 14,15 
187 96-37-7 Methylcyclopentane - 0.93 1,6,8,10,11,12,14,15,16,20,21,22,23,24 
188 37350-58-6 Metoprolol Beta-blocker 1.15 17 
189 24219-97-4 Mianserin Antidepressant 0.99 1,3,4,5,7,10,12,14,15,16,17,18,19 
190 59467-64-0 Midazolam Benzodiazepine 0.38 1,3,5,6,7,8,9,10,11,12,14,15,16,17,18,19,20,21,24 
191 37065-29-5 Miloxacin Antibacterial -0.92 14,15 
192 85650-52-8  Mirtazapine (Mirtazepine) Antidepressant 0.53 1,4,10,12,14,15,16,17,18 
193 13551-89-8 Misonidazolefluoro (Fluoromisonidazole) Metabolic marker -0.01 14,15 
194 57-27-2 Morphine Opioid analgesic -0.27 1,3,10,12,13,14,15,16,17 
195 108-38-3 m-Xylene - 0.26 10,14,15,16 
196  389-08-2  Nalidixic acid Antibiotic -0.66 14,15 
197 159989-64-7 Nelfinavir (AG-1341) HIV -0.93 17 
198 7440-01-9 Neon - 0.20 10,11,15,16 
199  129618-40-2  Nevirapine HIV/ aids 0.00 1,6,8,10,11,13,14,15,16,17,18,20,21,22,24 
200  54-11-5  Nicotine Stimulant 0.36 3,14,15,17 
201 7727-37-9 Nitrogen - 0.03 6,10,11,14,15,16,21,23 
202 10024-97-2 Nitrous Oxide Anesthetic/ Analgesic 0.03 6,10,11,14,15,16,21 
203 5638-76-6 N-methyl-2-pyridineethanamine (Betahistine) Anti-vertigo -0.33 1,7,10,11,12,14,15,16,17,18,20,21,23 
204 111-84-2 Nonane - 0.52 14,15 
205 1225-64-5 Nor-1-Chlorpromazine Neuroleptic 1.37 1,6,10,12,16,17 
206  1088-11-5 Nordazepam (Desmethyldiazepam) Benzodiazepine 0.52 1,6,10,12,13,14,15,16,17 
207  5746-86-1  Nor-nicotine Stimulant 0.32 17 
208 10538-32-6 Northioridazine Neuroleptic 0.75 1,6,10,12,14,15,16,17 
209 67018-85-3 Norverapamil Antihypertensive -0.64 16 
210 111-65-9 Octane - 0.69 14,15 
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211 132539-06-1 Olanzapine Antipsychotic 0.78 14,15 
212  73590-58-6 Omeprazole Peptic ulcer -0.82 6,7,12,17 
213 210821-63-9 Org-12962 5-HT2 agonist 1.64 1,4,10,12,17,18 
214 65576-45-6 Org-5222 (asenapine) Neuroleptic/ Antipsychotic 1.03 1,4,10,12,14,15,17,18 
215  604-75-1 Oxazepam Benzodiazepine 0.60 1,2,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,24 
216 95-47-6 o-Xylene - 0.39 10,14,15,16 
217  611-59-6  Paraxanthine Stimulant 0.06 1,6,10,12,14,15,16 
218 109-66-0 Pentane - 0.72 1,6,8,10,11,12,14,15,16,20,21,22,23,24 
219 359-83-1 Pentazocine Opioid analgesic 0.54 14,15 
220 76-74-4 Pentobarbital Barbiturate/Hypnotic 0.09 1,5,6,7,8,9,10,11,12,13,14,15,16,18,19,20,21,24 
221 628-63-7 Pentyl acetate  - 0.40 14,15 
222  54-95-5 Pentylenetetrazole (metrazole) Anxiogenic -0.03 14,15 
223 66104-22-1 Pergolide Parkinson's 0.30 16 
224 77-10-1 Phencyclidine Anesthetic 0.56 13,14,15,16 
225 50-06-6 Phenobarbital (Luminal) Barbiturate/ Anticonvulsant -0.12 17 
226  101246-66-6 Phenserine Alzheimer's 1.00 1,6,8,11,12,16,18,20,21,24 
227 50-33-9 Phenylbutazone Analgesic -0.52 1,2,5,6,7,10,12,13,14,15,16 
228 3376-24-7  Phenyl-N-tert-butylnitrone - 0.09 12,14,15 
229 57-41-0  Phenytoin Anticonvulsant -0.06 1,2,5,6,7,10,12,13,14,15,16,19,22 
230  13523-86-9 Pindolol Beta-blocker -0.14 14,15 
231 85532-75-8 PK-11195 - 0.48 14,15 
232 92-92-2 p-Phenylbenzoic acid - -1.26 14,15 
233 6673-35-4 Practolol Beta-blocker -0.55 17 
234  125-33-7 Primidone Anticonvulsant -0.07 13,16 
235 59-46-1 Procaine Local anesthetic 0.05 14,15 
236 57-83-0 Progesterone Luteal support in IVF 1.95 2 
237 58-40-2 Promazine Neuroleptic 1.07 1,3,6,8,9,10,11,12,13,14,15,16,17,18,19,20,21,24 
238 146-21-4 Promazine-Sulfoxide  Neuroleptic -0.48 17 
239 60-87-7 Promethazine Antihistamine 0.82 3 
240  107-19-7  propargyl alcohol - -0.23 14,15 
241 115-07-1 Propene (Propylene) - -0.06 14,15 
242 525-66-6 Propranolol Beta-blocker 0.84 1,3,5,6,7,10,12,13,14,15,16,17,19,22 
243 109-60-4 Propyl acetate  - 0.12 14,15 
244  3595-11-7 Propylhexedrine Nasal congestion 1.08 17 
245 106-42-3 p-Xylene  - 0.35 10,14,15,16 
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246  129-00-0  Pyrene - 0.23 14,15 
247 91-84-9 Pyrilamine (Mepyramine) Antihistamine 0.49 1,4,6,9,10,11,12,13,14,15,16,17,18,19,20,21,23 
248 56-54-2  Quinidine Antiarrhythmic -0.30 1,5,6,7,10,12,13,14,15,16,17 
249 10043-92-2 Radon Arthritis -0.12 15 
250 66357-35-5 Ranitidine Antihistamine -1.23 1,3,4,6,7,9,10,11,12,16,17,18,19,20,21,23 
251 87226-41-3 R-Etodolac Analgesic/ NSAID -1.42 14,15 
252  36791-04-5  Ribavirin Hepatitis C -0.67 22 
253 106266-06-2 Risperidone Antipsychotic -0.02 1,4,5,7,10,12,14,15,16,18 
254 123441-03-2 Rivastigmine Cholinergic 0.88 17 
255 99632-94-7 RO19-4603 Benzodiazepine -0.25 10,17 
256 61413-54-5  Rolipram Anti-inflammatory 0.61 14,15 
257 91374-21-9 Ropinirole (SKF101468) Dopamine agonist 0.11 1,6,10,11,12,14,15,16,17,18,20,21,23 
258  18559-94-9  Salbutamol (albuterol) Bronchospasm -1.14 7,13,14,15,16 
259  69-72-7  Salicylic Acid Analgesic/ NSAID -1.12 1,2,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,24 
260 487-54-7 Salicyluric acid - -0.44 1,6,10,12,13,16 
261 127779-20-8 Saquinavir Antiviral/ HIV -0.97 14,15,17,22 
262  174635-69-9  SB 222200 - 0.30 1,8,11,12,14,15,16,20,21,24 
263 51-34-3 Scopolamine Anticholinergic 0.23 17 
264  76-73-3  Secobarbital Barbiturate/ Anticonvulsant 0.20 17 
265 79617-96-2 Sertraline Antidepressant 1.60 17 
266 28523-86-6 Sevoflurane Inhalational anesthetic 0.30 14,15 
267 81654-62-8 SKF 89124 Dopamine agonist -0.33 1,10,11,12,14,15,16,17,18,20,21,23 
268 2986-19-8 S-methylisothiourea - -0.60 14,15 
269 3930-20-9 Sotalol Beta-blocker -0.28 17 
270  749-02-0  Spiperone Antipsychotic 0.26 14,15 
271 3056-17-5 Stavudine Antiviral/ HIV -0.48 14,15,22 
272 79637-11-9 Styrene - 0.45 14,15 
273 14759-06-9 Sulforidazine Neuroleptic 0.18 1,6,10,12,13,14,15,16,17 
274 2551-62-4 Sulfur Hexafluoride - 0.37 6,10,11,14,15,16,21 
275 321-64-2 Tacrine Cholinergic -0.13 13,16 
276 142852-50-4 TAK-147 (Zanapezil) Cholinergic 1.14 17 
277 21489-20-3 Talsupram (LU 5-003) Antidepressant 0.22 17 
278 10540-29-1 Tamoxifen Breast cancer 0.92 1 
279 75-65-0 t-Butanol - 0.11 14,15 
280 98-06-6 t-Butylbenzene  - 0.43 14,15 
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281 3178-22-1 t-Butylcyclohexane  - 0.61 14,15 
282 124-72-1 Teflurane Inhalational anesthetic 0.27 1,6,8,10,11,14,15,16,20,21,22,23,24 
283 86181-42-2 Temelastine (SKF93944) Antihistamine -1.88 1,4,6,11,12,16,17,18,20,21,24 
284 91161-71-6 Terbinafine Antifungal 0.09 14,15,17 
285  50679-08-8  Terfenadine Antihistamine/ Anti-allergic 0.64 17 
286 994-05-8 tertiary-Amyl methyl ether  - 0.17 14,15 
287 127-18-4 Tetrachloroethylene - 0.37 14,15 
288 83-67-0  Theobromine (3,7-Dimethylxanthine) Vasodilation -0.28 1,2,6,10,12,13,14,15,16,17 
289  58-55-9  Theophylline Asthma -0.31 1,2,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,24 
290  76-75-5 Thiopental (Thiopentone) Barbiturate/ General anesthetic -0.17 1,2,10,12,13,14,15,16,17 
291 106243-16-7 Thioperamide Antihistamine -0.16 1,6,11,12,14,15,16,18,20,21 
292  50-52-2  Thioridazine Neuroleptic 0.26 1,6,7,8,9,10,11,12,14,15,16,17,18,19,20,21,24 
293 5630-53-5  Tibolone Steroid hormone 0.40 1,4,5,10,12,14,15,16,17,18 
294 69014-14-8 Tiotidine (SKB10, Y-G10) Antihistamine -0.82 1,6,10,11,12,14,15,16,17,18,20,21,23 
295 2933-94-0 Toliprolol Beta-blocker 0.28 14,15 
296 108-88-3 Toluene - 0.34 1,2,5,6,8,10,11,14,15,16,19,20,21,22,23,24 
297 156-60-5 trans 1,2-dichloroethene - 0.04 14,15 
298 28911-01-5  Triazolam Benzodiazepine 0.69 1,5,6,10,12,13,14,15,16,17 
299 79-01-6 Trichloroethene General anesthetic 0.26 1,8,10,11,12,14,15,16,20,21,23,24 
300 117-89-5 Trifluoperazine (Trifluoroperazine) Neuroleptic 1.43 1,6,7,9,11,12,13,14,15,16,17,19,20,21,24 
301 146-54-3 Trifluopromazine Neuroleptic 1.44 8,10,18 
302 57-13-6 Urea Diuretic -0.14 22 
303  99-66-1  Valproic Acid Anticonvulsant -0.32 1,6,8,9,10,11,12,14,15,16,17,18,20,21,22,24 
304 52-53-9 Verapamil Antiarrhythmic -0.61 1,5,6,7,8,9,11,12,13,14,15,16,18,19,20,21,24 
305 865-21-4 Vinblastine Chemotherapy -0.07 22 
306 57-22-7 Vincristine Chemotherapy -1.03 22 
307 7440-63-3 Xenon General anesthetic 0.06 10,11,15,16 
308 7481-89-2 Zalcitabine HIV/ aids -1.18 17,22 
309  30516-87-1 Zidovudine HIV/ aids -0.72 1,6,8,10,11,14,15,16,17,20,21,22,24 
310 104076-38-2 Zolantidine (SKB41) Antihistamine 0.14 1,4,6,11,12,14,15,16,17,18,20,21,23 
311  82626-48-0 Zolpidem Insomnia -0.48 17 
312 66893-81-0  α-(4-pyridyl-1-oxide)-N-tert-butylnitrone - -0.30 12,14,15 
313  37115-43-8  α-Hydroxyalprazolam Benzodiazepine -1.27 16 
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Appendix B. Structural formulas of tested molecules 
Name CAS number Structural formula 
2,2,2-Trifluoroethyl vinyl ether 406-90-6 
 
2,6-diisopropylphenol 2078-54-8 
 
Acetaminophen 103-90-2 
 
Acetylsalicylic acid 50-78-2 
 
Aminopyrine 58-15-1 
 
Amitriptyline 50-48-6 
 
Amobarbital 57-43-2 
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Antipyrine 60-80-0 
 
Atenolol 29122-68-7 
 
Benzene 71-43-2 
 
Caffeine 58-08-2 
 
Carbamazepine 298-46-4 
 
Chlorambucil 305-03-3 
 
Chlorpromazine 50-53-3 
 
Cimetidine 51481-61-9 
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Clonidine 4205-90-7 
 
Cotinine 486-56-6 
 
Desipramine 50-47-5 
 
Domperidone 57808-66-9 
 
Eserine 57-47-6 
 
Ethylbenzene 100-41-4 
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Fluphenazine 69-23-8 
 
Haloperidol 52-86-8 
 
Halothane 151-67-7 
 
Hexobarbital 56-29-1 
 
Hydroxyzine 68-88-2 
 
Ibuprofen 15687-27-1 
 
Imipramine 50-49-7 
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Indomethacin 53-86-1 
 
Mianserin 24219-97-4 
 
N-methyl-2-pyridineethanamine 5638-76-6 
 
Omeprazole 73590-58-6 
 
Oxazepam 604-75-1 
 
Pentobarbital 76-74-4 
 
Phenylbutazone 50-33-9 
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Phenytoin 57-41-0 
 
Promazine 58-40-2 
 
Propranolol 525-66-6 
 
Pyrilamine 91-84-9 
 
Quinidine 56-54-2 
 
Ranitidine 66357-35-5 
 
Ropinirole 91374-21-9 
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Salicylic acid 69-72-7 
 
Theobromine 83-67-0 
 
Theophylline 58-55-9 
 
Toluene 108-88-3 
 
Valproic acid 99-66-1 
 
Verapamil 52-53-9 
 
Zidovudine 30516-87-1 
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Appendix C. Wavelengths & computed parameters of evaluated compounds 
 
Table C-1: Experimental values of the logarithm of the brain-blood distribution coefficient (log BB) and calculated structural and physicochemical parameter values. 
nr Compounds UV log BB α MW MR  MV  Pr  Polarizability Log P Log D7.4 Log WSo WS7.4 PB MI MIA HIA 
  (nm)    (cm³) (cm³) (cm³) (x 10-24) (cm³)         
1 2,2,2-trifluoroethyl vinyl ether 210 0.13 0.0000 126.08 22.50 112.4 223.5 8.92 1.64 1.64 -1.30 6.25 34.210 0 1 79.2 
2 2,6-diisopropylphenol 210 0.48 -0.0002 178.27 56.50 188.0 452.3 22.40 3.66 3.66 -3.45 0.06 94.454 0 0 83.2 
3 acetaminophen 254 -0.31 -0.0104 151.16 42.40 120.9 326.0 16.81 0.67 0.67 -1.50 5.15 30.134 1 0 90.6 
4 acetylsalicylic acid 230 -0.50 -0.9999 180.16 44.52 139.5 370.9 17.65 1.11 -1.93 -1.89 31.70 61.163 0 0 94.9 
5 aminopyrine 254 0.00 0.0040 231.29 68.33 196.0 518.8 27.08 0.15 0.15 -0.52 70.20 34.747 0 0 96.0 
6 amitriptyline 254 0.98 0.9905 277.40 91.52 257.7 675.1 36.28 4.45 2.68 -5.19 0.11 94.195 0 0 89.5 
7 amobarbital 210 0.04 -0.2847 226.27 57.95 211.4 507.3 22.97 1.90 1.90 -2.79 0.37 57.057 0 0 91.5 
8 antipyrine 240 -0.10 0.0000 188.23 54.55 162.7 416.1 21.62 0.30 0.29 -0.26 104.00 15.609 0 0 96.4 
9 atenolol 270 -1.42 0.9937 266.34 74.25 236.6 613.0 29.43 0.40 -0.63 -1.93 25.30 9.577 0 1 64.3 
10 benzene 210 0.37 0.0000 78.11 26.25 89.4 207.2 10.40 1.83 1.83 -1.93 0.93 11.773 0 0 90.9 
11 caffeine 210 -0.05 0.0000 194.19 50.38 133.3 364.5 19.97 -0.28 -0.28 -0.63 45.70 15.912 0 0 93.2 
12 carbamazepine 210 0.00 0.0000 236.27 69.68 186.5 513.4 27.62 1.84 1.84 -3.53 0.07 72.015 0 0 88.8 
13 chlorambucil 254 -1.70 -0.9781 304.21 79.91 243.6 643.7 31.67 2.48 0.87 -3.12 10.20 94.996 1 1 85.2 
14 cimetidine 210 -1.42 0.2008 252.34 70.70 198.2 526.0 28.03 0.48 -0.57 -2.11 18.20 46.912 0 0 77.3 
15 clonidine 270 0.11 0.7597 230.09 57.28 153.1 409.2 22.70 1.42 1.41 -2.58 0.62 38.729 0 0 95.2 
16 cotinine 260 -0.32 0.0013 176.22 49.38 153.6 399.4 19.57 -0.37 -0.37 -0.44 64.10 11.321 0 0 91.1 
17 desipramine 254 1.20 0.9987 266.38 84.16 254.2 639.3 33.36 3.10 1.94 -3.57 1.07 92.559 0 0 93.9 
18 domperidone 270 -0.78 -0.2403 425.91 114.03 317.4 867.0 45.20 3.73 3.65 -3.34 0.24 95.369 0 0 82.1 
19 eserine 240 0.08 0.0499 275.35 77.18 236.0 602.3 30.59 1.99 1.94 -2.17 2.05 70.319 1 1 91.2 
20 ethylbenzene 210 0.20 0.0000 106.17 35.80 122.2 283.8 14.19 2.89 2.89 -2.92 0.13 62.578 0 0 86.7 
21 fluphenazine 263 1.51 0.7597 437.52 114.30 343.8 885.9 45.31 3.81 3.71 -4.20 0.03 95.557 0 1 91.2 
22 hexobarbital 254 0.10 -0.1368 236.27 60.38 192.8 501.8 23.93 1.49 1.49 -2.60 0.60 52.440 0 1 90.7 
23 hydroxyzine 210 0.39 0.2847 374.90 105.91 317.1 833.7 41.98 3.18 2.16 -2.96 4.51 92.934 0 0 93.1 
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Table C-1 (continued) 
nr Compounds UV log BB α MW MR  MV  Pr  Polarizability Log P Log D7.4 Log WSo WS7.4 PB MI MIA HIA 
  (nm)    (cm³) (cm³) (cm³) (x 10-24) (cm³)         
24 ibuprofen 270 -0.18 -0.9937 206.28 60.77 200.3 497.6 24.09 3.68 0.94 -4.01 3.51 99.931 0 0 92.4 
25 imipramine 240 1.06 0.9844 280.41 88.92 269.2 677.5 35.25 3.97 2.17 -3.98 1.92 93.399 0 0 90.5 
26 indomethacin 210 -1.26 -0.9987 357.79 94.59 269.5 707.6 37.49 3.64 1.04 -4.69 3.46 99.088 0 0 91.6 
27 mianserin 280 0.99 0.3339 264.36 82.88 223.6 605.9 32.85 4.03 3.15 -3.54 0.59 89.139 0 0 91.0 
28 N-methyl-2-pyridineethanamine 254 -0.30 0.9980 136.19 42.12 140.7 345.7 16.69 0.37 -0.22 -0.17 377.00 7.656 0 0 93.0 
29 omeprazole 300 -0.82 -0.0467 345.42 94.02 251.8 741.6 37.27 1.99 1.99 -3.75 0.06 94.344 1 0 82.6 
30 oxazepam 230 0.61 -0.0001 286.71 76.43 201.8 548.8 30.30 2.18 2.18 -3.68 0.06 92.968 1 1 92.9 
31 pentobarbital 210 0.12 -0.2008 226.27 57.89 209.1 507.3 22.95 1.94 1.94 -2.71 0.45 59.667 0 0 91.9 
32 phenylbutazone 240 -0.52 0.0013 308.37 88.70 262.7 689.4 35.16 1.93 1.93 -3.56 0.09 92.130 0 0 96.7 
33 phenytoin 210 -0.04 -0.1051 252.27 69.58 200.5 531.3 27.58 2.61 2.61 -4.01 0.02 89.658 1 0 95.3 
34 propranolol 290 0.64 0.9921 259.34 78.98 237.1 606.1 31.31 1.71 0.58 -3.63 2.74 84.800 1 1 92.2 
35 pyrilamine 300 0.49 0.9617 285.38 87.44 262.1 677.3 34.66 1.53 0.45 -2.97 3.96 77.312 0 0 95.7 
36 quinidine 254 -0.46 0.9353 324.42 95.78 266.3 728.7 37.97 2.92 1.97 -3.16 2.27 86.151 0 0 95.2 
37 ranitidine 230 -1.23 0.8632 314.40 85.64 265.4 687.5 33.95 0.69 -0.22 -4.39 0.50 21.099 0 1 79.8 
38 ropinirole 254 0.25 0.9844 260.37 78.36 250.1 630.9 31.06 2.79 0.67 -2.40 12.30 69.841 1 0 88.3 
39 salicylic acid 300 -1.10 -1.0000 138.12 35.06 100.3 284.4 13.90 1.86 -1.65 -1.41 52.90 83.046 0 1 90.6 
40 theobromine 270 -0.28 -0.0032 180.16 45.05 112.0 319.0 17.86 -0.50 -0.50 -1.47 6.15 29.355 0 1 87.3 
41 theophylline 270 -0.29 -0.0592 180.16 43.14 122.9 352.4 17.10 -0.30 -0.30 -0.76 31.40 17.155 0 0 96.7 
42 toluene 210 0.37 0.0000 92.14 31.07 105.7 244.9 12.32 2.49 2.49 -2.43 0.34 45.204 0 0 88.5 
43 valproic acid  210 -0.22 -0.9968 144.21 40.63 155.5 369.6 16.10 2.59 0.25 -1.97 22.30 86.214 0 0 92.3 
44 verapamil 210 -0.70 0.9523 454.60 131.86 429.3 1063.9 52.27 3.77 3.27 -4.95 0.02 92.662 0 0 94.8 
45 zidovudine 270 -0.72 0.9937 267.24 68.56 206.9 536.3 27.18 0.25 0.25 -1.43 9.93 30.855 1 1 87.6 
α: total molar charge at pH 7.4; MW: molecular weight; MR: molar refractivity; MV: molar volume; Pr: parachor; log P: logarithm of the partition coefficient in an n-octanol/water system of the 
neutral form of the compound; log D7.4: distribution coefficient of the compound in an n-octanol/water system at pH 7.4; log WSo: intrinsic aqueous solubility; WS7.4: aqueous solubility at pH 
7.4; PB: plasma protein binding; MI(A): Ames test mutagenic index; HIA: human intestinal absorption 
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Table C-2: Experimental values of the logarithm of the brain-blood distribution coefficient (log BB) and calculated structural and physicochemical parameter values. 
No. Compound UV log BB α MW MR MV Pr Polarizability Log P Log D7.4 Log WSo WS7.4 PB MI MIA HIA 
  (nm)    (cm³) (cm³) (cm³) (x 10-24) (cm³)         
1 2,2,2-trifluoroethyl vinyl ether 210 0.13 0.0000 126.08 22.50 112.4 223.5 8.92 1.64 1.64 -1.30 6.25 34.210 0 1 79.2 
2 2,6-diisopropylphenol 210 0.48 -0.0002 178.27 56.50 188.0 452.3 22.40 3.66 3.66 -3.45 0.06 94.454 0 0 83.2 
3 acetaminophen 254 -0.31 -0.0104 151.16 42.40 120.9 326.0 16.81 0.67 0.67 -1.50 5.15 30.134 1 0 90.6 
4 acetylsalicylic acid 230 -0.50 -0.9999 180.16 44.52 139.5 370.9 17.65 1.11 -1.93 -1.89 31.70 61.163 0 0 94.9 
5 aminopyrine 254 0.00 0.0013 231.29 68.33 196.0 518.8 27.08 0.15 0.15 -0.52 70.20 34.747 0 0 96.0 
6 amitriptyline 254 0.98 0.9905 277.40 91.52 257.7 675.1 36.28 4.45 2.68 -5.19 0.11 94.195 0 0 89.5 
7 amobarbital 210 0.04 -0.2847 226.27 57.95 211.4 507.3 22.97 1.90 1.90 -2.79 0.37 57.057 0 0 91.5 
8 antipyrine 240 -0.10 0.0000 188.23 54.55 162.7 416.1 21.62 0.30 0.29 -0.26 104.00 15.609 0 0 96.4 
9 atenolol 270 -1.42 0.9937 266.34 74.25 236.6 613.0 29.43 0.40 -0.63 -1.93 25.30 9.577 0 1 64.3 
10 benzene 210 0.37 0.0000 78.11 26.25 89.4 207.2 10.40 1.83 1.83 -1.93 0.93 11.773 0 0 90.9 
11 caffeine 210 -0.05 0.0000 194.19 50.38 133.3 364.5 19.97 -0.28 -0.28 -0.63 45.70 15.912 0 0 93.2 
12 carbamazepine 210 0.00 1.0000 236.27 69.68 186.5 513.4 27.62 1.84 1.84 -3.53 0.07 72.015 0 0 88.8 
13 chlorambucil 254 -1.70 -0.9781 304.21 79.91 243.6 643.7 31.67 2.48 0.87 -3.12 10.20 94.996 1 1 85.2 
14 chloropromazine 254 1.06 0.9844 318.86 92.75 262.9 686.9 36.77 5.01 4.17 -5.05 0.02 97.606 0 0 85.9 
15 cimetidine 210 -1.42 0.2008 252.34 70.70 198.2 526.0 28.03 0.48 -0.57 -2.11 18.20 46.912 0 0 77.3 
16 clonidine 270 0.11 0.7597 230.09 57.28 153.1 409.2 22.70 1.42 1.41 -2.58 0.62 38.729 0 0 95.2 
17 cotinine 260 -0.32 0.0013 176.22 49.38 153.6 399.4 19.57 -0.37 -0.37 -0.44 64.10 11.321 0 0 91.1 
18 desipramine 254 1.20 0.9987 266.38 84.16 254.2 639.3 33.36 3.10 1.94 -3.57 1.07 92.559 0 0 93.9 
19 domperidone 270 -0.78 -0.2403 425.91 114.03 317.4 867.0 45.20 3.73 3.65 -3.34 0.24 95.369 0 0 82.1 
20 eserine 240 0.08 -0.9501 275.35 77.18 236.0 602.3 30.59 1.99 1.94 -2.17 2.05 70.319 1 1 91.2 
21 ethylbenzene 210 0.20 0.0000 106.17 35.80 122.2 283.8 14.19 2.89 2.89 -2.92 0.13 62.578 0 0 86.7 
22 fluphenazine 263 1.51 0.7597 437.52 114.30 343.8 885.9 45.31 3.81 3.71 -4.20 0.03 95.557 0 1 91.2 
23 haloperidol 254 1.34 0.9479 375.86 101.01 303.2 797.8 40.04 3.63 2.69 -4.88 0.04 92.115 1 1 90.0 
24 halothane 210 0.35 0.0000 197.38 24.31 102.8 223.3 9.63 2.53 2.53 -2.18 1.30 56.404 0 0 77.3 
25 hexobarbital 254 0.10 -0.1368 236.27 60.38 192.8 501.8 23.93 1.49 1.49 -2.60 0.60 52.440 0 1 90.7 
26 hydroxyzine 210 0.39 0.2847 374.90 105.91 317.1 833.7 41.98 3.18 2.16 -2.96 4.51 92.934 0 0 93.1 
27 ibuprofen 270 -0.18 -0.9937 206.28 60.77 200.3 497.6 24.09 3.68 0.94 -4.01 3.51 99.931 0 0 92.4 
28 imipramine 240 1.06 0.9844 280.41 88.92 269.2 677.5 35.25 3.97 2.17 -3.98 1.92 93.399 0 0 90.5 
29 indomethacin 210 -1.26 -0.9987 357.79 94.59 269.5 707.6 37.49 3.64 1.04 -4.69 3.46 99.088 0 0 91.6 
30 mianserin 280 0.99 0.3339 264.36 82.88 223.6 605.9 32.85 4.03 3.15 -3.54 0.59 89.139 0 0 91.0 
31 N-methyl-2-pyridineethanamine 254 -0.30 0.9980 136.19 42.12 140.7 345.7 16.69 0.37 -0.22 -0.17 377.00 7.656 0 0 93.0 
32 omeprazole 300 -0.82 -0.0467 345.42 94.02 251.8 741.6 37.27 1.99 1.99 -3.75 0.06 94.344 1 0 82.6 
33 oxazepam 230 0.61 -0.0001 286.71 76.43 201.8 548.8 30.30 2.18 2.18 -3.68 0.06 92.968 1 1 92.9 
34 pentobarbital 210 0.12 -0.2008 226.27 57.89 209.1 507.3 22.95 1.94 1.94 -2.71 0.45 59.667 0 0 91.9 
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Table C-2 (continued) 
No. Compound UV log BB α MW MR MV Pr Polarizability Log P Log D7.4 Log WSo WS7.4 PB MI MIA HIA 
  (nm)    (cm³) (cm³) (cm³) (x 10-24) (cm³)         
35 phenylbutazone 240 -0.52 -0.9987 308.37 88.70 262.7 689.4 35.16 1.93 1.93 -3.56 0.09 92.130 0 0 96.7 
36 phenytoin 210 -0.04 -0.1051 252.27 69.58 200.5 531.3 27.58 2.61 2.61 -4.01 0.02 89.658 1 0 95.3 
37 promazine 254 1.23 0.9844 284.42 87.85 250.9 649.7 34.82 4.18 2.56 -4.41 0.46 90.319 0 0 88.6 
38 propranolol 290 0.64 0.9921 259.34 78.98 237.1 606.1 31.31 1.71 0.58 -3.63 2.74 84.800 1 1 92.2 
39 pyrilamine 300 0.49 0.9617 285.38 87.44 262.1 677.3 34.66 1.53 0.45 -2.97 3.96 77.312 0 0 95.7 
40 quinidine 254 -0.46 0.9353 324.42 95.78 266.3 728.7 37.97 2.92 1.97 -3.16 2.27 86.151 0 0 95.2 
41 ranitidine 230 -1.23 0.8632 314.40 85.64 265.4 687.5 33.95 0.69 -0.22 -4.39 0.50 21.099 0 1 79.8 
42 ropinirole 254 0.25 0.9844 260.37 78.36 250.1 630.9 31.06 2.79 0.67 -2.40 12.30 69.841 1 0 88.3 
43 salicylic acid 300 -1.10 -1.0000 138.12 35.06 100.3 284.4 13.90 1.86 -1.65 -1.41 52.90 83.046 0 1 90.6 
44 theobromine 270 -0.28 -0.0032 180.16 45.05 112.0 319.0 17.86 -0.50 -0.50 -1.47 6.15 29.355 0 1 87.3 
45 theophylline 270 -0.29 -0.0592 180.16 43.14 122.9 352.4 17.10 -0.30 -0.30 -0.76 31.40 17.155 0 0 96.7 
46 toluene 210 0.37 0.0000 92.14 31.07 105.7 244.9 12.32 2.49 2.49 -2.43 0.34 45.204 0 0 88.5 
47 valproic acid  210 -0.22 -0.9968 144.21 40.63 155.5 369.6 16.10 2.59 0.25 -1.97 22.30 86.214 0 0 92.3 
48 verapamil 210 -0.70 0.9523 454.60 131.86 429.3 1063.9 52.27 3.77 3.27 -4.95 0.02 92.662 0 0 94.8 
49 zidovudine 270 -0.72 0.9937 267.24 71.74 215.0 558.7 28.44 0.25 0.25 -1.43 9.93 30.855 1 1 87.6 
α: total molar charge at pH 7.4; MW: molecular weight; MR: molar refractivity; MV: molar volume; Pr: parachor; log P: logarithm of the partition coefficient in an n-octanol/water system of the 
neutral form of the compound; log D7.4: distribution coefficient of the compound in an n-octanol/water system at pH 7.4; logWSo: intrinsic aqueous solubility; WS7.4: aqueous solubility at pH 
7.4; PB: plasma protein binding; MI(A): Ames test mutagenic index; HIA: human intestinal absorption 
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Table C-3: Overview of the values of the calculated structural and physicochemical parameters. In vitro models were created based on the log k values and these parameters. 
No. α MW MR MV Pr Polarizability Log P Log D7.4 Log WSo WS7.4 PB MI MIA HIA PSA HBA HBD MSA 
   (cm³) (cm³) (cm³) (x 10-24) (cm³)             
1 0.0000 126.08 22.50 112.4 223.5 8.92 1.64 1.64 -1.30 6.25 34.210 0 1 79.2 9.23 1 0 158.11 
2 -0.0002 178.27 56.50 188.0 452.3 22.40 3.66 3.66 -3.45 0.06 94.454 0 0 83.2 20.23 1 1 331.14 
3 -0.0104 151.16 42.40 120.9 326.0 16.81 0.67 0.67 -1.50 5.15 30.134 1 0 90.6 49.33 3 2 222.56 
4 -0.9999 180.16 44.52 139.5 370.9 17.65 1.11 -1.93 -1.89 31.70 61.163 0 0 94.9 63.60 4 1 246.17 
5 0.0040 231.29 68.33 196.0 518.8 27.08 0.15 0.15 -0.52 70.20 34.747 0 0 96.0 26.79 4 0 367.02 
6 0.9905 277.40 91.52 257.7 675.1 36.28 4.45 2.68 -5.19 0.11 94.195 0 0 89.5 3.24 1 0 457.27 
7 -0.2847 226.27 57.95 211.4 507.3 22.97 1.90 1.90 -2.79 0.37 57.057 0 0 91.5 75.27 5 2 368.83 
8 0.0000 188.23 54.55 162.7 416.1 21.62 0.30 0.29 -0.26 104.00 15.609 0 0 96.4 23.55 3 0 280.13 
9 0.9937 266.34 74.25 236.6 613.0 29.43 0.40 -0.63 -1.93 25.30 9.577 0 1 64.3 84.58 5 4 440.41 
10 0.0000 78.11 26.25 89.4 207.2 10.40 1.83 1.83 -1.93 0.93 11.773 0 0 90.9 0.00 0 0 135.86 
11 0.0000 194.19 50.38 133.3 364.5 19.97 -0.28 -0.28 -0.63 45.70 15.912 0 0 93.2 58.44 6 0 269.15 
12 0.0000 236.27 69.68 186.5 513.4 27.62 1.84 1.84 -3.53 0.07 72.015 0 0 88.8 46.33 3 2 312.24 
13 -0.9781 304.21 79.91 243.6 643.7 31.67 2.48 0.87 -3.12 10.20 94.996 1 1 85.2 40.54 3 1 443.08 
14 0.9844 318.86 92.75 262.9 686.9 36.77 5.01 4.17 -5.05 0.02 97.606 0 0 85.9 6.48 2 0 456.64 
15 0.2008 252.34 70.70 198.2 526.0 28.03 0.48 -0.57 -2.11 18.20 46.912 0 0 77.3 88.89 6 3 370.53 
16 0.7597 230.09 57.28 153.1 409.2 22.70 1.42 1.41 -2.58 0.62 38.729 0 0 95.2 36.42 3 2 273.18 
17 0.0013 176.22 49.38 153.6 399.4 19.57 -0.37 -0.37 -0.44 64.10 11.321 0 0 91.1 33.20 3 0 272.90 
18 0.9987 266.38 84.16 254.2 639.3 33.36 3.10 1.94 -3.57 1.07 92.559 0 0 93.9 15.27 2 1 443.34 
19 -0.2403 425.91 114.03 317.4 867.0 45.20 3.73 3.65 -3.34 0.24 95.369 0 0 82.1 67.92 7 2 583.57 
20 0.0499 275.35 77.18 236.0 602.3 30.59 1.99 1.94 -2.17 2.05 70.319 1 1 91.2 44.81 5 1 441.72 
21 0.0000 106.17 35.80 122.2 283.8 14.19 2.89 2.89 -2.92 0.13 62.578 0 0 86.7 0.00 0 0 198.54 
22 0.7597 437.52 114.30 343.8 885.9 45.31 3.81 3.71 -4.20 0.03 95.557 0 1 91.2 29.95 4 1 617.34 
23 0.9479 375.86 101.01 303.2 797.8 40.04 3.63 2.69 -4.88 0.04 92.115 1 1 90.0 40.54 3 1 544.82 
24 0.0000 197.38 24.31 102.8 223.3 9.63 2.53 2.53 -2.18 1.30 56.404 0 0 77.3 0.00 0 0 140.12 
25 -0.1368 236.27 60.38 192.8 501.8 23.93 1.49 1.49 -2.60 0.60 52.440 0 1 90.7 66.48 5 1 346.43 
26 0.2847 374.90 105.91 317.1 833.7 41.98 3.18 2.16 -2.96 4.51 92.934 0 0 93.1 35.94 4 1 579.98 
27 -0.9937 206.28 60.77 200.3 497.6 24.09 3.68 0.94 -4.01 3.51 99.931 0 0 92.4 37.30 2 1 356.78 
28 0.9844 280.41 88.92 269.2 677.5 35.25 3.97 2.17 -3.98 1.92 93.399 0 0 90.5 6.48 2 0 478.35 
29 -0.9987 357.79 94.59 269.5 707.6 37.49 3.64 1.04 -4.69 3.46 99.088 0 0 91.6 68.53 5 1 476.27 
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Table C-3 (continued) 
No. α MW MR MV Pr Polarizability Log P Log D7.4 Log WSo WS7.4 PB MI MIA HIA PSA HBA HBD MSA 
   (cm³) (cm³) (cm³) (x 10-24) (cm³)             
30 0.3339 264.36 82.88 223.6 605.9 32.85 4.03 3.15 -3.54 0.59 89.139 0 0 91.0 6.48 2 0 415.95 
31 0.9980 136.19 42.12 140.7 345.7 16.69 0.37 -0.22 -0.17 377.00 7.656 0 0 93.0 24.92 2 1 242.37 
32 -0.0467 345.42 94.02 251.8 741.6 37.27 1.99 1.99 -3.75 0.06 94.344 1 0 82.6 77.10 6 1 501.87 
33 -0.0001 286.71 76.43 201.8 548.8 30.30 2.18 2.18 -3.68 0.06 92.968 1 1 92.9 61.69 4 2 346.15 
34 -0.2008 226.27 57.89 209.1 507.3 22.95 1.94 1.94 -2.71 0.45 59.667 0 0 91.9 75.27 5 2 367.89 
35 0.0013 308.37 88.70 262.7 689.4 35.16 1.93 1.93 -3.56 0.09 92.130 0 0 96.7 40.62 4 0 466.42 
36 -0.1051 252.27 69.58 200.5 531.3 27.58 2.61 2.61 -4.01 0.02 89.658 1 0 95.3 58.20 4 2 340.95 
37 0.9844 284.42 87.85 250.9 649.7 34.82 4.18 2.56 -4.41 0.46 90.319 0 0 88.6 6.48 2 0 440.29 
38 0.9921 259.34 78.98 237.1 606.1 31.31 1.71 0.58 -3.63 2.74 84.800 1 1 92.2 41.49 3 2 426.96 
39 0.9617 285.38 87.44 262.1 677.3 34.66 1.53 0.45 -2.97 3.96 77.312 0 0 95.7 28.60 4 0 485.16 
40 0.9353 324.42 95.78 266.3 728.7 37.97 2.92 1.97 -3.16 2.27 86.151 0 0 95.2 45.59 4 1 483.55 
41 0.8632 314.40 85.64 265.4 687.5 33.95 0.69 -0.22 -4.39 0.50 21.099 0 1 79.8 83.58 6 2 484.00 
42 0.9844 260.37 78.36 250.1 630.9 31.06 2.79 0.67 -2.40 12.30 69.841 1 0 88.3 32.34 3 1 459.72 
43 -1.0000 138.12 35.06 100.3 284.4 13.90 1.86 -1.65 -1.41 52.90 83.046 0 1 90.6 57.53 3 2 183.54 
44 -0.0032 180.16 45.05 112.0 319.0 17.86 -0.50 -0.50 -1.47 6.15 29.355 0 1 87.3 67.23 6 1 237.27 
45 -0.0592 180.16 43.14 122.9 352.4 17.10 -0.30 -0.30 -0.76 31.40 17.155 0 0 96.7 69.30 6 1 235.19 
46 0.0000 92.14 31.07 105.7 244.9 12.32 2.49 2.49 -2.43 0.34 45.204 0 0 88.5 0.00 0 0 168.11 
47 -0.9968 144.21 40.63 155.5 369.6 16.10 2.59 0.25 -1.97 22.30 86.214 0 0 92.3 37.30 2 1 281.48 
48 0.9523 454.60 131.86 429.3 1063.9 52.27 3.77 3.27 -4.95 0.02 92.662 0 0 94.8 63.95 6 0 781.98 
α total molar charge at pH 7.4; MW: molecular weight; MR: molar refractivity; MV: molar volume; Pr: parachor; log P: logarithm of the partition coefficient in an n-octanol/water system of the 
neutral form of the compound; log D7.4: distribution coefficient of the compound in an n-octanol/water system at pH 7.4; log WSo: intrinsic aqueous solubility; WS7.4: aqueous solubility at pH 
7.4; PB: plasma protein binding; MI(A): Ames test mutagenic index; HIA: human intestinal absorption; PSA: polar surface area; HBA: hydrogen bond acceptor; HBD: hydrogen bond donor; 
MSA: molecular surface area 
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Table C-4: Overview of the values of the calculated structural and physicochemical parameters. In vitro models were created based on the log k values and these parameters. 
No. α MW MR MV Pr Polarizability Log P Log D7.4 Log WSo WS7.4 PB MI MIA HIA PSA HBA HBD MSA 
   (cm³) (cm³) (cm³) (x 10-24) (cm³)             
1 0.0000 126.08 22.50 112.4 223.5 8.92 1.64 1.64 -1.30 6.25 34.210 0 1 79.2 9.23 1 0 158.11 
2 -0.0002 178.27 56.50 188.0 452.3 22.40 3.66 3.66 -3.45 0.06 94.454 0 0 83.2 20.23 1 1 331.14 
3 -0.0104 151.16 42.40 120.9 326.0 16.81 0.67 0.67 -1.50 5.15 30.134 1 0 90.6 49.33 3 2 222.56 
4 -0.9999 180.16 44.52 139.5 370.9 17.65 1.11 -1.93 -1.89 31.70 61.163 0 0 94.9 63.60 4 1 246.17 
5 0.0040 231.29 68.33 196.0 518.8 27.08 0.15 0.15 -0.52 70.20 34.747 0 0 96.0 26.79 4 0 367.02 
6 0.9905 277.40 91.52 257.7 675.1 36.28 4.45 2.68 -5.19 0.11 94.195 0 0 89.5 3.24 1 0 457.27 
7 -0.2847 226.27 57.95 211.4 507.3 22.97 1.90 1.90 -2.79 0.37 57.057 0 0 91.5 75.27 5 2 368.83 
8 0.0000 188.23 54.55 162.7 416.1 21.62 0.30 0.29 -0.26 104.00 15.609 0 0 96.4 23.55 3 0 280.13 
9 0.9937 266.34 74.25 236.6 613.0 29.43 0.40 -0.63 -1.93 25.30 9.577 0 1 64.3 84.58 5 4 440.41 
10 0.0000 78.11 26.25 89.4 207.2 10.40 1.83 1.83 -1.93 0.93 11.773 0 0 90.9 0.00 0 0 135.86 
11 0.0000 194.19 50.38 133.3 364.5 19.97 -0.28 -0.28 -0.63 45.70 15.912 0 0 93.2 58.44 6 0 269.15 
12 0.0000 236.27 69.68 186.5 513.4 27.62 1.84 1.84 -3.53 0.07 72.015 0 0 88.8 46.33 3 2 312.24 
13 -0.9781 304.21 79.91 243.6 643.7 31.67 2.48 0.87 -3.12 10.20 94.996 1 1 85.2 40.54 3 1 443.08 
14 0.9844 318.86 92.75 262.9 686.9 36.77 5.01 4.17 -5.05 0.02 97.606 0 0 85.9 6.48 2 0 456.64 
15 0.2008 252.34 70.70 198.2 526.0 28.03 0.48 -0.57 -2.11 18.20 46.912 0 0 77.3 88.89 6 3 370.53 
16 0.7597 230.09 57.28 153.1 409.2 22.70 1.42 1.41 -2.58 0.62 38.729 0 0 95.2 36.42 3 2 273.18 
17 0.0013 176.22 49.38 153.6 399.4 19.57 -0.37 -0.37 -0.44 64.10 11.321 0 0 91.1 33.20 3 0 272.90 
18 0.9987 266.38 84.16 254.2 639.3 33.36 3.10 1.94 -3.57 1.07 92.559 0 0 93.9 15.27 2 1 443.34 
19 -0.2403 425.91 114.03 317.4 867.0 45.20 3.73 3.65 -3.34 0.24 95.369 0 0 82.1 67.92 7 2 583.57 
20 0.0499 275.35 77.18 236.0 602.3 30.59 1.99 1.94 -2.17 2.05 70.319 1 1 91.2 44.81 5 1 441.72 
21 0.0000 106.17 35.80 122.2 283.8 14.19 2.89 2.89 -2.92 0.13 62.578 0 0 86.7 0.00 0 0 198.54 
22 0.7597 437.52 114.30 343.8 885.9 45.31 3.81 3.71 -4.20 0.03 95.557 0 1 91.2 29.95 4 1 617.34 
23 0.9479 375.86 101.01 303.2 797.8 40.04 3.63 2.69 -4.88 0.04 92.115 1 1 90.0 40.54 3 1 544.82 
24 0.0000 197.38 24.31 102.8 223.3 9.63 2.53 2.53 -2.18 1.30 56.404 0 0 77.3 0.00 0 0 140.12 
25 -0.1368 236.27 60.38 192.8 501.8 23.93 1.49 1.49 -2.60 0.60 52.440 0 1 90.7 66.48 5 1 346.43 
26 0.2847 374.90 105.91 317.1 833.7 41.98 3.18 2.16 -2.96 4.51 92.934 0 0 93.1 35.94 4 1 579.98 
27 -0.9937 206.28 60.77 200.3 497.6 24.09 3.68 0.94 -4.01 3.51 99.931 0 0 92.4 37.30 2 1 356.78 
28 0.9844 280.41 88.92 269.2 677.5 35.25 3.97 2.17 -3.98 1.92 93.399 0 0 90.5 6.48 2 0 478.35 
29 -0.9987 357.79 94.59 269.5 707.6 37.49 3.64 1.04 -4.69 3.46 99.088 0 0 91.6 68.53 5 1 476.27 
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Table C-4 (continued) 
No. α MW MR MV Pr Polarizability Log P Log D7.4 Log WSo WS7.4 PB MI MIA HIA PSA HBA HBD MSA 
   (cm³) (cm³) (cm³) (x 10-24) (cm³)             
30 0.3339 264.36 82.88 223.6 605.9 32.85 4.03 3.15 -3.54 0.59 89.139 0 0 91.0 6.48 2 0 415.95 
31 0.9980 136.19 42.12 140.7 345.7 16.69 0.37 -0.22 -0.17 377.00 7.656 0 0 93.0 24.92 2 1 242.37 
32 -0.0467 345.42 94.02 251.8 741.6 37.27 1.99 1.99 -3.75 0.06 94.344 1 0 82.6 77.10 6 1 501.87 
33 -0.0001 286.71 76.43 201.8 548.8 30.30 2.18 2.18 -3.68 0.06 92.968 1 1 92.9 61.69 4 2 346.15 
34 -0.2008 226.27 57.89 209.1 507.3 22.95 1.94 1.94 -2.71 0.45 59.667 0 0 91.9 75.27 5 2 367.89 
35 0.0013 308.37 88.70 262.7 689.4 35.16 1.93 1.93 -3.56 0.09 92.130 0 0 96.7 40.62 4 0 466.42 
36 -0.1051 252.27 69.58 200.5 531.3 27.58 2.61 2.61 -4.01 0.02 89.658 1 0 95.3 58.20 4 2 340.95 
37 0.9844 284.42 87.85 250.9 649.7 34.82 4.18 2.56 -4.41 0.46 90.319 0 0 88.6 6.48 2 0 440.29 
38 0.9921 259.34 78.98 237.1 606.1 31.31 1.71 0.58 -3.63 2.74 84.800 1 1 92.2 41.49 3 2 426.96 
39 0.9617 285.38 87.44 262.1 677.3 34.66 1.53 0.45 -2.97 3.96 77.312 0 0 95.7 28.60 4 0 485.16 
40 0.9353 324.42 95.78 266.3 728.7 37.97 2.92 1.97 -3.16 2.27 86.151 0 0 95.2 45.59 4 1 483.55 
41 0.8632 314.40 85.64 265.4 687.5 33.95 0.69 -0.22 -4.39 0.50 21.099 0 1 79.8 83.58 6 2 484.00 
42 0.9844 260.37 78.36 250.1 630.9 31.06 2.79 0.67 -2.40 12.30 69.841 1 0 88.3 32.34 3 1 459.72 
43 -1.0000 138.12 35.06 100.3 284.4 13.90 1.86 -1.65 -1.41 52.90 83.046 0 1 90.6 57.53 3 2 183.54 
44 -0.0032 180.16 45.05 112.0 319.0 17.86 -0.50 -0.50 -1.47 6.15 29.355 0 1 87.3 67.23 6 1 237.27 
45 -0.0592 180.16 43.14 122.9 352.4 17.10 -0.30 -0.30 -0.76 31.40 17.155 0 0 96.7 69.30 6 1 235.19 
46 0.0000 92.14 31.07 105.7 244.9 12.32 2.49 2.49 -2.43 0.34 45.204 0 0 88.5 0.00 0 0 168.11 
47 -0.9968 144.21 40.63 155.5 369.6 16.10 2.59 0.25 -1.97 22.30 86.214 0 0 92.3 37.30 2 1 281.48 
48 0.9523 454.60 131.86 429.3 1063.9 52.27 3.77 3.27 -4.95 0.02 92.662 0 0 94.8 63.95 6 0 781.98 
49 0.9937 267.24 61.71 220.9 558.7 23.69 0.25 0.25 -1.43 9.93 30.855 1 1 87.6 108.30 8 2 342.98 
α total molar charge at pH 7.4; MW: molecular weight; MR: molar refractivity; MV: molar volume; Pr: parachor; log P: logarithm of the partition coefficient in an n-octanol/water system of the 
neutral form of the compound; log D7.4: distribution coefficient of the compound in an n-octanol/water system at pH 7.4; log WSo: intrinsic aqueous solubility; WS7.4: aqueous solubility at pH 
7.4; PB: plasma protein binding; MI(A): Ames test mutagenic index; HIA: human intestinal absorption; PSA: polar surface area; HBA: hydrogen bond acceptor; HBD: hydrogen bond donor; 
MSA: molecular surface area 
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Appendix D. Details of the PLS regression analysis (Figure 
IV-3) 
The Partial Least Squares (PLS) regression analysis, shown in Figure IV-3, was performed 
with Matlab software. For 23 test compounds, in vivo log BB values were used to construct 
the y-block (response variable), while calculated molecular descriptors and experimental log 
kIAM values were used to construct the X-block (descriptor variables) in a log BB prediction 
model [1]. Both were normalized before PLS analysis. 
The kIAM (IAM retention factor) and corresponding log kIAM values on both IAM.PC.DD2 
column 1 and Sphingo-IAM column 2 were determined for the 23 test compounds from 
retention time measurements (kIAM = (tr - t0) / t0), as detailed in Table D-1. 
Using the IAM.PC.DD2 column 1, the correlation between in vivo log BB values and 
predicted in vitro log BB values can be expressed with the following equation. This model 
explains 96 % of variance in the data. 
 
log BB = - 0.24 + 0.03 α - 0.53 MW - 217.78 MR - 1.31 MV + 2.48 Pr + 216.82 Pol - 0.14 
log P - 0.21 log D7.4 + 0.21 log WSo - 0.39 WS7.4 + 0.17 PB - 0.15 MI + 0.04 MIA + 0.59 
HIA + 0.85 log kIAM 
 
Using the Sphingo-IAM column 2, the correlation between in vivo log BB values and 
predicted in vitro log BB values can be expressed with the following equation. This model 
explains 89 % of variance in the data. The data is visually presented in Figure IV-3. 
 
log BB = - 0.25 + 0.37 α - 0.29 MW - 36.38 MR + 0.57 MV + 0.10 Pr + 35.88 Pol - 0.06 log 
P + 0.20 log D7.4 + 0.36 log WSo - 0.22 WS7.4 + 0.05 PB + 0.15 MI + 0.15 MIA + 0.28 HIA 
+ 0.33 log kIAM 
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Table D-1: kIAM values (= (tr - t0) / t0) of 23 test compounds measured on IAM.PC.DD2 column 1 and Sphingo-
IAM column 2.
a
 
                  20 µL, 50 µg/mL 
                     t0 = 1.20 min 
  IAM.PC.DD2 Sphingo-IAM 
  column 1 column 2 
No. Compound 15 cm x 4.6 mm 15 cm x 3 mm 
  Flow 1 mL/min Flow 0.5 mL/min 
1 acetaminophen 0.51 0.72 
2 acetylsalicylic acid 0.08 2.49 
3 aminopyrine 0.63 0.81 
4 amobarbital 1.81 2.78 
5 antipyrine 0.51 0.63 
6 benzene 1.89 2.87 
7 carbamazepine 2.31 3.04 
8 cimetidine 1.05 0.83 
9 eserine 4.63 1.18 
10 ethylbenzene 6.07 11.43 
11 hexobarbital 1.27 1.89 
12 ibuprofen 0.73 11.95 
13 indomethacin 1.66 27.72 
14 N-methyl-2-pyridineethanamine 2.85 0.51 
15 omeprazole 2.34 3.31 
16 oxazepam 5.93 7.77 
17 pentobarbital 1.89 2.93 
18 phenylbutazone 0.54 10.32 
19 phenytoin 3.16 5.07 
20 ranitidine 2.75 0.68 
21 ropinirole 6.76 1.04 
22 salicylic acid 0.06 2.18 
23 toluene 3.45 5.66 
a
 Conditions: Isocratic elution (25 °C); NH4OAcAq buffer (10 mM, pH 7.4) + MeOH (40 % v/v) [2]; Waters 2690 
Alliance HPLC chromatograph + Waters 2487 dual λ absorbance detector (210 - 300 nm). Data acquisition/ 
processing: PeakSimple Chromatography Data System (model 202). 
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